<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">104901</article-id><article-id pub-id-type="doi">10.7554/eLife.104901</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.104901.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Harnessing AlphaFold to reveal hERG channel conformational state secrets</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Ngo</surname><given-names>Khoa</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7454-2924</contrib-id><email>khoango@ucdavis.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Pei-Chi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5753-1131</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Yarov-Yarovoy</surname><given-names>Vladimir</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2325-4834</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund14"/><xref ref-type="other" rid="fund15"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Clancy</surname><given-names>Colleen E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6849-4885</contrib-id><email>ceclancy@ucdavis.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund14"/><xref ref-type="other" rid="fund15"/><xref ref-type="other" rid="fund16"/><xref ref-type="other" rid="fund17"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Vorobyov</surname><given-names>Igor</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4767-5297</contrib-id><email>ivorobyov@ucdavis.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund14"/><xref ref-type="other" rid="fund15"/><xref ref-type="other" rid="fund16"/><xref ref-type="other" rid="fund17"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05rrcem69</institution-id><institution>Center for Precision Medicine and Data Science, University of California, Davis</institution></institution-wrap><addr-line><named-content content-type="city">Davis</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05rrcem69</institution-id><institution>Department of Physiology and Membrane Biology, University of California, Davis</institution></institution-wrap><addr-line><named-content content-type="city">Davis</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05rrcem69</institution-id><institution>Department of Anesthesiology and Pain Medicine, University of California, Davis</institution></institution-wrap><addr-line><named-content content-type="city">Davis</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05rrcem69</institution-id><institution>Department of Pharmacology, University of California, Davis</institution></institution-wrap><addr-line><named-content content-type="city">Davis</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Panchenko</surname><given-names>Anna</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02y72wh86</institution-id><institution>Queen's University</institution></institution-wrap><country>Canada</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Maduke</surname><given-names>Merritt</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Stanford University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>14</day><month>07</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP104901</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-11-02"><day>02</day><month>11</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-10-25"><day>25</day><month>10</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.01.27.577468"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-12-17"><day>17</day><month>12</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.104901.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-06-06"><day>06</day><month>06</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.104901.2"/></event></pub-history><permissions><copyright-statement>Â© 2024, Ngo et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Ngo et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-104901-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-104901-figures-v1.pdf"/><abstract><p>To design safe, selective, and effective new therapies, there must be a deep understanding of the structure and function of the drug target. One of the most difficult problems to solve has been the resolution of discrete conformational states of transmembrane ion channel proteins. An example is K<sub>V</sub>11.1 (hERG), comprising the primary cardiac repolarizing current, <italic>I</italic><sub>kr</sub>. hERG is a notorious drug anti-target against which all promising drugs are screened to determine potential for arrhythmia. Drug interactions with the hERG inactivated state are linked to elevated arrhythmia risk, and drugs may become trapped during channel closure. While prior studies have applied AlphaFold to predict alternative protein conformations, we show that the inclusion of carefully chosen structural templates can guide these predictions toward distinct functional states. This targeted modeling approach is validated through comparisons with experimental data, including proposed state-dependent structural features, drug interactions from molecular docking, and ion conduction properties from molecular dynamics simulations. Remarkably, AlphaFold not only predicts inactivation mechanisms of the hERG channel that prevent ion conduction but also uncovers novel molecular features explaining enhanced drug binding observed during inactivation, offering a deeper understanding of hERG channel function and pharmacology. Furthermore, leveraging AlphaFold-derived states enhances computational screening by significantly improving agreement with experimental drug affinities, an important advance for hERG as a key drug safety target where traditional single-state models miss critical state-dependent effects. By mapping protein residue interaction networks across closed, open, and inactivated states, we identified critical residues driving state transitions validated by prior mutagenesis studies. This innovative methodology sets a new benchmark for integrating deep learning-based protein structure prediction with experimental validation. It also offers a broadly applicable approach using AlphaFold to predict discrete protein conformations, reconcile disparate data, and uncover novel structureâfunction relationships, ultimately advancing drug safety screening and enabling the design of safer therapeutics.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>voltage-gated potassium channel</kwd><kwd>hERG</kwd><kwd>AlphaFold</kwd><kwd>molecular docking</kwd><kwd>molecular dynamics simulation</kwd><kwd>arrhythmia</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>OT2OD026580</award-id><principal-award-recipient><name><surname>Clancy</surname><given-names>Colleen E</given-names></name><name><surname>Vorobyov</surname><given-names>Igor</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>R01HL128537</award-id><principal-award-recipient><name><surname>Yarov-Yarovoy</surname><given-names>Vladimir</given-names></name><name><surname>Clancy</surname><given-names>Colleen E</given-names></name><name><surname>Vorobyov</surname><given-names>Igor</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>R01HL174001</award-id><principal-award-recipient><name><surname>Yarov-Yarovoy</surname><given-names>Vladimir</given-names></name><name><surname>Clancy</surname><given-names>Colleen E</given-names></name><name><surname>Vorobyov</surname><given-names>Igor</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>R01HL085844</award-id><principal-award-recipient><name><surname>Yarov-Yarovoy</surname><given-names>Vladimir</given-names></name><name><surname>Vorobyov</surname><given-names>Igor</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>R01HL152681</award-id><principal-award-recipient><name><surname>Clancy</surname><given-names>Colleen E</given-names></name><name><surname>Vorobyov</surname><given-names>Igor</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>U01HL126273</award-id><principal-award-recipient><name><surname>Yarov-Yarovoy</surname><given-names>Vladimir</given-names></name><name><surname>Clancy</surname><given-names>Colleen E</given-names></name><name><surname>Vorobyov</surname><given-names>Igor</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>19CDA34770101</award-id><principal-award-recipient><name><surname>Vorobyov</surname><given-names>Igor</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>2032486</award-id><principal-award-recipient><name><surname>Vorobyov</surname><given-names>Igor</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>T32HL086350</award-id><principal-award-recipient><name><surname>Ngo</surname><given-names>Khoa</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100016257</institution-id><institution>University of California Davis School of Medicine</institution></institution-wrap></funding-source><award-id>Department of Physiology and Membrane Biology Research Partnership Fund</award-id><principal-award-recipient><name><surname>Clancy</surname><given-names>Colleen E</given-names></name><name><surname>Vorobyov</surname><given-names>Igor</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004682</institution-id><institution>Oracle</institution></institution-wrap></funding-source><award-id>Oracle for Research fellowship</award-id><principal-award-recipient><name><surname>Vorobyov</surname><given-names>Igor</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution>Advanced Cyberinfrastructure Coordination Ecosystem: Services &amp; Support (ACCESS)</institution></institution-wrap></funding-source><award-id>MCB170095</award-id><principal-award-recipient><name><surname>Vorobyov</surname><given-names>Igor</given-names></name><name><surname>Clancy</surname><given-names>Colleen E</given-names></name><name><surname>Yarov-Yarovoy</surname><given-names>Vladimir</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution>Texas Advanced Computing Center (TACC)</institution></institution-wrap></funding-source><award-id>MCB20010</award-id><principal-award-recipient><name><surname>Vorobyov</surname><given-names>Igor</given-names></name><name><surname>Clancy</surname><given-names>Colleen E</given-names></name><name><surname>Yarov-Yarovoy</surname><given-names>Vladimir</given-names></name></principal-award-recipient></award-group><award-group id="fund14"><funding-source><institution-wrap><institution>Pittsburgh Supercomputing Center (PSC)</institution></institution-wrap></funding-source><award-id>PSCA17085P</award-id><principal-award-recipient><name><surname>Vorobyov</surname><given-names>Igor</given-names></name><name><surname>Clancy</surname><given-names>Colleen E</given-names></name><name><surname>Yarov-Yarovoy</surname><given-names>Vladimir</given-names></name></principal-award-recipient></award-group><award-group id="fund15"><funding-source><institution-wrap><institution>Pittsburgh Supercomputing Center (PSC)</institution></institution-wrap></funding-source><award-id>MCB160089P</award-id><principal-award-recipient><name><surname>Vorobyov</surname><given-names>Igor</given-names></name><name><surname>Clancy</surname><given-names>Colleen E</given-names></name><name><surname>Yarov-Yarovoy</surname><given-names>Vladimir</given-names></name></principal-award-recipient></award-group><award-group id="fund16"><funding-source><institution-wrap><institution>Pittsburgh Supercomputing Center (PSC)</institution></institution-wrap></funding-source><award-id>PSCA18077P</award-id><principal-award-recipient><name><surname>Vorobyov</surname><given-names>Igor</given-names></name><name><surname>Clancy</surname><given-names>Colleen E</given-names></name></principal-award-recipient></award-group><award-group id="fund17"><funding-source><institution-wrap><institution>Pittsburgh Supercomputing Center (PSC)</institution></institution-wrap></funding-source><award-id>PSCA16108P</award-id><principal-award-recipient><name><surname>Vorobyov</surname><given-names>Igor</given-names></name><name><surname>Clancy</surname><given-names>Colleen E</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Customized AlphaFold-based modeling of distinct functional states of the hERG channel, a major drug anti-target, significantly improves drug affinity predictions, enhancing cardiac safety screening for arrhythmia risk.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Understanding the dynamic conformational changes of proteins is fundamental to elucidating their functions, interactions, and roles in biological processes. Many proteins, especially membrane proteins that constitute a significant portion of drug targets, exist in multiple functionally distinct states. Capturing these various conformations is crucial for predicting how proteins interact with ligands, designing drugs that selectively target-specific states, and uncovering the mechanisms that regulate these interactions. However, experimental techniques like cryo-electron microscopy (cryo-EM) often provide only static snapshots of proteins, typically capturing a single conformational state due to experimental constraints. Computational methods such as molecular dynamics (MD) simulations can sample alternative conformations but are limited by timescales and computational resources, often failing to observe meaningful conformational changes that result in functional effects. Enhanced sampling simulation techniques can help extend the timescales, but the biasing factors introduced to accelerate the simulations can sometimes push proteins into non-physiological conformations, potentially skewing the accuracy of the predictions and limiting their biological relevance.</p><p>Recent advances in deep learning have revolutionized protein structure prediction, with tools like AlphaFold2 (<xref ref-type="bibr" rid="bib53">Jumper et al., 2021a</xref>) achieving remarkable success in predicting protein structures based on amino acid sequences. However, conventional applications of these AI-based methods often result in the prediction of a single, static conformation, akin to experimental snapshots. This raises a significant question: <italic>Can we harness the capabilities of artificial intelligence to predict different physiologically relevant conformations of proteins, thereby capturing the dynamic spectrum of states essential for understanding protein function and drug interactions?</italic></p><p>To address this question, we employed and validated different strategies to guide AlphaFold2 to predict multiple physiologically relevant conformations, surpassing the usual single-state predictions. As a proof of concept, we applied this approach to the human voltage-gated potassium channel K<sub>V</sub>11.1, encoded by the KCNH2 or human Ether-Ã -go-go-Related Gene (hERG) gene, a well-known drug anti-target in pharmacology and cardiology due to its role in drug-induced arrhythmias. hERG is a key player in cardiac electrophysiology, underpinning the rapid component of the delayed rectifier K<sup>+</sup> current (<italic>I</italic><sub>Kr</sub>) in cardiac myocytes (<xref ref-type="bibr" rid="bib125">Vandenberg et al., 2012</xref>). This current plays a crucial role in the repolarization phase of the cardiac action potential (<xref ref-type="bibr" rid="bib110">Sanguinetti and Tristani-Firouzi, 2006</xref>). Perturbation to hERG channel function, resulting from genetic anomalies or pharmacological interventions, can precipitate multiple arrhythmogenic disorders (<xref ref-type="bibr" rid="bib110">Sanguinetti and Tristani-Firouzi, 2006</xref>).</p><p>The hERG channel is a homotetramer, with each subunit containing six membrane-spanning segments (S1âS6) (<xref ref-type="bibr" rid="bib131">Wang and MacKinnon, 2017</xref>). The segments S5 and S6, along with the intervening loops and pore helix, form the channel pore domain (PD), crucial for potassium ion passage along the central pore, while segments S1âS4 form the voltage-sensing domain (VSD), responding to voltage changes across the cell membrane. Notably, the hERG channel also features specialized intracellular regions: the Per-Arnt-Sim (PAS) domain at the N-terminus and the cyclic nucleotide-binding domain at the C-terminus.</p><p>The distinctive pharmacological promiscuity of the hERG channel makes it prone to blockade by a diverse array of drugs, creating cardiac safety pharmacology risk in the drug discovery process. Blockade of the hERG channel by drugs can lead to QT interval prolongation known as acquired long QT syndrome (aLQTS) and escalate the risk of <italic>torsades de pointes</italic> (TdP), a potentially fatal arrhythmia (<xref ref-type="bibr" rid="bib71">Li and Ramos, 2017</xref>). This issue has prompted the withdrawal of various drugs from the market and underscored the necessity of incorporating hERG safety evaluations in the drug development pipeline (<xref ref-type="bibr" rid="bib32">Ferri et al., 2013</xref>; <xref ref-type="bibr" rid="bib61">Kocadal et al., 2019</xref>; <xref ref-type="bibr" rid="bib127">Waldo et al., 1996</xref>). The susceptibility for drug blockade is not uniform but varies depending on the channel conformational state, a phenomenon known as state-dependent drug block. Drugs may preferentially bind to and block the channel in specific states (open, closed, or inactivated), which can differentially affect cardiac repolarization and rhythm (<xref ref-type="bibr" rid="bib98">Perrin et al., 2008</xref>; <xref ref-type="bibr" rid="bib103">Priest et al., 2008</xref>) and thus confer different risks for aLQTS and TdP arrhythmias as shown in our previous study (<xref ref-type="bibr" rid="bib137">Yang et al., 2020</xref>).</p><p>However, capturing the dynamic spectrum of hERG channel states poses a formidable challenge. While cryo-EM has offered invaluable insights into the putative open state of the channel (<xref ref-type="bibr" rid="bib5">Asai et al., 2021</xref>; <xref ref-type="bibr" rid="bib131">Wang and MacKinnon, 2017</xref>), a comprehensive view of the closed and inactivated states has remained elusive. Thus, even as we embark on a scientific era of explosive growth fueled by the convergence of protein structure insights, computational capabilities, and artificial intelligence based modeling and synthetic data, the next frontier is marked by the need to reveal all relevant conformational states of proteins. The existing knowledge gaps constrain both predictive capabilities regarding drugâprotein interactions and the creation of therapies through drug discovery to find specific and selective drugs, or in the case of hERG, to minimize their adverse interactions. For example, our recent study by Yang et al. introduced a multiscale model framework to forecast drug-induced cardiotoxicity at cellular and tissue levels, utilizing atomistic simulations of drug interactions with the hERG channel (<xref ref-type="bibr" rid="bib137">Yang et al., 2020</xref>). However, the absence of hERG structural models in the inactivated and closed states limited the predictive potential of atomistic scale simulations of state-specific drug binding.</p><p>The emergence of AlphaFold2, a protein structure prediction tool driven by machine learning, has brought a paradigm shift in structural biology (<xref ref-type="bibr" rid="bib53">Jumper et al., 2021a</xref>). AlphaFold2 represents a significant advance over previous methods by using deep learning to predict the three-dimensional structures of proteins (<xref ref-type="bibr" rid="bib53">Jumper et al., 2021a</xref>). AlphaFold2 primarily requires a proteinâs amino acid sequence as input, but it also leverages other critical data sources. In addition to the sequence, it incorporates multiple sequence alignments (MSAs) of related proteins from different species, available structural templates, and information on homologous proteins (<xref ref-type="bibr" rid="bib53">Jumper et al., 2021a</xref>). While the primary sequence encodes the 3D structure, AlphaFold2 harnesses evolutionary conservation from MSAs to reveal structural insights that extend beyond what a single protein sequence can provide. These additional inputs help the model to identify evolutionary and structural constraints that are crucial for accurate predictions. The output of AlphaFold2 is a predicted 3D structure of the protein that includes inter-residue distance predictions, whereby the model predicts the distances between every pair of amino acid residues in the protein. Predictions about the angles between bonds that connect amino acid residues are also generated as angle predictions that are crucial for determining the precise shape of the protein fold.</p><p>AlphaFold2âs limitation, in its default configuration, is that it generates only a single-state structure (<xref ref-type="bibr" rid="bib64">Lane, 2023</xref>), which for the hERG channel corresponds to the open state. In this study, we introduced an easily replicable and generally applicable approach to guide AlphaFold2 in predicting multiple, physiologically relevant conformations of proteins. By employing multiple structural templates and refining input parameters, we enhanced the predictive capabilities of AlphaFold2, enabling it to generate highly relevant and physically plausible protein conformations beyond the default single-state prediction. We conducted drug docking simulations to predict how specific drugs interact with the hERG channel in different conformational states and performed MD simulations to assess ion conduction across these states. Throughout the process, we validated our predictions by comparing them with experimental data, ensuring that both the drug interactions and ion conductive properties aligned with observed experimental outcomes. This method opens new possibilities for in silico studies of protein dynamics, drug design, and safety assessments, allowing researchers to explore the full range of conformational states that proteins may adopt.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Generating hERG channel conformational states</title><p>It is well known that the hERG channel resides in discrete functional states, minimally comprising closed, open, and inactivated states, which interconnect as a function of time and membrane voltage (<xref ref-type="bibr" rid="bib125">Vandenberg et al., 2012</xref>). In the open state, the channel conducts K<sup>+</sup> ions through a central pore. In contrast, the closed and inactivated states are non-conductive due to either a constricted pore at the intracellular gate (closed state) or a distorted selectivity filter (SF; inactivated state) (<xref ref-type="bibr" rid="bib125">Vandenberg et al., 2012</xref>). So far, published experimental cryo-EM structures resolved the channel in an open state (<xref ref-type="bibr" rid="bib5">Asai et al., 2021</xref>; <xref ref-type="bibr" rid="bib131">Wang and MacKinnon, 2017</xref>). Starting with the experimental structure, computational studies explored hERG inactivation by simulating how different membrane voltages can change the SF and thus affect ion conduction through the channel (<xref ref-type="bibr" rid="bib73">Li et al., 2021b</xref>; <xref ref-type="bibr" rid="bib83">Miranda et al., 2020</xref>; <xref ref-type="bibr" rid="bib137">Yang et al., 2020</xref>). These studies are essential but have some limitations, as the high voltages applied can force the channel into unnatural conformations, and the simulations are not long enough to allow observation of state transitions (<xref ref-type="bibr" rid="bib115">Shi et al., 2020</xref>). To overcome these limitations, we adopted different modeling strategies to guide AlphaFold2 in producing diverse conformations relevant to specific functional states of the hERG channel.</p><p>The first modeling strategy involves using a structural fragment from an experimental structure of a homologous protein that exhibits the desired characteristics of the target state we aim to model in our channel. This fragment serves as a structural template, and AlphaFold2 is used to rebuild the rest of the channel while adhering to the constraints of the template. For example, to model the closed state of the hERG channel, it is known that channel closure requires the voltage sensor in the voltage-sensing domain to be in a deactivated conformation. To achieve this, we used the deactivated voltage-sensing domain from the closed-state rat EAG channel cryo-EM structure (PDB 8EP1, residues H208âH343) (<xref ref-type="bibr" rid="bib80">Mandala and MacKinnon, 2022</xref>) and combined it with the SF from the open-state hERG cryo-EM structure (PDB 5VA2, residues I607âT634) (<xref ref-type="bibr" rid="bib131">Wang and MacKinnon, 2017</xref>). This hybrid structure was used as the template for AlphaFold2 predictions, as illustrated in <xref ref-type="fig" rid="fig1">Figure 1a</xref>. Using these discrete structural fragments, AlphaFold2 was then applied to generate 100 models, specifically configured to encourage diverse prediction outcomes for further analysis.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Generation of hERG channel models in the closed (<bold>a</bold>), open (<bold>b</bold>), and inactivated (<bold>c</bold>) states.</title><p>The lower limit of the pore radius color profile (1.15 Ã) indicates the minimum radius to accommodate a water molecule, and the upper limit (2.30 Ã) indicates sufficient space to fit two water molecules side-by-side. âMax seqâ is a setting in ColabFold that denotes the maximum number of cluster centers and extra sequences that the multiple sequence alignment (MSA) used for AlphaFold2 will be subsampled to. â# modelsâ indicates the number of models predicted using the provided structural templates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104901-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 1.</label><caption><title>An example illustrating the extension of our strategy to model alternative ion channel states using AlphaFold.</title><p>Deactivated VSD II from the cryo-EM structure of Na<sub>V</sub>1.7 (PDB 6N4R) (<xref ref-type="bibr" rid="bib135">Xu et al., 2019</xref>) is isolated and used as a structural template input for AlphaFold with a subsampled MSA. This guides AlphaFold to generate an Na<sub>V</sub>1.5 model with VSDs in the deactivated (S4 helices downward) conformation, representing a plausible closed state. Compared to a cryo-EM open-state Na<sub>V</sub>1.5 structure (PDB 6LQA, rightmost) (<xref ref-type="bibr" rid="bib72">Li et al., 2021a</xref>) with activated VSDs (S4 helices upward), the AlphaFold-predicted model displays a visibly narrower pore. This example demonstrates how our approach using targeted structural biasing can be used to model different ion channel states beyond hERG.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104901-fig1-figsupp1-v1.tif"/></fig></fig-group><p>For modeling the open hERG channel state, we utilized the existing cryo-EM structure of hERG (PDB 5VA2) (<xref ref-type="bibr" rid="bib131">Wang and MacKinnon, 2017</xref>) and rebuilt the missing extracellular loops using Rosetta (<xref ref-type="bibr" rid="bib34">Fleishman et al., 2011</xref>) with the results shown in <xref ref-type="fig" rid="fig1">Figure 1b</xref>. This reconstructed model served as a basis for MD and drug docking simulations.</p><p>The second modeling strategy addresses situations where structural information about state transitions is either limited or inconsistent. In this approach, we erase regions expected to undergo changes during state transition from an existing structure and use AlphaFold2 to sample potential conformations for these regions. This allows AlphaFold2 to identify possible substates, which are then grouped into clusters of structurally similar models for further analysis. For example, during hERG inactivation, the SF shifts from an open, conductive to a distorted, non-conductive conformation, as shown by numerous studies on hERG and other K<sup>+</sup> channels (<xref ref-type="bibr" rid="bib12">Butler et al., 2019</xref>; <xref ref-type="bibr" rid="bib24">Cuello et al., 2010</xref>; <xref ref-type="bibr" rid="bib31">Fan et al., 1999</xref>; <xref ref-type="bibr" rid="bib73">Li et al., 2021b</xref>; <xref ref-type="bibr" rid="bib100">Pettini et al., 2023</xref>; <xref ref-type="bibr" rid="bib113">SchÃ¶nherr and Heinemann, 1996</xref>; <xref ref-type="bibr" rid="bib120">Tan et al., 2022</xref>; <xref ref-type="bibr" rid="bib134">Wu et al., 2025</xref>). Moreover, there are a number of studies that do not uniformly suggest a single discrete structure of the inactivated-state SF but propose several alternative conformations (<xref ref-type="bibr" rid="bib65">Lau et al., 2024</xref>; <xref ref-type="bibr" rid="bib73">Li et al., 2021b</xref>).</p><p>To model the inactivated state of hERG, first we configured AlphaFold2 to introduce more uncertainty into the sampling process. As illustrated in <xref ref-type="fig" rid="fig1">Figure 1c</xref>, starting with the open-state cryo-EM structure (PDB 5VA2) (<xref ref-type="bibr" rid="bib131">Wang and MacKinnon, 2017</xref>), we removed everything except for the cytosolic domain (S660âR863), then let AlphaFold2 reconstruct the transmembrane domain. In half of the resulting predictions, including the top-ranked model by prediction confidence, the SF showed a distinct lateral flip of the backbone carbonyl oxygens at residue V625 compared to the open-state structure. This flip created a potential barrier that could prevent K<sup>+</sup> ions from crossing between the S3 and S2 ion-binding sites. To further investigate this conformation, we extracted the predicted SF region (residues Y607âT634) and merged them with the activated VSDs (W398âV549) and the cytosolic domain (S660âR863) from the open-state hERG structure (PDB 5VA2) (<xref ref-type="bibr" rid="bib131">Wang and MacKinnon, 2017</xref>) to create a new structural template. Then, we generated 100 more models for further analysis.</p></sec><sec id="s2-2"><title>Clustering of AlphaFold2-generated hERG models reveals predominant substates</title><p>A key distinction of our approach is that, rather than relying solely on single-model predictions, we generated a diverse population of models to better explore the conformational landscape. By clustering these models, we identified predominant substates, represented as clusters of structurally similar models. To determine which of these substates are likely to be physiologically relevant, we quantitatively assessed the structural reliability within each cluster using the predicted Local Distance Difference Test (pLDDT). Higher pLDDT scores indicate more reliable and accurate structural predictions (<xref ref-type="bibr" rid="bib53">Jumper et al., 2021a</xref>). This clustering approach helps to capture a range of conformations that might represent stable states of the protein.</p><p>For each predicted conformational state of hERG, we clustered 100 predicted structural models based by their degree of similarity, quantified by the root-mean-square deviation (RMSD), as shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Clustering of AlphaFold2-predicted hERG channel models.</title><p>(<bold>a</bold>) Clusters created from 100 models predicted for each state. Each structure visualized is colored according to the per-residue confidence metric (predicted Local Distance Difference Test, pLDDT). The closed-state models are clustered based on the backbone C<sub>Î±</sub> RMSD of the entire protein models. The inactivated and open-state models are clustered based on the all-atom RMSD of the selectivity filter (residues S624âG628). To represent each cluster, the top 5 models ranked by an average pLDDT are shown. The bar graphs display the mean pLDDT values for the clustered segments across all models within each cluster, with the standard deviations shown as error bars. Clusters containing less than three models are categorized as outliers. (<bold>b</bold>) The models chosen for subsequent analysis colored by per-residue pLDDT values.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104901-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2âfigure supplement 1.</label><caption><title>Protein backbone dihedral angle distributions of AlphaFold predicted models during inactivated-state-sampling and reference structures across key residues involved in ion selectivity and drug binding.</title><p>Histograms show the distribution of Phi (Ï) and Psi (Ï) protein backbone dihedral angles across 100 AlphaFold-predicted models and associated subunits (four each) for residues in the selectivity filter (S624 â G628) and drug-binding site residues in the pore-lining S6 segment (Y652 and F656). Overlayed colored markers represent Ï or Ï dihedral angles from the reference models used in the study: Open (PDB 5VA2, blue circles), AlphaFold inactivated-state-sampling representative models from cluster 2 and 3 (orange squares and purple diamonds, respectively), and closed (green triangles). The marker positions, representing the Ï or Ï dihedral angles of the key residues from all four subunits of the reference models, are placed along the x-axis at their corresponding angle values. Their height on the y-axis does not reflect how often they occur, but it is simply adjusted to prevent the markers from overlapping with each other. These distributions reveal that reference models span the dominant conformational populations of selectivity filter and drug binding residues predicted by AlphaFold. Since the reference models were relaxed using Rosetta to resolve steric clashes and improve structural quality, some of these marker angles may deviate slightly from the populated regions in the histograms.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104901-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2âfigure supplement 2.</label><caption><title>Comparison of the SF in hERG closed- (<bold>a, d</bold>), open- (<bold>b, e</bold>), and inactivated-state (<bold>c, f</bold>) models.</title><p>(<bold>a-c</bold>) Measurement of the distances between each carbonyl oxygen lining the conduction pathway in the SF. In the open- and closed-state models, S620 backbone carbonyl interacts with G626 and S624 backbone amide NH groups. In the inactivated-state model, the hydrogen bond between S620 and G626 is absent due to a reorientation of V625 backbone. However, at the bottom of the SF, S624 sidechain interacts with S623 backbone carbonyl from an adjacent subunit (denoted by *). (<bold>d-f</bold>) View of the SF from the extracellular side. For the closed- and inactivated-state models large black arrows indicate the rotation of the F627 side chains, while small black arrows show the rotation of the loops that connect the upper SF to the S6 helix, all relative to the equivalent structural elements in the open-state model.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104901-fig2-figsupp2-v1.tif"/></fig></fig-group><sec id="s2-2-1"><title>Closed-state clusters</title><p>The analysis of closed-state clusters showed only minor differences in RMSD and pLDDT values between them. When comparing the top-ranked models from each cluster, the all-atom RMSD between Cluster 1 (the cluster with the highest confidence) and Cluster 2 was just 0.36 Ã, while the RMSD between Cluster 1 and the outlier cluster was 0.95 Ã (outlier clusters are those with fewer than three members). This indicates small structural differences among the models. Aside from the outlier cluster, the average pLDDT scores for Clusters 1 and 2 were also very similar. The low RMSD values suggest that the predictions are converging on a similar overall conformation, with the minor differences likely due to slight variations in the positioning of the intracellular loop regions. As a result, the top-ranked model from Cluster 1 (<xref ref-type="fig" rid="fig2">Figure 2b</xref>) was selected for further simulations.</p></sec><sec id="s2-2-2"><title>Inactivated-state clusters</title><p>As inactivation is known to affect the SF, we grouped the models by focusing exclusively on similarity of the SF (S624âG628) conformations. We ranked the clusters according to the average pLDDT of these specific residues. This method led to the identification of four main clusters and one outlier. Cluster 1, which has the highest confidence score (pLDDT = 90.3 Â± 2.3, <italic>n</italic> = 27), contains models in which most SF carbonyl oxygens point inward, that is, toward the central axis, resembling an open-state SF conformation. In contrast, Cluster 2 (pLDDT = 85.2 Â± 1.6, <italic>n</italic> = 5) is distinguished by the outward flipping of the V625 carbonyl and a noticeable pore narrowing between the G626 carbonyls. Cluster 3 (pLDDT = 77.5 Â± 2.5, <italic>n</italic> = 27) is characterized by reorientation of the G626 carbonyls and, in rare cases, those of F627 residues. Cluster 4 (pLDDT = 57.5 Â± 1.7, <italic>n</italic> = 6) exhibits a mixed conformation that combines features of both Clusters 2 and 3, along with occasional rearrangement of S624 residues, although this rearrangement introduces steric clashes with neighboring side chains. In most models, particularly those in Clusters 2 and 3, the S6 helix undergoes varying degrees of rotation, leading to repositioning of the pore-lining drug-binding residues Y652 and F656, whose side chains extend further into the central cavity. The remaining models display SF conformations with varying combinations of features from previous clusters, but due to subunit-to-subunit variability, these were grouped as outliers.</p><p>Interestingly, the inactivated-state SF conformations predicted by AlphaFold coincide with proposed hERG C-type inactivation mechanisms as highlighted in other experimental and computational studies (<xref ref-type="bibr" rid="bib65">Lau et al., 2024</xref>; <xref ref-type="bibr" rid="bib73">Li et al., 2021b</xref>). Specifically, the flipping of V625 and the constriction at G626 carbonyls in Cluster 2 was previously reported in a recent study (<xref ref-type="bibr" rid="bib65">Lau et al., 2024</xref>). Moreover, Li et al<italic>.</italic>âs computational work revealed an asymmetric SF conformation, where two opposing subunits exhibited similar V625 flipping and G626 narrowing characteristics, while the other two subunits displayed the G626 and F627 carbonyl reorientation characteristic of our Cluster 3 (<xref ref-type="bibr" rid="bib73">Li et al., 2021b</xref>). Remarkably, AlphaFold2 was able to independently predict these conformations, despite the fact that they were not part of its training dataset, which had a cutoff year of 2021 (<xref ref-type="bibr" rid="bib53">Jumper et al., 2021a</xref>) and did not include simulated models.</p><p>To assess conformational variability, we examined backbone dihedral angles (phi Ï and psi Ï) at key residues in the SF (S624âG628) and drug-binding region on the pore-lining S6 segment (Y652 and F656), of all 100 models sampled here as shown in <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>. By overlaying the Ï and Ï dihedral angles from different models, including the open state (PDB 5VA2-based), the closed state, and representative models from AlphaFold inactivated-state-sampling Clusters 2 and 3, we found that these conformations consistently fall within or near high-probability regions of the dihedral angle distributions. This indicates that these structural states are well represented within the ensemble of conformations sampled by AlphaFold within the scope of this study, particularly at functionally critical positions.</p><p>Since the SF conformation in Cluster 2 has been observed experimentally (<xref ref-type="bibr" rid="bib65">Lau et al., 2024</xref>), but its overall pore architecture differs from our models, we selected the highest confidence model from this cluster as the representative model for initial structural comparisons and analyses. This model consistently shows flipping of SF residue V625 carbonyls, pinching (decreased distance) between SF residue G626 carbonyls, and rearrangement of drug-binding residues across all subunits. To broaden our assessment of potential inactivated structural models, we also conducted molecular simulations with the top model from Cluster 3 to evaluate its conformational behavior and functional relevance.</p></sec><sec id="s2-2-3"><title>Open-state clusters</title><p>As a control, we combined parts of the presumed open-state cryo-EM hERG structure (PDB 5VA2) (<xref ref-type="bibr" rid="bib131">Wang and MacKinnon, 2017</xref>), specifically the conductive SF, the activated VSDs, and the cytosolic domain, as the structural template for AlphaFold2 to test whether it would predict changes to the pore region similar to those observed in other statesâ predicted clusters. Post-prediction, all 100 generated models are nearly identical, converging almost uniformly into a single cluster. The highest scoring model closely mirrors the experimental open-state cryo-EM structure (<xref ref-type="bibr" rid="bib131">Wang and MacKinnon, 2017</xref>), with a virtually identical pore region. Given the minimal differences between the open-state models with Rosetta-rebuilt and AlphaFold-predicted loops, we would not expect any significant impact on our results had either been used. For consistency with prior studies and to facilitate direct comparison, we selected the experimental cryo-EM structure (PDB 5VA2) with loops rebuilt by Rosetta to represent the open state, as this structure and approach have been widely used as an open-state reference in our previous hERG channel studies (<xref ref-type="bibr" rid="bib83">Miranda et al., 2020</xref>; <xref ref-type="bibr" rid="bib137">Yang et al., 2020</xref>). As such, no models from this prediction were considered for further testing.</p></sec></sec><sec id="s2-3"><title>Comparison of hERG channel state models reveals structural differences in the SF and channel pore</title><p>After further structural refinement in Rosetta (<xref ref-type="bibr" rid="bib34">Fleishman et al., 2011</xref>; <xref ref-type="bibr" rid="bib69">Leman et al., 2020</xref>) to resolve steric clashes, the resulting models are compared in <xref ref-type="fig" rid="fig3">Figure 3</xref>. In <xref ref-type="fig" rid="fig3">Figure 3a, b</xref>, the closed-state model displayed the most constricted channel pore, followed by the inactivated state and then the open-state model. In the pore-lining S6 helix, the canonical drug-binding residue Y652 (<xref ref-type="bibr" rid="bib125">Vandenberg et al., 2012</xref>) retains a relatively consistent position with minor variation across all channel state models. The rotation and shift of the S6 helix in the inactivated and closed states affect the position of another canonical drug-binding residue, F656 (<xref ref-type="bibr" rid="bib125">Vandenberg et al., 2012</xref>). The adjustment caused the F656 side chain to extend more into the hERG inner cavity in both the closed and inactivated states, compared to the open state.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Structural comparison of different hERG channel state models.</title><p>(<bold>a</bold>) Visual comparison of the closed-, open-, and inactivated-state models. (<bold>b</bold>) Pore radius for the selectivity filter (SF) and drug-binding region (upper) and for the entire pore (lower). (<bold>c</bold>) Comparison of the voltage sensing domain (VSD) conformation in each model, showcasing the positively charged Arg and Lys gating-charge residues (yellow), located on the S4 helix, and the gating charge transfer center residue, F463 (magenta), on the S2 helix. (<bold>d</bold>) Distances between the C<sub>Î±</sub> atom of residue F463 to the C<sub>Î±</sub> atom of each of the gating-charge residues.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104901-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3âfigure supplement 1.</label><caption><title>Distance-based contact maps comparing intra- and intersubunit contacts between each model.</title><p>Two residues whose C<sub>Î±</sub> atoms are within 6 Ã of each other are considered to be in contact, provided there are no C<sub>Î±</sub> atoms belonging to a third residue in between. Black cells indicate no contacts. Gray cells indicate a contact is present in both states being compared. Blue, orange, and green colored cells indicate the interaction is present only in the open, inactivated, or closed state, respectively, but not in the other state being compared in the map. Colored topology labels are included along the left and bottom edges of the maps showing the specific segments of the hERG channel to which the residues correspond.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104901-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3âfigure supplement 2.</label><caption><title>Comparison of the S6 helix conformation for the hERG closed- (<bold>a</bold>), open- (<bold>b</bold>), and inactivated-state (<bold>c</bold>) models.</title><p>Residues E575 â L666 from the pore domain are visualized as dark gray ribbons. Selectivity filter (SF) residues and those on the S6 helix are shown with their backbone and side chains displayed as colored sticks. C atoms are gray, O are red, N are blue, S are yellow, H are not shown. The drug binding residues Y652 and F656 are highlighted in green.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104901-fig3-figsupp2-v1.tif"/></fig></fig-group><sec id="s2-3-1"><title>Selectivity filters</title><p>Shown in <xref ref-type="fig" rid="fig2s2">Figure 2âfigure supplement 2a, b</xref>, the SFs of the open- and closed-state models display similar conformations, with carbonyl oxygens along the ion path all oriented toward the central axis as in other K<sup>+</sup> channel structures, for example, KcsA and K<sub>V</sub>1.2, enabling efficient knock-on K<sup>+</sup> conduction (<xref ref-type="bibr" rid="bib28">Doyle et al., 1998</xref>; <xref ref-type="bibr" rid="bib78">Long et al., 2005</xref>). In contrast, the inactivated-state model SF is distinct, marked by the lateral rotation of the V625 backbone carbonyls away from the central axis (<xref ref-type="fig" rid="fig2s2">Figure 2âfigure supplement 2c</xref>), thereby creating a potential barrier preventing ion crossing. Additionally, we noted a constriction between the G626 backbone carbonyls and a repositioning of the S624 side chain hydroxyl oxygens. In the model representing the inactivated state, the carbonyl oxygens of G628 and F627 exhibit an upward shift relative to their positions in the open-state model. <xref ref-type="fig" rid="fig2s2">Figure 2âfigure supplement 2d-f</xref> presents the SF of all three models from an extracellular perspective. In both the closed- and inactivated-state models, the F627 side chain undergoes a clockwise rotation when contrasted with its orientation in the open state. This rotational behavior aligns with findings from a prior simulation study (<xref ref-type="bibr" rid="bib83">Miranda et al., 2020</xref>) where it was noted in a metastable non-conductive state. The loop that links the upper SF to the S6 helix rotates anti-clockwise relative to its position in the open-state model, consequently narrowing the upper part of the SF.</p></sec><sec id="s2-3-2"><title>VSDs</title><p>For the VSD, we measured the distances between the backbone C<sub>Î±</sub> atoms of the gating charge residues (K525, R528, R531, R534, R537, and K538) on the S4 helix and the gating charge transfer center residue F463 on the S2 helix, as shown in <xref ref-type="fig" rid="fig3">Figure 3c</xref>. Although we observed an increased distance between the gating charge residues and the charge transfer center residue in the closed state, this separation was not due to a straight downward movement of the S4 helix. Instead, the closed-state model S4 exhibited a minor kink around residue R531 and lateral movement toward the channel center, impacting the S4âS5 linker and consequently nudging the S5 helix inward, effectively narrowing the pore. The predicted closed-state model exhibits lower confidence levels for the S4 helix and S4âS5 linker residues (pLDDT â¤75) when compared to their counterparts in models of other states, necessitating caution in interpreting the physiological implications of this observation. Conversely, the pore region, which demonstrates closure, is characterized by a higher prediction confidence (pLDDT â¥75), suggesting a more robust and reliable structural representation. <xref ref-type="video" rid="video1">Video 1</xref> shows an animation of state changes of the hERG channel models.</p><media mimetype="video" mime-subtype="mp4" xlink:href="elife-104901-video1.mp4" id="video1"><label>Video 1.</label><caption><title>Animation depicting the hERG channel transitioning through various states, beginning in the open state and ending in the closed state using the structural models developed in this study.</title></caption></media></sec><sec id="s2-3-3"><title>Interaction networks</title><p>We aimed to further investigate the molecular interactions that contributed to channel inactivation through modulation of the SF conformation. In <xref ref-type="fig" rid="fig4">Figure 4</xref>, we analyzed residue-residue interactions of extracellular S5-P linker (I583âQ592) along with SF and surrounding SF residues (S620âN633, <xref ref-type="fig" rid="fig4">Figure 4a</xref>) through heatmaps detailing hydrogen bonding, Ï stacking, cationâÏ, and salt bridge formation similarities and differences (<xref ref-type="table" rid="table1">Table 1</xref> shows detection criteria; distance-based contact maps (<xref ref-type="bibr" rid="bib91">Noel et al., 2012</xref>) for all residues are shown in <xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1</xref>). Distinct interaction patterns between open- and inactivated-state models were observed in these regions (<xref ref-type="fig" rid="fig4">Figure 4b, c</xref>). In the open-state model, N633 atop the SF forms hydrogen bonds with S5-P linker G584 from the same and Q592 from an adjacent subunit, while N629 forms hydrogen bonds with an adjacent-subunit S631. Additionally, SF G626 forms an intra-subunit hydrogen bond with S620 behind the SF. Within the S5-P linker, N588 and D591 also display hydrogen bonding. However, these stabilizing interactions in the open-state model SF region are absent in the inactivated-state model, where only intra-subunit hydrogen bonds between I583 (S5-P linker) and N633 (SF) occur, along with V630 hydrogen bonding with the same-subunit N629 atop the SF. To corroborate our findings, mutations involving the residues discussed above have been shown to impact hERG inactivation as evidenced in numerous clinical and experimental studies (<xref ref-type="bibr" rid="bib11">Butler et al., 2018</xref>; <xref ref-type="bibr" rid="bib21">Clarke et al., 2006</xref>; <xref ref-type="bibr" rid="bib23">Cordeiro et al., 2005</xref>; <xref ref-type="bibr" rid="bib30">Dun et al., 1999</xref>; <xref ref-type="bibr" rid="bib31">Fan et al., 1999</xref>; <xref ref-type="bibr" rid="bib33">Ficker et al., 1998</xref>; <xref ref-type="bibr" rid="bib83">Miranda et al., 2020</xref>; <xref ref-type="bibr" rid="bib88">Nakajima et al., 1998</xref>; <xref ref-type="bibr" rid="bib111">Satler et al., 1998</xref>) (see <xref ref-type="table" rid="table2">Table 2</xref> for more details).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Interaction network analysis showcasing residueâresidue interactions in the S5-P linker (residues I583âQ592) and region surrounding the selectivity filter (SF) (residues S620âN633).</title><p>(<bold>a</bold>) An image of a hERG channel subunit with the analyzed S5-P linker and SF regions colored in light green and light blue, respectively. (<bold>b</bold>) Heatmaps showing intrasubunit and intersubunit (marked by X) interactions between each residue in the analyzed regions. The interactions analyzed are hydrogen bonding, Ï stacking, cationâÏ, and salt bridges. Black cells indicate no interactions. Gray cells indicate an interaction is present in both states. Blue, orange, and green colored cells indicate the interaction is present only in the open, inactivated, or closed state, respectively, but not in the other state being compared in the map. White lines are added to separate S5-P linker residues from the SF region residues. (<bold>câe</bold>) Visualization of the interactions being present in one state but not the other. Gold-colored residues are involved in the interactions. Green-colored residues, named with an asterisk at the end, are from an adjacent subunit but are interacting with gold-colored residues. Dashed lines represent hydrogen bonds.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104901-fig4-v1.tif"/></fig><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Criteria for different types of non-bonded interactions used in analyses.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Types of interaction</th><th align="left" valign="bottom">Detection criteria</th><th align="left" valign="bottom">Filtering criteria</th></tr></thead><tbody><tr><td align="left" valign="bottom">Hydrogen bonds</td><td align="left" valign="bottom">Distance between the hydrogen bond donor (D) and acceptor (A) should be less than 3.8 Ã.<break/>The angle D-H...A should be above 110Â°.</td><td align="left" valign="bottom">Hydrogen bonds between atoms that already form a salt bridge are excluded.<break/>A hydrogen bond donor can participate in only one hydrogen bond, while acceptor atoms can form multiple hydrogen bonds.</td></tr><tr><td align="left" valign="bottom">Salt bridges</td><td align="left" valign="bottom">Geometric centers of oppositely charged groups that come within 4.5 Ã.</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">CationâÏ</td><td align="left" valign="bottom">Pairing of a positive charge and an aromatic ring if the distance between the charge center and the aromatic ring center is less than 6 Ã.</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Ï-Stacking</td><td align="left" valign="bottom">Geometric centers of two aromatic rings within 5.5 Ã. The angle between the rings should deviate no more than 30Â° from the optimal angle (90Â° for T-stacking, 180Â° for P-stacking). When projecting each ring center onto the opposite ring plane, the distance between the other ring center and the projected point (offset) should be less than 2 Ã.</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Mutations known to affect hERG channel inactivation.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Mutation(s)</th><th align="left" valign="bottom">Reported impact on hERG channel</th><th align="left" valign="bottom">References</th></tr></thead><tbody><tr><td align="left" valign="bottom">N629D, N629S, N633S</td><td align="left" valign="bottom">Disrupt inactivation and K<sup>+</sup> selectivity</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib68">Lees-Miller et al., 2000b</xref>; <xref ref-type="bibr" rid="bib111">Satler et al., 1998</xref></td></tr><tr><td align="left" valign="bottom">H587P/K</td><td align="left" valign="bottom">Disrupts C-type inactivation and K<sup>+</sup> selectivity</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib30">Dun et al., 1999</xref></td></tr><tr><td align="left" valign="bottom">S631A</td><td align="left" valign="bottom">Causes positive shift in half-inactivation voltage</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib11">Butler et al., 2018</xref>; <xref ref-type="bibr" rid="bib143">Zou et al., 1998</xref></td></tr><tr><td align="left" valign="bottom">S631C</td><td align="left" valign="bottom">Speeds up fast inactivation</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib31">Fan et al., 1999</xref></td></tr><tr><td align="left" valign="bottom">N588K/E, Q592K</td><td align="left" valign="bottom">Modulate rapid inactivation</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib21">Clarke et al., 2006</xref>; <xref ref-type="bibr" rid="bib23">Cordeiro et al., 2005</xref></td></tr><tr><td align="left" valign="bottom">D591R/Q592R</td><td align="left" valign="bottom">Inhibit inactivation</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib21">Clarke et al., 2006</xref></td></tr><tr><td align="left" valign="bottom">G584S</td><td align="left" valign="bottom">Leads to inactivation gating defects</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib141">Zhao et al., 2009</xref></td></tr><tr><td align="left" valign="bottom">S620T</td><td align="left" valign="bottom">Abolishes hERG inactivation</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib33">Ficker et al., 1998</xref></td></tr><tr><td align="left" valign="bottom">V630L</td><td align="left" valign="bottom">Causes negative shift in steady-state inactivation</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib88">Nakajima et al., 1998</xref></td></tr><tr><td align="left" valign="bottom">N588C, I583C</td><td align="left" valign="bottom">High and intermediate impact on hERG inactivation</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib77">Liu et al., 2002</xref></td></tr></tbody></table></table-wrap><p>The open- and closed-state models show fewer differences in their SF hydrogen bond networks compared to those between the open and inactivated states (<xref ref-type="fig" rid="fig4">Figure 4b, d</xref>). In the open-state model, D591 from the S5-P linker forms an intra-subunit hydrogen bond with N588, and G584 hydrogen-bonds with N633 at the top of the SF. These interactions are absent in the closed-state model, where H587 (instead of N588) hydrogen-bonds with D591 within the S5-P linker, and I583 (replacing G584) interacts with N633 at the SF top. Additionally, G628 from an adjacent subunit forms a hydrogen bond with N629 atop the SF. Analyzing the differences between the inactivated- and closed-state model (<xref ref-type="fig" rid="fig4">Figure 4e</xref>), the inactivated-state model uniquely features an intra-subunit V630âN629 hydrogen bond, whereas the closed-state model exhibits intersubunit hydrogen bonds between N633 and Q592, and between S631/G628 and N629. Furthermore, in the closed-state model, S620 forms an intra-subunit hydrogen bond with G626, stabilizing the SF conformation.</p></sec><sec id="s2-3-4"><title>S6 pore-lining helix</title><p>In <xref ref-type="fig" rid="fig3s2">Figure 3âfigure supplement 2</xref>, we compared the S6 helix orientation across various models. The closed-state model features a mostly straight S6 helix. On the contrary, both the open- and inactivated-state models exhibit a pronounced kink around I655, as identified in a prior study (<xref ref-type="bibr" rid="bib122">Thouta et al., 2014</xref>), which facilitates pore opening and distinguishes the inactivated state from the closed-state model. Notably, a slight rotation differentiates the S6 helix in the open- and inactivated-state models, altering the conformation of drug-binding residues Y652 and to a greater extent, F656. The interaction network analysis results from <xref ref-type="fig" rid="fig4">Figure 4b, c</xref> suggest that alterations in the hydrogen bond network around the SF region, during the transition from open to inactivated state, might pull on the S6 helix and influence its orientation (<xref ref-type="fig" rid="fig3s2">Figure 3âfigure supplement 2b, c</xref>) â a subtle yet potentially impactful change for drug binding. In agreement with our observations, a study by Helliwell et al. also suggested that a slight clockwise rotation of the S6 helix in the hERG open-state cryo-EM structure (<xref ref-type="bibr" rid="bib131">Wang and MacKinnon, 2017</xref>) could align the S6 aromatic side chains, particularly F656, into a configuration enabling interactions with inactivation-dependent blockers that more accurately reflects experimental data (<xref ref-type="bibr" rid="bib43">Helliwell et al., 2018</xref>).</p></sec></sec><sec id="s2-4"><title>MD simulations show K<sup>+</sup> ion conduction in the open-state model but not in the inactivated state</title><p>We performed all-atom MD simulations on two hERG channel models described above, one in the open state and the other in the predicted inactivated state, to evaluate their ion conduction capabilities. Unlike the closed-state model, both open- and inactivated-state models should allow ions and water to enter and traverse the channel pore reaching the SF region. However, only the open-state model is expected to facilitate ion conduction through its SF.</p></sec><sec id="s2-5"><title>Ion conductivity</title><p>To investigate ion conduction in the SF, we considered two conditions, as shown in <xref ref-type="fig" rid="fig5s1">Figure 5âfigure supplement 1a</xref> one in which the SF initially contained only K<sup>+</sup> ions and another in which both ions and water were present to test previously proposed direct (or Coulombic) and water-mediated K<sup>+</sup> conduction knock-on mechanisms (<xref ref-type="bibr" rid="bib63">Lam and de Groot, 2023</xref>; <xref ref-type="bibr" rid="bib106">Roux, 2017</xref>) as in a previous study (<xref ref-type="bibr" rid="bib83">Miranda et al., 2020</xref>). In the direct knock-on (ions-only) scenario, we manually positioned K<sup>+</sup> atoms in the putative K<sup>+</sup>-binding sites of S0, S2, S3, and S4 within the SF. For the water-mediated knock-on (the alternating ions and water molecules) scenario, K<sup>+</sup> ions were placed in the S1, S3, and S<sub>cav</sub> positions, while water molecules were inserted into the S0, S2, and S4 positions. These models were incorporated into phospholipid bilayers consisting of <italic>1-palmitoyl-2-oleoylphosphatidylcholine</italic> (POPC) molecules and hydrated by 0.30 M KCl, as depicted in <xref ref-type="fig" rid="fig5s1">Figure 5âfigure supplement 1b</xref>. Subsequently, we conducted MD simulations for each case under three membrane voltage conditions: 0, 500, and 750 mV, each lasting 1 Î¼s. This resulted in a total of six MD simulations for each model.</p><p>In all instances where a non-zero membrane voltage was applied after equilibration, we observed K<sup>+</sup> conduction for the open-state model (<xref ref-type="fig" rid="fig5">Figure 5a, c</xref> and <xref ref-type="fig" rid="fig5s2">Figure 5âfigure supplement 2a, c</xref>), whereas such conduction was not observed for the inactivated-state model (<xref ref-type="fig" rid="fig5">Figure 5b, d</xref> and <xref ref-type="fig" rid="fig5s2">Figure 5âfigure supplement 2b, d</xref>). For ions-only initial SF arrangement, we observed that all K<sup>+</sup> ions initially located in the SF went across during 1 Î¼s MD runs under applied 750 and 500 mV membrane voltages (<xref ref-type="fig" rid="fig5">Figure 5a</xref> and <xref ref-type="fig" rid="fig5s2">Figure 5âfigure supplement 2</xref>), whereas for the alternating water-ion initial SF configuration, we observed conduction of SF ions as well as additional K<sup>+</sup> ions moving all the way across the channel pore (<xref ref-type="fig" rid="fig5">Figure 5c</xref> and <xref ref-type="fig" rid="fig5s2">Figure 5âfigure supplement 2c</xref>). In both cases, we saw a combination of direct and water-mediated knock-on mechanisms, as in our previous hERG channel MD simulations (<xref ref-type="bibr" rid="bib83">Miranda et al., 2020</xref>; <xref ref-type="bibr" rid="bib137">Yang et al., 2020</xref>). Control MD simulations conducted under zero voltage conditions revealed a single K<sup>+</sup> SF conduction event for the open-state model (<xref ref-type="fig" rid="fig5s2">Figure 5âfigure supplement 2g</xref>) when the SF was initially filled with water molecules and ions, while no conduction events were observed in the remaining cases (<xref ref-type="fig" rid="fig5s2">Figure 5âfigure supplement 2e, f, h</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Movement of K<sup>+</sup> ions through hERG selectivity filter (SF) during all-atom molecular dynamics (MD) simulations with the applied membrane voltage.</title><p>The <italic>z</italic> coordinates of K<sup>+</sup> ions are tracked as they traverse the pore of the hERG channel from the intracellular gate (lower <italic>y</italic>-axis limit) to the extracellular space (upper <italic>y</italic>-axis limit) under the membrane voltage of 750 mV. Putative K<sup>+</sup>-binding sites in the SF (S0âS5) are marked using blue dashed lines in the plots. Results from MD simulations on the open-state model with the SF occupancy initially configured to have only K<sup>+</sup> ions (<bold>a</bold>) or alternating K<sup>+</sup>/water molecules (<bold>c</bold>), respectively. Results from MD simulations on the inactivated model with the SF occupancy initially configured to have only K<sup>+</sup> ions (<bold>b</bold>) or alternating K<sup>+</sup>/water molecules (<bold>d</bold>), respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104901-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5âfigure supplement 1.</label><caption><title>Setup of MD simulations to assess ion conduction in the open and inactivated hERG channel models.</title><p>(<bold>a</bold>) Initial configuration of the SF, set to fill with either all K<sup>+</sup> ions (top), or alternating K<sup>+</sup> and water molecules (bottom). (<bold>b</bold>) An example MD simulation box showing a hERG channel model (shown in yellow surface representation) embedded in POPC lipid bilayer (shown as sticks) and solvated by an aqueous 0.3 M KCl solution (shown as a transparent surface with K<sup>+</sup> and Cl<sup>-</sup> ions shown as purple and green balls, respectively).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104901-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5âfigure supplement 2.</label><caption><title>Movement of K<sup>+</sup> ions through hERG selectivity filter (SF).</title><p>The z coordinates of K<sup>+</sup> ions are tracked as they traverse through the pore of the channel from the intracellular gate (lower y-axis limit) to the extracellular space (upper y-axis limit). Putative K<sup>+</sup> binding sites in the SF (S0 â S5) are marked using blue dashed lines in the plots. (<bold>a, c</bold>) Molecular dynamics (MD) simulations with the applied 500 mV membrane voltage of the open-state model with the SF initially configured to have only K<sup>+</sup> ions (<bold>a</bold>) or alternating K<sup>+</sup> / water molecules (<bold>c</bold>), respectively. (<bold>b, d</bold>) MD simulations with the applied 500 mV membrane voltage of the inactivated-state model with the SF initially configured to have only K<sup>+</sup> ions (<bold>b</bold>) or alternating K+ / water molecules (<bold>d</bold>), respectively. (<bold>e, g</bold>) MD simulations without applied membrane voltage of the open-state model with the SF initially configured to have only K<sup>+</sup> ions (<bold>e</bold>) or alternating K<sup>+</sup> / water molecules (<bold>g</bold>), respectively. (<bold>f, h</bold>) MD simulations without applied membrane voltage of the inactivated-state model with the SF initially configured to have only K<sup>+</sup> ions (<bold>f</bold>) or alternating K<sup>+</sup> / water molecules (<bold>h</bold>), respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104901-fig5-figsupp2-v1.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5âfigure supplement 3.</label><caption><title>Analysis of modulations of the selectivity filter (SF) conformations and pore radii over the course of the 1 Âµs long molecular dynamics (MD) simulations.</title><p>The blue/orange-colored lines represent the average pore radii, and the shaded regions represent the standard deviation measured in MD simulations for a given Z value. The black lines represent the initial pore radii. The label on the left indicates the voltage of the MD simulations in each row.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104901-fig5-figsupp3-v1.tif"/></fig><fig id="fig5s4" position="float" specific-use="child-fig"><label>Figure 5âfigure supplement 4.</label><caption><title>Analysis of dynamics of the SF and pore conformations over the course of the 1 Âµs MD simulations.</title><p>(<bold>a</bold>) Pore radius averaged over each 1 Âµs long MD simulations with (right) or without (left) applied membrane voltage. Open- and inactivated-state model MD simulations are notated as O and I, respectively, with the subscripts KK and WK denoting whether the SF initially configured to have only K<sup>+</sup> ions or alternating K<sup>+</sup> / water molecules, respectively. (<bold>b</bold>) Ensembles of SF conformation over the course of each MD simulation superimposed. The golden-colored conformation indicates the initial conformation.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104901-fig5-figsupp4-v1.tif"/></fig><fig id="fig5s5" position="float" specific-use="child-fig"><label>Figure 5âfigure supplement 5.</label><caption><title>Representative model from the AlphaFold predicted inactivated-state-sampling cluster 3 (AF ic3).</title><p>(<bold>a</bold>) Structural overview of the representative model from AlphaFold inactivated-state sampling cluster 3, with pore radius mapped along the ion conduction pathway. The SF is highlighted, showing a flipped G626 carbonyl oxygen, deviating from the canonical ion-coordination geometry. (<bold>b</bold>) Structural comparison of the cluster 3 model with closed, open, and inactivated state models. Despite the G626 rearrangement, the overall pore conformation most closely resembles the open-state structure. (c-d) Molecular dynamics simulations under 750 mV applied voltage show Kâº ion permeation through the inactivated-state-sampling cluster 3 model. The z-coordinates of Kâº ions are plotted over time, tracking their position along the pore axis from intracellular (bottom) to extracellular (top) side. Horizontal dashed lines indicate canonical Kâº binding sites in the selectivity filter (S0âS5). (<bold>c</bold>) MD simulation with Kâº ions initially placed in the selectivity filter. (<bold>d</bold>) MD simulation with both Kâº ions and water molecules initially placed in the selectivity filter. In both cases, Kâº ions stably occupied and permeated the SF across on the microsecond timescales, demonstrating that this model supports Kâº conduction. These results suggest that, despite structural deviations from the PDB 5VA2-based open-state model, the cluster 3 model represents an alternative open-like conformation functionally capable of ion conduction.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104901-fig5-figsupp5-v1.tif"/></fig><fig id="fig5s6" position="float" specific-use="child-fig"><label>Figure 5âfigure supplement 6.</label><caption><title>Cross-subunit distances between carbonyl oxygens of open-state hERG selectivity filter residues during MD simulations under different applied voltage and initial K<sup>+</sup> ion position conditions.</title><p>Movement of potassium ions (denoted by differently colored lines) across the SF is shown at the bottom for reference. In top graphs red lines indicate initial distances. Labels 1 and 2 in red and blue, respectively, indicate a sequential dilation process exhibited by the hERG channel: the SF near residues F627 dilates first, followed by that around G628 SF residues.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104901-fig5-figsupp6-v1.tif"/></fig><fig id="fig5s7" position="float" specific-use="child-fig"><label>Figure 5âfigure supplement 7.</label><caption><title>Sequential dilation steps of hERG upper selectivity filter (SF).</title><p>SF residues are shown as gray sticks, water molecules as red and white spheres, and K<sup>+</sup> as purple spheres. The first step, occurring around 100 ns, involves the flipping of F627 carbonyl oxygen, creating a small dilation at this level. At 500 ns, further dilation can be seen at the level of residues F627 and G628 in one subunit. At 1000 ns, the entire upper region of the SF dilates further. Frames were taken from an MD simulation of the open-state hERG channel with K<sup>+</sup> and water initially in the SF prior to application of the transmembrane voltage of 750 mV.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104901-fig5-figsupp7-v1.tif"/></fig></fig-group><sec id="s2-5-1"><title>Conformational changes during MD</title><p>Subsequently, we conducted an analysis of pore radius changes throughout the MD simulations (see full results in <xref ref-type="fig" rid="fig5s3">Figure 5âfigure supplement 3</xref>). In under zero voltage conditions, we observed consistent and distinct pore radius profiles across all simulations within their respective models (left panel in <xref ref-type="fig" rid="fig5s4">Figure 5âfigure supplement 4a</xref>). Specifically, MD simulations featuring the inactivated-state model consistently displayed a narrower pore radius when compared to simulations involving the open-state model. However, when subjected to high-voltage conditions, the open-state model exhibited a shift toward an inactivated-like state, leading to a reduction in the pore width (right panel in <xref ref-type="fig" rid="fig5s4">Figure 5âfigure supplement 4a</xref>), which is consistent with an increased hERG channel inactivation propensity at more depolarized voltages (<xref ref-type="bibr" rid="bib125">Vandenberg et al., 2012</xref>).</p><p>Although we did not observe the outward flipping of the V625 backbone carbonyl oxygens in the SF during the 1 Î¼s long MD simulations of the open-state model, we did observe the flipping of the F627 backbone carbonyl oxygens as shown in <xref ref-type="fig" rid="fig5s4">Figure 5âfigure supplement 4b</xref>. Interestingly, this specific SF conformation, with flipped F627 but inward-facing V625 carbonyl oxygens, is also present in Cluster 3 of the AlphaFold-predicted models in <xref ref-type="fig" rid="fig2">Figure 2</xref>. To explore this further, we investigated the top model from inactivated-state-sampling Cluster 3, which had not been included in prior simulations (<xref ref-type="fig" rid="fig5s5">Figure 5âfigure supplement 5</xref>). This model features flipped G626 and G628 backbone carbonyls while maintaining an inward-facing V625 carbonyl oxygen conformation (<xref ref-type="fig" rid="fig5s5">Figure 5âfigure supplement 5a, b</xref>). To evaluate the functional relevance of this SF configuration in the new model, we performed additional MD simulations (two replicates, 1 Î¼s each at 750 mV) with varied initial K<sup>+</sup> ion and water arrangements. Both simulations showed multiple K<sup>+</sup> conduction events (<xref ref-type="fig" rid="fig5s5">Figure 5âfigure supplement 5c, d</xref>) for this model, supporting our earlier observation that dilation of the upper SF can still permit ion conduction, provided that residue V625 backbone carbonyls remain inward-facing. As a result, we named this model Open (AlphaFold inactivated-state-sampling Cluster 3, or AF ic3) to differentiate it from the Open (PDB 5VA2-based) model.</p><p>These findings further highlight the critical role of V625 in regulating ion conduction through the SF of the hERG channel. In the inactivated-state model simulations, elevated membrane voltage increased the likelihood of V625 backbone carbonyls adopting a conductive orientation (inward-facing). However, even a single outward-facing V625 carbonyl oxygen was sufficient to block K<sup>+</sup> conduction through the SF.</p></sec></sec><sec id="s2-6"><title>Comparison with previously reported K<sup>+</sup> channel C-type inactivation mechanisms</title><p>Cuello et al. in their study of KcsA channel identified a similar constriction at G77 within the SF and a corresponding reorientation of the V76 carbonyl, resulting in a dilation in the SF at this location and corresponding loss of the S2 and S3 ion-binding sites (<xref ref-type="bibr" rid="bib24">Cuello et al., 2010</xref>). They suggested this backbone rearrangement as a fundamental molecular mechanism underlying C-type inactivation in K<sup>+</sup> channels (<xref ref-type="bibr" rid="bib24">Cuello et al., 2010</xref>). In other studies on Shaker and K<sub>v</sub>1.3 channels, dilation in the upper SF that disrupts the S1 and S2 K<sup>+</sup>-binding sites has been proposed to be a potential C-type inactivation mechanism (<xref ref-type="bibr" rid="bib18">Chandy et al., 2023</xref>; <xref ref-type="bibr" rid="bib114">Selvakumar et al., 2022</xref>; <xref ref-type="bibr" rid="bib120">Tan et al., 2022</xref>; <xref ref-type="bibr" rid="bib124">Tyagi et al., 2022</xref>). Similar dilations in the SF are also predicted by AlphaFold2, particularly within Cluster 3 of the predicted inactivated-state hERG channel clusters shown in <xref ref-type="fig" rid="fig2">Figure 2a</xref>. Although these models were not simulated under our study, such dilated conformations of the SF also emerged during our MD simulations of the open-state model under applied voltage.</p><p>We further compared SF conformations by plotting the cross-subunit distances between the carbonyl oxygen atoms of SF residues of open-state hERG channel MD simulations at 750 and 500 mV applied voltages, as shown in <xref ref-type="fig" rid="fig5s6">Figure 5âfigure supplement 6</xref>. The dilation observed in the hERG channel, which also occurs in the upper SF, differs from that in the aforementioned K<sup>+</sup> channels. In Shaker-family channels, the most considerable widening occurs at the SF tyrosine residue (Y445 in Shaker/Y377 in K<sub>V</sub>1.2) immediately below the topmost SF residue (G446 in Shaker/G378 in K<sub>V</sub>1.2) (<xref ref-type="bibr" rid="bib120">Tan et al., 2022</xref>; <xref ref-type="bibr" rid="bib134">Wu et al., 2025</xref>). Conversely, in the hERG channel, the topmost SF residue (G628) exhibits the most significant widening, followed by the residue immediately below it (F627). Our MD simulations of the hERG channel reveal that its dilation process involves two sequential steps: SF near residues F627 dilates first, followed by SF near topmost G628 residues. The latter step occurs faster at higher voltages (750 mV) compared to lower voltages (500 mV). We present these steps in <xref ref-type="fig" rid="fig5s7">Figure 5âfigure supplement 7</xref>. Notably, despite the dilation of the hERG SF, ion conduction is still observed across all replicas, in contrast to the Shaker channel (<xref ref-type="bibr" rid="bib18">Chandy et al., 2023</xref>; <xref ref-type="bibr" rid="bib114">Selvakumar et al., 2022</xref>; <xref ref-type="bibr" rid="bib120">Tan et al., 2022</xref>; <xref ref-type="bibr" rid="bib124">Tyagi et al., 2022</xref>).</p></sec><sec id="s2-7"><title>Computational drug docking reveals state-specific differences in drug-binding affinities</title><p>We utilized Rosetta GALigandDock software (<xref ref-type="bibr" rid="bib95">Park et al., 2021</xref>) to dock 19 drugs from different classes, considering their multiple protonation states, into our hERG state-specific channel models. This process aimed to evaluate and corroborate state-dependent binding interactions with experimental studies, specifically in terms of relative binding affinities. <xref ref-type="fig" rid="fig6s1">Figure 6âfigure supplement 1</xref> presents these findings in the form of Rosetta GALigandDock (<xref ref-type="bibr" rid="bib95">Park et al., 2021</xref>) binding energies (lower, more negative values mean more favorable binding). Consistent with published studies, most drugs showed stronger binding to the inactivated-state hERG channel model, including astemizole, terfenadine, cisapride, d/l-sotalol, dofetilide (<xref ref-type="bibr" rid="bib33">Ficker et al., 1998</xref>; <xref ref-type="bibr" rid="bib57">Kamiya et al., 2008</xref>; <xref ref-type="bibr" rid="bib98">Perrin et al., 2008</xref>), haloperidol (<xref ref-type="bibr" rid="bib119">Suessbrich et al., 1997</xref>), and E-4031 (<xref ref-type="bibr" rid="bib92">Numaguchi et al., 2000</xref>; <xref ref-type="bibr" rid="bib129">Wang et al., 1997</xref>). Drugs like moxifloxacin (<xref ref-type="bibr" rid="bib3">Alexandrou et al., 2006</xref>), quinidine (<xref ref-type="bibr" rid="bib98">Perrin et al., 2008</xref>), verapamil (<xref ref-type="bibr" rid="bib29">Duan et al., 2007</xref>), and perhexiline (<xref ref-type="bibr" rid="bib98">Perrin et al., 2008</xref>) did not show strong preference for the inactivated-state model, aligning with findings from hERG experimental studies using inactivation-deficient mutants (<xref ref-type="bibr" rid="bib98">Perrin et al., 2008</xref>) or âstep-rampâ voltage protocol (<xref ref-type="bibr" rid="bib3">Alexandrou et al., 2006</xref>).</p><p>As a control, we also included docking results for the presumed open-state model from inactivated-state-sampling Cluster 3 (referred to as Open, AF ic3). Although its SF differs from both the experimental open and predicted inactivated-state models, our previous simulations confirmed that it supports ion conduction. Structurally, its pore most closely resembles the open state (<xref ref-type="fig" rid="fig5s5">Figure 5âfigure supplement 5b</xref>) with only minor differences, and accordingly, its drug docking profile aligns well with that of the open-state model. These results further support the interpretation that the Cluster 3 model represents an alternative open-state conformation. <xref ref-type="table" rid="table3">Table 3</xref> provides an overview of all models examined, along with qualitative insights into their observed behaviors thus far.</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Overview of models and qualitative observations.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Model</th><th align="left" valign="bottom">Origin</th><th align="left" valign="bottom">K<sup>+</sup> ion conduction</th><th align="left" valign="bottom">Qualitative drug-binding trend</th></tr></thead><tbody><tr><td align="left" valign="bottom">Open (5VA2)</td><td align="left" valign="bottom">Based on hERG cryo-EM structure PDB 5VA2 (<xref ref-type="bibr" rid="bib131">Wang and MacKinnon, 2017</xref>) with loops rebuilt using Rosetta</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Low affinity for drugs known to bind preferentially to the inactivated state</td></tr><tr><td align="left" valign="bottom">Inactivated</td><td align="left" valign="bottom">Top model from Cluster 2 in AlphaFold inactivated-state-sampling attempt</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">High affinity for drugs known to bind preferentially to the inactivated state</td></tr><tr><td align="left" valign="bottom">Closed</td><td align="left" valign="bottom">Top model from Cluster 1 in AlphaFold closed-state-sampling attempt</td><td align="left" valign="bottom">Not tested (pore is closed)</td><td align="left" valign="bottom">High affinity for most drugs, assuming pore closure does not eject bound compounds</td></tr><tr><td align="left" valign="bottom">Open (AF ic3)</td><td align="left" valign="bottom">Top model from Cluster 3 in AlphaFold inactivated-state-sampling attempt</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Low affinity for drugs known to bind preferentially to the inactivated state</td></tr><tr><td align="left" valign="bottom">Open (AF control)</td><td align="left" valign="bottom">Top model from Cluster 1 (only cluster) in AlphaFold open-state-sampling attempt. Produced solely as a control to show that AlphaFold could reproduce complete models resembling PDB 5VA2.</td><td align="left" valign="bottom">Not tested as the model is structurally identical to Open (5VA2)</td><td align="left" valign="bottom">Not tested as the model is structurally identical to Open (5VA2)</td></tr></tbody></table></table-wrap><p>In our GALigandDock docking results, most drugs exhibited increased binding affinity to the closed-state hERG channel model compared to the open-state hERG channel model. Drugs are unable to bind to the closed state from the intracellular space because the pore is closed. However, they can become trapped if they are already bound when the channel transitions from an open to a closed state, as shown in experiments for dofetilide (<xref ref-type="bibr" rid="bib133">Windley et al., 2017</xref>), cisapride (<xref ref-type="bibr" rid="bib133">Windley et al., 2017</xref>), terfenadine (<xref ref-type="bibr" rid="bib132">Windisch et al., 2011</xref>; <xref ref-type="bibr" rid="bib133">Windley et al., 2017</xref>), E-4031 (<xref ref-type="bibr" rid="bib132">Windisch et al., 2011</xref>), and nifekalant (<xref ref-type="bibr" rid="bib56">Kamiya et al., 2006</xref>).</p><p>To model drug trapping, we placed the drug in a pocket beneath the SF in the closed pore configuration before docking. However, this method does not consider how the conformational shift from the open to the closed state might influence drug binding. Under physiological conditions, the pore gating motion from open to closed might expel drugs from the pore instead of pushing them deeper. This limitation might account for some inconsistencies noted in our docking study, particularly regarding the apparent trapping of drugs such as amiodarone and haloperidol, which is at odds with experimental results (<xref ref-type="bibr" rid="bib118">Stork et al., 2007</xref>). However, these preliminary results could pave the way for more thorough investigations, employing advanced computational techniques to delve deeper into the dynamics of drug trapping (<xref ref-type="bibr" rid="bib8">Branduardi and Faraldo-GÃ³mez, 2013</xref>; <xref ref-type="bibr" rid="bib81">Miao et al., 2020</xref>).</p></sec><sec id="s2-8"><title>State-specific molecular determinants of hERG channel block by terfenadine, dofetilide, moxifloxacin, astemizole, and E-4031</title><p><xref ref-type="fig" rid="fig6">Figure 6</xref> highlights the binding profiles of terfenadine, dofetilide, and moxifloxacin. Terfenadine and dofetilide are modeled in their cationic forms, while moxifloxacin is in its zwitterionic form. Experimental evidence (<xref ref-type="bibr" rid="bib33">Ficker et al., 1998</xref>; <xref ref-type="bibr" rid="bib57">Kamiya et al., 2008</xref>; <xref ref-type="bibr" rid="bib98">Perrin et al., 2008</xref>) indicates that terfenadine and dofetilide preferentially bind to the inactivated state of hERG, whereas moxifloxacin does not show this state-specific preference. Notably, both terfenadine and dofetilide have been associated with TdP arrhythmia and have been withdrawn or restricted in clinical use, while moxifloxacin is generally considered safer (<xref ref-type="bibr" rid="bib3">Alexandrou et al., 2006</xref>; <xref ref-type="bibr" rid="bib49">Jaiswal and Goldbarg, 2014</xref>; <xref ref-type="bibr" rid="bib87">Monahan et al., 1990</xref>; <xref ref-type="bibr" rid="bib93">Orvos et al., 2019</xref>; <xref ref-type="bibr" rid="bib137">Yang et al., 2020</xref>). Here, we investigate whether molecular differences in state-dependent binding modes, particularly to the inactivated state, and corresponding differences in binding affinities may help explain their varying proarrhythmic risks.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Visualization of interactions for terfenadine (<bold>a</bold>), dofetilide (<bold>b</bold>), and moxifloxacin (<bold>c</bold>) with different hERG channel models.</title><p>Each panel includes four subpanels showcasing drug interactions with the open- (PDB 5VA2-derived and AlphaFold-predicted from inactivated-state-sampling Cluster 3, i.e., AF ic3), inactivated-, and closed-state hERG channel models. The estimated drug-binding free energies, Î<italic>G</italic><sub>bind</sub>, are given in Rosetta energy units (R.E.U.) and shown as averages Â± standard deviations. In each subpanel, an overview of where the drug binds within the hERG channel pore is shown on the upper left, a 3D visualization of interactions between each channel residue (blue, red, green, and tan colored residues are from the subunit A, B, C, or D, respectively) to the drug (magenta) is shown on the upper right, and a 2D ligandâprotein interaction map is shown at the bottom. A continuous gray line depicts the contour of the protein-binding site, and any breaks in this line indicate areas where the ligand is exposed to the solvent.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104901-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6âfigure supplement 1.</label><caption><title>GALigandDock drug docking free energies for different hERG channel models.</title><p>Each bar plot displays the estimated binding free energy (Rosetta Energy Units, R.E.U.) for the specified drug across hERG channel models: Open (PDB 5VA2-based, blue), Open (AlphaFold inactivated-state-sampling Cluster 3, AFic3, purple), Inactivated (AlphaFold inactivated-state-sampling Cluster 2, orange), and Closed (green) states, with lower values indicating more favorable binding. For each drug and hERG channel model, 25,000 docking poses were generated, and the top 100 lowest-energy poses were clustered. The plotted values represent the mean and standard deviation of the best cluster, selected using a hybrid scoring method that considers both binding free energy and cluster size, with preference given to non-outlier clusters within a defined Î<italic>G</italic> tolerance of 0.25 R.E.U. Suffixes (0), (+), and (Â±) denote the drugâs neutral, cationic, or zwitterionic form, respectively. Additional suffixes indicate experimental validation (<xref ref-type="bibr" rid="bib3">Alexandrou et al., 2006</xref>; <xref ref-type="bibr" rid="bib29">Duan et al., 2007</xref>; <xref ref-type="bibr" rid="bib92">Numaguchi et al., 2000</xref>; <xref ref-type="bibr" rid="bib98">Perrin et al., 2008</xref>; <xref ref-type="bibr" rid="bib119">Suessbrich et al., 1997</xref>; <xref ref-type="bibr" rid="bib129">Wang et al., 1997</xref>) for preferential binding to the inactivated state (*) or no preference (â ).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104901-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6âfigure supplement 2.</label><caption><title>Astemizole (a) and E-4031 (b) binding to different hERG channel models and cryo-EM structures.</title><p>Each panel includes 4 subpanels showcasing drug interactions with the open- (PDB 5VA2-derived and AlphaFold-predicted from inactivated-state-sampling cluster 3 i.e., AF ic3) and inactivated hERG channel models as well as the cryo-EM drug-bound hERG channel structures (PDB IDs 8ZYO and 8ZYP for astemizole and E-4031, respectively). The estimated drug binding free energies, Î<italic>G</italic><sub>bind</sub>, are given in Rosetta energy units (R.E.U) and shown as averages Â± standard deviations. In each subpanel, an overview of where the drug binds within the hERG channel pore is shown on the upper left, a 3D visualization of interactions between each hERG channel residue (blue, red, green, and tan colored residues are from the subunit A, B, C, or D, respectively) to the drug (magenta) is shown on the upper right, and a 2D ligand â protein interaction map is shown at the bottom. A continuous gray line depicts the contour of the protein binding site, and any breaks in this line indicate areas where the ligand is exposed to the solvent.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104901-fig6-figsupp2-v1.tif"/></fig></fig-group><sec id="s2-8-1"><title>Terfenadine (<xref ref-type="fig" rid="fig6">Figure 6a</xref>)</title><list list-type="bullet" id="list1"><list-item><p>In the PDB 5VA2-derived open-state model, terfenadine forms strong ÏâÏ stacking interactions with the phenol side chains of Y652 (for 3 subunits), anchoring its aromatic rings just below the Y652 ring plane. Y652 and S660 engage in hydrogen bonding with terfenadine, while F656 contributes a hydrophobic contact via its backbone, further stabilizing the ligand within the central cavity.</p></list-item><list-item><p>In the AF ic3 open-state model, terfenadine adopts a more vertical orientation. It forms ÏâÏ stacking with the phenol ring of Y652 and engages in hydrogen bonding with residue S660. The binding pose is further supported by hydrophobic contacts with residues T623, Y652 (on 2 subunits), and S660.</p></list-item><list-item><p>In the inactivated-state model, terfenadine binds much deeper in the pore and forms a broader array of interactions. It engages in ÏâÏ stacking with Y652 and F557, while its hydroxyl group forms hydrogen bonds with residues L622, S624, and S649. Additional hydrophobic contacts occur with L622, T623, S649, M651, and F656, creating a tightly packed interaction network.</p></list-item><list-item><p>In the closed-state model, terfenadine becomes further embedded in the pore. Two F656 residues form ÏâÏ stacking interactions with its phenol ring, and the ligand is stabilized by hydrophobic interactions with residues S621, L622, T623, S624, M645, S649, Y652, and additional F656 residues.</p></list-item><list-item><p>Supporting our findings, Kamiya et al. demonstrated that alanine substitutions at T623, S624, Y652, and F656 significantly reduced the sensitivity of hERG to block by terfenadine (<xref ref-type="bibr" rid="bib56">Kamiya et al., 2006</xref>). In addition, Saxena et al. reported that F557L and Y652A mutations significantly reduced terfenadine-induced hERG inhibition (<xref ref-type="bibr" rid="bib112">Saxena et al., 2016</xref>).</p></list-item></list></sec><sec id="s2-8-2"><title>Dofetilide (<xref ref-type="fig" rid="fig6">Figure 6b</xref>)</title><list list-type="bullet" id="list2"><list-item><p>In the PDB 5VA2-derived open-state model, dofetilide predominantly forms polar interactions, with hydrogen bonds involving residues S660 and A653 across multiple subunits, and hydrophobic contacts with residue G657 contributing to its stabilization within the central cavity.</p></list-item><list-item><p>In the AF ic3 open-state model, dofetilide binds slightly deeper and adopts a more upright orientation. It forms ÏâÏ stacking interactions with the phenol side chains of Y652 (of 2 subunits), anchoring its aromatic core. It also engages in hydrogen bonding with Y652 and hydrophobic contacts with residues Y652, S660, and F656.</p></list-item><list-item><p>In the inactivated-state model, dofetilide engages in its most extensive interaction network. It binds deep in the pore, forming ÏâÏ stacking with Y652 and forming hydrogen bonds with residues T623 and S649. Additional polar contacts are observed with Y652 and T623, while hydrophobic stabilization is provided by contacts with residues S624, S649, M554, and F557. This comprehensive interaction profile reflects the experimentally observed preference of dofetilide for the inactivated state (<xref ref-type="bibr" rid="bib98">Perrin et al., 2008</xref>), which might contribute to its increased proarrhythmic risk (<xref ref-type="bibr" rid="bib33">Ficker et al., 1998</xref>; <xref ref-type="bibr" rid="bib49">Jaiswal and Goldbarg, 2014</xref>; <xref ref-type="bibr" rid="bib137">Yang et al., 2020</xref>).</p></list-item><list-item><p>In the closed-state model, dofetilide is positioned even deeper in the pore, likely retained by the narrowed cavity. Though it lacks strong polar contacts in this state, the surrounding residues, including S624, Y652, A653, and F656, encase the ligand and contribute to its stabilization via hydrophobic interactions.</p></list-item><list-item><p>Consistent with our docking results, experimental data support the involvement of these residues in dofetilide binding: Saxena et al. reported reduced binding following F557L and M554A mutations (<xref ref-type="bibr" rid="bib112">Saxena et al., 2016</xref>); Lees-Miller et al. showed that the F656V mutation weakens dofetilide block (<xref ref-type="bibr" rid="bib67">Lees-Miller et al., 2000a</xref>). Kamiya et al.âs alanine-scanning mutagenesis identified T623A, S624A, Y652A, and F656A as significantly reducing dofetilide potency, along with spatially adjacent residues G648A and V659A (<xref ref-type="bibr" rid="bib56">Kamiya et al., 2006</xref>). Additional work by Stepanovic et al. demonstrated that residue A653 mutations also alter hERG block by dofetilide (<xref ref-type="bibr" rid="bib117">Stepanovic et al., 2009</xref>).</p></list-item></list></sec><sec id="s2-8-3"><title>Moxifloxacin (<xref ref-type="fig" rid="fig6">Figure 6c</xref>)</title><list list-type="bullet" id="list3"><list-item><p>Across all the models, the geometry of moxifloxacin favors a vertically oriented binding pose within the hERG channel pore, with minimal bending of the molecule.</p></list-item><list-item><p>In the PDB 5VA2-derived open-state model, moxifloxacin reaches deep into the pore, where it forms hydrogen bonds with residues S624 and Y652 via the secondary ammonium group. The carboxylate oxygen engages in hydrogen bonding with residue S660.</p></list-item><list-item><p>The AF ic3 open-state model shows a similar deep binding pose, stabilized primarily through hydrogen bonds with S624 and S660.</p></list-item><list-item><p>In contrast, the inactivated-state model reveals a shallower binding position. Despite this, moxifloxacin is stabilized through multiple ÏâÏ stacking interactions between its quinolone ring system and F656 residues from opposing subunits, along with hydrogen bonds involving its carboxylate group and Y652 side chains from multiple subunits. Unlike terfenadine and dofetilide, moxifloxacin does not show enhanced binding in the inactivated state.</p></list-item><list-item><p>The closed-state model similarly features ÏâÏ stacking with F656 residues and a network of hydrogen bonds involving S660, Y652, and S624, effectively enclosing the ligand.</p></list-item><list-item><p>Previous studies reported that mutation at Y652 significantly reduced the sensitivity of hERG channel inhibition by moxifloxacin (<xref ref-type="bibr" rid="bib3">Alexandrou et al., 2006</xref>; <xref ref-type="bibr" rid="bib116">Shinozawa et al., 2017</xref>), consistent with our observation that Y652 plays a central role in stabilizing moxifloxacin binding across all the states we tested. Compared to other drugs, hERG residue F656 in this case only engages in Ï-stacking in two channel states and appears less essential for binding as moxifloxacin can be anchored through other polar and hydrophobic contacts, thus explaining the limited effect of the F656 mutation (<xref ref-type="bibr" rid="bib3">Alexandrou et al., 2006</xref>).</p></list-item></list><p>Recently cryo-EM structures of the hERG channel in complex with astemizole and E-4031 were reported (<xref ref-type="bibr" rid="bib86">Miyashita et al., 2024</xref>). Here, we compare drug binding in our open- and inactivated-state models, using the cationic forms of astemizole and E-4031, with the corresponding experimental structures (<xref ref-type="fig" rid="fig6s2">Figure 6âfigure supplement 2</xref>). Binding in the closed state is excluded as the pore architecture deviates too much from those in the cryo-EM structures. Experimental data (<xref ref-type="bibr" rid="bib98">Perrin et al., 2008</xref>) indicate that both astemizole and E-4031 bind more potently to the inactivated state.</p></sec><sec id="s2-8-4"><title>Astemizole (<xref ref-type="fig" rid="fig6s2">Figure 6âfigure supplement 2a</xref>)</title><list list-type="bullet" id="list4"><list-item><p>In the PDB 5VA2-derived open-state model, astemizole binds centrally within the pore cavity, adopting a bent conformation that allows both aromatic ends of the molecule to engage in ÏâÏ stacking with the side chains of Y652 from two opposing subunits. Hydrophobic contacts are observed with S649 and F656.</p></list-item><list-item><p>In the AF ic3 open-state model, the ligand is stabilized through multiple ÏâÏ stacking interactions with Y652 residues from three subunits, forming a tight aromatic cage around its triazine and benzimidazole rings. Hydrophobic interactions are observed with hERG residues T623, S624, Y652, F656, and S660.</p></list-item><list-item><p>In the inactivated-state model, astemizole adopts a compact, horizontally oriented pose deeper in the channel pore, forming the most extensive interaction network among all the states. The ligand is tightly stabilized by multiple ÏâÏ stacking interactions with Y652 residues across three subunits and forms hydrogen bonds with residues S624 and Y652. Additional hydrophobic contacts are observed with residues F557, L622, S649, and Y652.</p></list-item><list-item><p>Consistent with our findings, the electrophysiology study by Saxena et al. identified hERG residues F557 and Y652 as crucial for astemizole binding, as determined through mutagenesis (<xref ref-type="bibr" rid="bib112">Saxena et al., 2016</xref>).</p></list-item><list-item><p>In the cryo-EM structure (PDB 8ZYO) (<xref ref-type="bibr" rid="bib86">Miyashita et al., 2024</xref>), astemizole is stabilized by ÏâÏ stacking with Y652 residues. However, no hydrogen bonds are detected, which may reflect limitations in cryo-EM resolution rather than true absence of contacts. Additional hydrophobic interactions are observed with L622 and G648.</p></list-item></list></sec><sec id="s2-8-5"><title>E-4031 (<xref ref-type="fig" rid="fig6s2">Figure 6âfigure supplement 2b</xref>)</title><list list-type="bullet" id="list5"><list-item><p>In the PDB 5VA2-derived open-state model, E-4031 binds within the central cavity primarily through polar interactions. It forms a ÏâÏ stacking interaction with residue Y652, anchoring one end of the molecule. Polar interactions are observed with residues A653 and S660. Additional hydrophobic contacts are observed with residues A652 and Y652.</p></list-item><list-item><p>In the AF ic3 open-state model, E-4031 adopts a slightly deeper pose within the central cavity stabilized by dual ÏâÏ stacking interactions between its aromatic rings and hERG residues Y652. Additional hydrogen bonds are observed with residues S624 and Y652, and hydrophobic contacts are observed with residues T623 and S624.</p></list-item><list-item><p>In the inactivated-state model, E-4031 adopts its deepest and most stabilized binding pose, consistent with its experimentally observed preference for this state. The ligand is stabilized by multiple ÏâÏ stacking interactions between its aromatic rings and hERG residues Y652 from opposing subunits. The sulfonamide NH group engages in hydrogen bonding with residue S649, while the piperidine nitrogen as well as the central carbonyl oxygen hydrogen bond with residues Y652. Hydrophobic contacts with residues S624 and F656 further reinforce the binding, enclosing the ligand in a densely packed aromatic and polar environment.</p></list-item><list-item><p>Previous mutagenesis study showed that mutations involving hERG residues F557, T623, S624, Y652, and F656 affect E-4031 binding (<xref ref-type="bibr" rid="bib44">Helliwell et al., 2023</xref>).</p></list-item><list-item><p>In the cryo-EM structure (PDB 8ZYP) (<xref ref-type="bibr" rid="bib86">Miyashita et al., 2024</xref>), E-4031 engages in a single ÏâÏ stacking interaction with hERG residue Y652, anchoring one end of the molecule. The remainder of the ligand is stabilized predominantly through hydrophobic contacts involving residues S621, L622, T623, S624, M645, G648, S649, and additional Y652 side chains, forming a largely non-polar environment around the binding pocket.</p></list-item></list><p>In both cryo-EM structures, astemizole and E-4031 adopt binding poses that closely resemble the inactivated-state model in our docking study, consistent with experimental evidence that these drugs preferentially bind to the inactivated state (<xref ref-type="bibr" rid="bib98">Perrin et al., 2008</xref>). This raises the possibility that the cryo-EM structures may capture an inactivated-like channel state. However, closer examination of the SF reveals that the cryo-EM conformations more closely resemble the open-state PDB 5VA2 structure (<xref ref-type="bibr" rid="bib131">Wang and MacKinnon, 2017</xref>), which has been shown to be conductive here and in previous studies (<xref ref-type="bibr" rid="bib83">Miranda et al., 2020</xref>; <xref ref-type="bibr" rid="bib137">Yang et al., 2020</xref>).</p><p>The conformational differences between the cryo-EM and open-state docking results may reflect limitations of the docking protocol itself, as GALigandDock assumes a rigid protein backbone and cannot account for ligand-induced shifts. In our open-state models, the hydrophobic pocket beneath the SF is too small to accommodate bulky ligands (<xref ref-type="fig" rid="fig3">Figure 3a, b</xref>), whereas the cryo-EM structures show a slight outward shift in the S6 helix that expands this space (<xref ref-type="fig" rid="fig6s2">Figure 6âfigure supplement 2</xref>). These allosteric rearrangements, though small, fall outside the scope of the current docking protocol, which lacks flexibility to capture these local, ligand-induced adjustments (<xref ref-type="bibr" rid="bib42">Harris et al., 2024</xref>).</p><p>In contrast, docking to the AlphaFold-predicted inactivated-state model reveals a reorganization beneath the SF that creates a larger cavity, allowing deeper ligand insertion. Notably, neither our inactivated-state docking nor the available cryo-EM structures show strong interactions with residues F656. However, in the AlphaFold-predicted inactivated-state model, the more extensive protrusion of F656 into the central cavity may further occlude the drugâs egress pathway, potentially trapping the ligand more effectively. This could explain why the mutation of F656 significantly reduces the binding affinity of E-4031 (<xref ref-type="bibr" rid="bib44">Helliwell et al., 2023</xref>). These findings suggest that inactivation may trigger a series of modular structural rearrangements that influence drug access and binding affinity, with different aspects potentially captured in various computational and experimental studies, rather than resulting from a single, uniform conformational change.</p></sec></sec><sec id="s2-9"><title>Validation of state-dependent drug block with experimental data using hERG Markov model</title><p>There are several complications that make it difficult to directly compare experimental binding affinities with predicted affinities from simulations. During electrophysiological recordings of hERG inhibition by various drugs, the hERG channel has been shown to adopt various functional states, presumably corresponding to protein conformation states. These states can be bound by drugs with varying affinities, with drug ionization state also being a contributing factor. Additionally, the variability in experimental protocols affects the measured affinities (<xref ref-type="bibr" rid="bib36">Gomis-Tena et al., 2020</xref>). In general, electrophysiological measurements report the IC<sub>50</sub>, the drug concentration required for 50% inhibition of current. However, the IC<sub>50</sub> value is not directly comparable to computed affinities from drug docking.</p><p>To address these challenges, we developed a novel computational approach that combines modeling and simulation to predict hERG channel conformational state probabilities (open, closed, and inactivated) over time. First, we collected a comprehensive set of experimental data and employed a hERG functional model with five functional states, which was extensively validated in our earlier study (<xref ref-type="bibr" rid="bib105">Romero et al., 2015</xref>). For each drug, we ran in silico electrophysiological experiments under the same conditions as the experimental studies, allowing us to calculate the relative probabilities of the various hERG channel states specific to the drug and protocol. These state probabilities were then used to refine the computed binding affinities from docking simulations. We adjusted the affinities for both neutral and charged forms of each drug according to their prevalence in each conformational state. This method allowed us to scale the binding predictions based on the likelihood of each channel state occurring during the experimental protocols. Finally, we compared the simulated binding affinities with experimental hERG drug potencies (<xref ref-type="table" rid="table4">Table 4</xref>), offering a new validation technique that enhances the accuracy of our predictions and helps reconcile the differences between experimental IC<sub>50</sub> measurements and computed affinities.</p><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Data used for validating binding affinities from hERG channel-drug docking simulations with experiments.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="2">Drugs</th><th align="left" valign="bottom" rowspan="2">Ionization states and prevalence at pH 7.4</th><th align="left" valign="bottom" colspan="4">Simulated binding affinities (Rosetta energy units)</th><th align="left" valign="bottom" colspan="3">hERG channel state distribution when the tail current was observed</th><th align="left" valign="bottom" rowspan="2">Î<italic>G</italic><sub>bind, sim</sub> (Rosetta energy units)</th><th align="left" valign="bottom" rowspan="2">Î<italic>G</italic><sub>pot, exp</sub> (kcal/mol)</th><th align="left" valign="bottom" rowspan="2">IC<sub>50</sub> (nM)</th><th align="left" valign="bottom" rowspan="2">Studies referenced</th></tr><tr><th align="left" valign="bottom">Open (5VA2)</th><th align="left" valign="bottom">Open (AF ic3)</th><th align="left" valign="bottom">Inact.</th><th align="left" valign="bottom">Closed</th><th align="left" valign="bottom">Open</th><th align="left" valign="bottom">Inact.</th><th align="left" valign="bottom">Closed</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="2">Astemizole</td><td align="left" valign="bottom">Neutral 1.50%*</td><td align="char" char="plusmn" valign="bottom">â 13.84<break/>Â± 1.15</td><td align="char" char="plusmn" valign="bottom">â 14.49<break/>Â±0.23</td><td align="char" char="plusmn" valign="bottom">â26.33 Â±0.82</td><td align="char" char="plusmn" valign="bottom">â22.61<break/>Â±2.34</td><td align="char" char="." valign="bottom" rowspan="2">43.96%</td><td align="char" char="." valign="bottom" rowspan="2">52.43%</td><td align="char" char="." valign="bottom" rowspan="2">3.61%</td><td align="char" char="plusmn" valign="bottom" rowspan="2">â26.58<break/>Â±0.80</td><td align="char" char="." valign="bottom" rowspan="2">â10.76</td><td align="char" char="." valign="bottom" rowspan="2">26</td><td align="char" char="." valign="bottom" rowspan="2"><xref ref-type="bibr" rid="bib20">Chiu et al., 2004</xref></td></tr><tr><td align="left" valign="bottom">Cationic 98.50%*</td><td align="char" char="plusmn" valign="bottom">â19.79<break/>Â± 1.55</td><td align="char" char="plusmn" valign="bottom">â 15.12<break/>Â±1.16</td><td align="char" char="plusmn" valign="bottom">â32.51<break/>Â±0.83</td><td align="char" char="plusmn" valign="bottom">â25.63<break/>Â±1.76</td></tr><tr><td align="left" valign="bottom" rowspan="2">Terfenadine</td><td align="left" valign="bottom">Neutral 1.50%</td><td align="char" char="plusmn" valign="bottom">â21.55<break/>Â± 0.80</td><td align="char" char="plusmn" valign="bottom">â 22.43<break/>Â± 1.61</td><td align="char" char="plusmn" valign="bottom">â31.51<break/>Â±0.01</td><td align="char" char="plusmn" valign="bottom">â30.56<break/>Â±0.35</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">45.21</styled-content><styled-content style="color: #D50000;">%</styled-content>;<break/>57.91%</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">53.93</styled-content><styled-content style="color: #D50000;">%</styled-content><styled-content style="color: #D50000;">;</styled-content><break/>40.71%</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">0.86</styled-content><styled-content style="color: #D50000;">%</styled-content>;<break/>1.38%</td><td align="char" char="plusmn" valign="bottom" rowspan="2"><styled-content style="color: #D50000;">â</styled-content><styled-content style="color: #D50000;">30.94</styled-content><break/><styled-content style="color: #D50000;">Â±</styled-content><styled-content style="color: #D50000;">1.22</styled-content>;<break/>â28.74<break/>Â±0.95</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">â</styled-content><styled-content style="color: #D50000;">10.65</styled-content>;<break/>â10.66</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">31</styled-content>;<break/>30.60</td><td align="left" valign="bottom" rowspan="2"><xref ref-type="bibr" rid="bib93">Orvos et al., 2019</xref>; <xref ref-type="bibr" rid="bib121">Tanaka et al., 2014</xref></td></tr><tr><td align="left" valign="bottom">Cationic 98.50%</td><td align="char" char="plusmn" valign="bottom">â21.73<break/>Â± 0.56</td><td align="char" char="plusmn" valign="bottom">â21.56<break/>Â± 1.47</td><td align="char" char="plusmn" valign="bottom">â38.80 Â±2.24</td><td align="char" char="plusmn" valign="bottom">â29.25<break/>Â±2.98</td></tr><tr><td align="left" valign="bottom" rowspan="2">Cisapride</td><td align="left" valign="bottom">Neutral 22.40%</td><td align="char" char="plusmn" valign="bottom">â11.23<break/>Â± 1.10</td><td align="char" char="plusmn" valign="bottom">â 15.72<break/>Â± 0.23</td><td align="char" char="plusmn" valign="bottom">â21.44<break/>Â±1.53</td><td align="char" char="plusmn" valign="bottom">â18.92<break/>Â±0.75</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">41.89</styled-content><styled-content style="color: #D50000;">%</styled-content>; 43.96%</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">51.15</styled-content><styled-content style="color: #D50000;">%</styled-content>; 52.43%</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">6.96</styled-content><styled-content style="color: #D50000;">%</styled-content>; 3.61%</td><td align="char" char="plusmn" valign="bottom" rowspan="2"><styled-content style="color: #D50000;">â</styled-content><styled-content style="color: #D50000;">22.03</styled-content><break/><styled-content style="color: #D50000;">Â±</styled-content><styled-content style="color: #D50000;">0.56</styled-content>;<break/>â21.97<break/>Â±0.58</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">â</styled-content><styled-content style="color: #D50000;">9.92</styled-content>;<break/>â11.58</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">44.5</styled-content>; 6.90</td><td align="left" valign="bottom" rowspan="2"><xref ref-type="bibr" rid="bib104">Rampe et al., 1997</xref>; <xref ref-type="bibr" rid="bib20">Chiu et al., 2004</xref></td></tr><tr><td align="left" valign="bottom">Cationic 77.60%</td><td align="char" char="plusmn" valign="bottom">â15.19<break/>Â± 0.90</td><td align="char" char="plusmn" valign="bottom">â 15.08<break/>Â± 0.84</td><td align="char" char="plusmn" valign="bottom">â30.43<break/>Â±1.09</td><td align="char" char="plusmn" valign="bottom">â22.35<break/>Â±0.76</td></tr><tr><td align="left" valign="bottom" rowspan="2">Verapamil</td><td align="left" valign="bottom">Neutral 0.60%</td><td align="char" char="plusmn" valign="bottom">â17.52<break/>Â± 1.40</td><td align="char" char="plusmn" valign="bottom">â 14.14<break/>Â± 0.83</td><td align="char" char="plusmn" valign="bottom">â16.68<break/>Â±0.22</td><td align="char" char="plusmn" valign="bottom">â21.12<break/>Â±1.71</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">56.98</styled-content><styled-content style="color: #D50000;">%</styled-content>;<break/>9.00%</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">40.07</styled-content><styled-content style="color: #D50000;">%</styled-content>;<break/>90.62%</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">2.94</styled-content><styled-content style="color: #D50000;">%</styled-content>;<break/>0.38%</td><td align="char" char="plusmn" valign="bottom" rowspan="2"><styled-content style="color: #D50000;">â</styled-content><styled-content style="color: #D50000;">20.44 </styled-content><styled-content style="color: #D50000;">Â±</styled-content><styled-content style="color: #D50000;">2.22</styled-content>;<break/>â20.06 Â±1.04</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">â</styled-content><styled-content style="color: #D50000;">9.24</styled-content>;<break/>â9.57</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">143</styled-content>;<break/>180.40</td><td align="left" valign="bottom" rowspan="2"><xref ref-type="bibr" rid="bib139">Zhang et al., 1999</xref>; <xref ref-type="bibr" rid="bib51">Johnson and Trudeau, 2023</xref></td></tr><tr><td align="left" valign="bottom">Cationic 99.40%</td><td align="char" char="plusmn" valign="bottom">â20.54<break/>Â± 3.84</td><td align="char" char="plusmn" valign="bottom">â15.12<break/>Â± 0.23</td><td align="char" char="plusmn" valign="bottom">â20.01<break/>Â±1.09</td><td align="char" char="plusmn" valign="bottom">â25.10<break/>Â±5.17</td></tr><tr><td align="left" valign="bottom" rowspan="2">d-Sotalol</td><td align="left" valign="bottom">Neutral 0.62%*</td><td align="char" char="plusmn" valign="bottom">â6.20<break/>Â± 0.06</td><td align="char" char="plusmn" valign="bottom">â 6.03<break/>Â±0.44</td><td align="char" char="plusmn" valign="bottom">â16.20<break/>Â±2.08</td><td align="char" char="plusmn" valign="bottom">â8.36<break/>Â±0.44</td><td align="char" char="." valign="bottom" rowspan="2">91.54%</td><td align="char" char="." valign="bottom" rowspan="2">4.50%</td><td align="char" char="." valign="bottom" rowspan="2">3.96%</td><td align="char" char="plusmn" valign="bottom" rowspan="2">â6.45<break/>Â±1.33</td><td align="char" char="." valign="bottom" rowspan="2">â4.66</td><td align="char" char="." valign="bottom" rowspan="2">515,500</td><td align="char" char="." valign="bottom" rowspan="2"><xref ref-type="bibr" rid="bib98">Perrin et al., 2008</xref></td></tr><tr><td align="left" valign="bottom">Cationic 99.38%*</td><td align="char" char="plusmn" valign="bottom">â 5.83<break/>Â± 1.46</td><td align="char" char="plusmn" valign="bottom">â 6.90<break/>Â±0.58</td><td align="char" char="plusmn" valign="bottom">â15.04<break/>Â±1.28</td><td align="char" char="plusmn" valign="bottom">â10.91<break/>Â±1.17</td></tr><tr><td align="left" valign="bottom" rowspan="2">l-Sotalol</td><td align="left" valign="bottom">Neutral 0.62%*</td><td align="char" char="plusmn" valign="bottom">â 6.59<break/>Â± 0.38</td><td align="char" char="plusmn" valign="bottom">â 7.44<break/>Â± 0.30</td><td align="char" char="plusmn" valign="bottom">â16.41<break/>Â±0.88</td><td align="char" char="plusmn" valign="bottom">â10.42<break/>Â±0.71</td><td align="char" char="." valign="bottom" rowspan="2">91.54%</td><td align="char" char="." valign="bottom" rowspan="2">4.50%</td><td align="char" char="." valign="bottom" rowspan="2">3.96%</td><td align="char" char="plusmn" valign="bottom" rowspan="2">â6.98<break/>Â±0.89</td><td align="char" char="." valign="bottom" rowspan="2">â4.66</td><td align="char" char="." valign="bottom" rowspan="2">515,500</td><td align="char" char="." valign="bottom" rowspan="2"><xref ref-type="bibr" rid="bib98">Perrin et al., 2008</xref></td></tr><tr><td align="left" valign="bottom">Cationic 99.38%*</td><td align="char" char="plusmn" valign="bottom">â 6.31<break/>Â± 0.98</td><td align="char" char="plusmn" valign="bottom">â 7.32<break/>Â± 1.21</td><td align="char" char="plusmn" valign="bottom">â16.64<break/>Â±0.27</td><td align="char" char="plusmn" valign="bottom">â11.48<break/>Â±1.10</td></tr><tr><td align="left" valign="bottom" rowspan="2">Dofetilide</td><td align="left" valign="bottom">Neutral 5.70%</td><td align="char" char="plusmn" valign="bottom">â7.30<break/>Â± 0.09</td><td align="char" char="plusmn" valign="bottom">â 3.20<break/>Â± 0.73</td><td align="char" char="plusmn" valign="bottom">â10.51<break/>Â±2.24</td><td align="char" char="plusmn" valign="bottom">â6.43<break/>Â±1.67</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">19.23</styled-content><styled-content style="color: #D50000;">%</styled-content>;<break/>57.04%</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">77.68</styled-content><styled-content style="color: #D50000;">%</styled-content>;<break/>40.14%</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">3.08</styled-content><styled-content style="color: #D50000;">%</styled-content>;<break/>2.83%</td><td align="char" char="plusmn" valign="bottom" rowspan="2"><styled-content style="color: #D50000;">â</styled-content><styled-content style="color: #D50000;">17.38</styled-content><break/><styled-content style="color: #D50000;">Â±</styled-content><styled-content style="color: #D50000;">1.00</styled-content>;<break/>â13.77<break/>Â±0.78</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">â</styled-content><styled-content style="color: #D50000;">8.77</styled-content>;<break/>â10.46</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">320</styled-content>;<break/>17.90</td><td align="left" valign="bottom" rowspan="2"><xref ref-type="bibr" rid="bib33">Ficker et al., 1998</xref>; <xref ref-type="bibr" rid="bib70">Li et al., 2012</xref></td></tr><tr><td align="left" valign="bottom">Cationic 94.30%</td><td align="char" char="plusmn" valign="bottom">â 10.04<break/>Â± 1.11</td><td align="char" char="plusmn" valign="bottom">â 10.08<break/>Â±0.75</td><td align="char" char="plusmn" valign="bottom">â20.05<break/>Â±1.32</td><td align="char" char="plusmn" valign="bottom">â11.00<break/>Â±2.67</td></tr><tr><td align="left" valign="bottom" rowspan="2">Haloperidol</td><td align="left" valign="bottom">Neutral 15.50%</td><td align="char" char="plusmn" valign="bottom">â 11.02<break/>Â± 0.06</td><td align="char" char="plusmn" valign="bottom">â 11.76<break/>Â± 0.04</td><td align="char" char="plusmn" valign="bottom">â20.85<break/>Â±0.18</td><td align="char" char="plusmn" valign="bottom">â19.72<break/>Â±0.84</td><td align="char" char="." valign="bottom" rowspan="2">54.25%</td><td align="char" char="." valign="bottom" rowspan="2">13.37%</td><td align="char" char="." valign="bottom" rowspan="2">32.38%</td><td align="char" char="plusmn" valign="bottom" rowspan="2">â17.17<break/>Â±0.69</td><td align="char" char="." valign="bottom" rowspan="2">â8.10</td><td align="char" char="." valign="bottom" rowspan="2">1,000</td><td align="left" valign="bottom" rowspan="2"><xref ref-type="bibr" rid="bib119">Suessbrich et al., 1997</xref></td></tr><tr><td align="left" valign="bottom">Cationic 84.50%</td><td align="char" char="plusmn" valign="bottom">â 12.84<break/>Â± 1.45</td><td align="char" char="plusmn" valign="bottom">â 13.05<break/>Â± 0.02</td><td align="char" char="plusmn" valign="bottom">â26.34<break/>Â±0.13</td><td align="char" char="plusmn" valign="bottom">â21.80Â±0.70</td></tr><tr><td align="left" valign="bottom" rowspan="2">Amiodarone</td><td align="left" valign="bottom">Neutral 2.00%</td><td align="char" char="plusmn" valign="bottom">â 10.76<break/>Â± 1.38</td><td align="char" char="plusmn" valign="bottom">â 16.87<break/>Â± 0.43</td><td align="char" char="plusmn" valign="bottom">â27.10<break/>Â±0.98</td><td align="char" char="plusmn" valign="bottom">â18.00<break/>Â±0.79</td><td align="char" char="." valign="bottom" rowspan="2">45.21%</td><td align="char" char="." valign="bottom" rowspan="2">53.93%</td><td align="char" char="." valign="bottom" rowspan="2">0.86%</td><td align="char" char="plusmn" valign="bottom" rowspan="2">â22.64<break/>Â±1.05</td><td align="char" char="plusmn" valign="bottom" rowspan="2">â10.42<break/>Â±0.07</td><td align="char" char="plusmn" valign="bottom" rowspan="2">45Â±5.20</td><td align="char" char="." valign="bottom" rowspan="2"><xref ref-type="bibr" rid="bib140">Zhang et al., 2016</xref></td></tr><tr><td align="left" valign="bottom">Cationic 98.00%</td><td align="char" char="plusmn" valign="bottom">â13.38<break/>Â± 1.95</td><td align="char" char="plusmn" valign="bottom">â 17.48<break/>Â± 1.21</td><td align="char" char="plusmn" valign="bottom">â30.49<break/>Â±1.12</td><td align="char" char="plusmn" valign="bottom">â23.95<break/>Â±1.55</td></tr><tr><td align="left" valign="bottom" rowspan="2">E-4031</td><td align="left" valign="bottom">Neutral 21.09%*</td><td align="char" char="plusmn" valign="bottom">â 9.87<break/>Â± 0.17</td><td align="char" char="plusmn" valign="bottom">â 9.73<break/>Â± 0.24</td><td align="char" char="plusmn" valign="bottom">â17.27<break/>Â±1.92</td><td align="char" char="plusmn" valign="bottom">â11.54<break/>Â±2.45</td><td align="char" char="." valign="bottom" rowspan="2">57.70%</td><td align="char" char="." valign="bottom" rowspan="2">40.54%</td><td align="char" char="." valign="bottom" rowspan="2">1.76%</td><td align="char" char="plusmn" valign="bottom" rowspan="2">â16.07<break/>Â±0.37</td><td align="char" char="." valign="bottom" rowspan="2">â11.51</td><td align="char" char="." valign="bottom" rowspan="2">7.7</td><td align="char" char="." valign="bottom" rowspan="2"><xref ref-type="bibr" rid="bib142">Zhou et al., 1998</xref></td></tr><tr><td align="left" valign="bottom">Cationic 78.91%*</td><td align="char" char="plusmn" valign="bottom">â 11.55<break/>Â± 0.60</td><td align="char" char="plusmn" valign="bottom">â 14.57<break/>Â± 1.64</td><td align="char" char="plusmn" valign="bottom">â24.76<break/>Â±0.59</td><td align="char" char="plusmn" valign="bottom">â11.96<break/>Â±1.78</td></tr><tr><td align="left" valign="bottom">Clozapine</td><td align="left" valign="bottom">Neutral 100%*</td><td align="char" char="plusmn" valign="bottom">â 8.62<break/>Â±0.45</td><td align="char" char="plusmn" valign="bottom">â 8.20<break/>Â± 0.29</td><td align="char" char="plusmn" valign="bottom">â13.96<break/>Â±0.41</td><td align="char" char="plusmn" valign="bottom">â16.84<break/>Â±0.99</td><td align="char" char="." valign="bottom">62.12%;<break/>67.97%</td><td align="char" char="." valign="bottom">25.62%;<break/>27.99%</td><td align="char" char="." valign="bottom">12.27%;<break/>4.05%</td><td align="char" char="plusmn" valign="bottom">â11.00<break/>Â±0.32;<break/>â10.45<break/>Â±0.33</td><td align="char" char="." valign="bottom">â6.14;<break/>â6.26</td><td align="char" char="." valign="bottom">28,300;<break/>22,900</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib66">Lee et al., 2006</xref></td></tr><tr><td align="left" valign="bottom">NS1643</td><td align="left" valign="bottom">Neutral 100%*</td><td align="char" char="plusmn" valign="bottom">â 13.72<break/>Â± 1.97</td><td align="char" char="plusmn" valign="bottom">â 13.89<break/>Â± 0.65</td><td align="char" char="plusmn" valign="bottom">â19.44<break/>Â±0.42</td><td align="char" char="plusmn" valign="bottom">â21.73<break/>Â±0.27</td><td align="char" char="." valign="bottom">69.21%</td><td align="char" char="." valign="bottom">28.79%</td><td align="char" char="." valign="bottom">2.00%</td><td align="char" char="plusmn" valign="bottom">â15.53<break/>Â±1.37</td><td align="char" char="." valign="bottom">â7.06</td><td align="char" char="." valign="bottom">10,500</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib40">Hansen et al., 2006</xref></td></tr><tr><td align="left" valign="bottom" rowspan="2">Moxifloxacin</td><td align="left" valign="bottom">Neutral 0%</td><td align="char" char="plusmn" valign="bottom">â 8.27<break/>Â± 0.54</td><td align="char" char="plusmn" valign="bottom">â 9.82<break/>Â± 0.34</td><td align="char" char="plusmn" valign="bottom">â10.00<break/>Â±0.27</td><td align="char" char="plusmn" valign="bottom">â19.85<break/>Â±0.84</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">34.82</styled-content><styled-content style="color: #D50000;">%</styled-content>;<break/>45.21%</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">42.72</styled-content><styled-content style="color: #D50000;">%</styled-content>;<break/>53.93%</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">22.46</styled-content><styled-content style="color: #D50000;">%</styled-content>;<break/>0.86%</td><td align="char" char="plusmn" valign="bottom" rowspan="2"><styled-content style="color: #D50000;">â</styled-content><styled-content style="color: #D50000;">10.62</styled-content><break/><styled-content style="color: #D50000;">Â±</styled-content><styled-content style="color: #D50000;">0.23</styled-content>;<break/>â10.94<break/>Â±0.07</td><td align="char" char="plusmn" valign="bottom" rowspan="2"><styled-content style="color: #D50000;">â</styled-content><styled-content style="color: #D50000;">5.65</styled-content><break/><styled-content style="color: #D50000;">Â±</styled-content><styled-content style="color: #D50000;">0.04</styled-content>;<break/>â6.31</td><td align="char" char="plusmn" valign="bottom" rowspan="2"><styled-content style="color: #D50000;">65,000</styled-content><styled-content style="color: #D50000;">Â±</styled-content><styled-content style="color: #D50000;">4,200</styled-content>;<break/>35,700</td><td align="left" valign="bottom" rowspan="2"><xref ref-type="bibr" rid="bib3">Alexandrou et al., 2006</xref>; <xref ref-type="bibr" rid="bib19">Chen et al., 2005</xref></td></tr><tr><td align="left" valign="bottom">Zwitterionic 100%*</td><td align="char" char="plusmn" valign="bottom">â 9.78<break/>Â± 0.03</td><td align="char" char="plusmn" valign="bottom">â 13.62<break/>Â± 0.08</td><td align="char" char="plusmn" valign="bottom">â11.93<break/>Â±0.12</td><td align="char" char="plusmn" valign="bottom">â9.45<break/>Â±0.99</td></tr><tr><td align="left" valign="bottom" rowspan="2">Quinidine</td><td align="left" valign="bottom">Neutral 2.20%</td><td align="char" char="plusmn" valign="bottom">â 7.66<break/>Â± 0.64</td><td align="char" char="plusmn" valign="bottom">â 10.89<break/>Â± 0.41</td><td align="char" char="plusmn" valign="bottom">â12.20<break/>Â±0.07</td><td align="char" char="plusmn" valign="bottom">â17.54<break/>Â±1.53</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">57.17</styled-content><styled-content style="color: #D50000;">%</styled-content>; 32.84%</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">23.59</styled-content><styled-content style="color: #D50000;">%</styled-content>; 66.68%</td><td align="char" char="." valign="bottom" rowspan="2"><styled-content style="color: #D50000;">19.24</styled-content><styled-content style="color: #D50000;">%</styled-content>; 0.48%</td><td align="char" char="plusmn" valign="bottom" rowspan="2"><styled-content style="color: #D50000;">â</styled-content><styled-content style="color: #D50000;">12.33</styled-content><break/><styled-content style="color: #D50000;">Â±</styled-content><styled-content style="color: #D50000;">0.28</styled-content>;<break/>â11.77<break/>Â±0.22</td><td align="char" char="plusmn" valign="bottom" rowspan="2"><styled-content style="color: #D50000;">â</styled-content><styled-content style="color: #D50000;">8.23</styled-content><break/><styled-content style="color: #D50000;">Â±</styled-content><styled-content style="color: #D50000;">0.07</styled-content>;<break/>â9.06</td><td align="char" char="plusmn" valign="bottom" rowspan="2"><styled-content style="color: #D50000;">800</styled-content><styled-content style="color: #D50000;">Â±</styled-content><styled-content style="color: #D50000;">100</styled-content>; 410</td><td align="left" valign="bottom" rowspan="2"><xref ref-type="bibr" rid="bib136">Yan et al., 2016</xref>; <xref ref-type="bibr" rid="bib96">Paul et al., 2002</xref></td></tr><tr><td align="left" valign="bottom">Cationic 97.70%</td><td align="char" char="plusmn" valign="bottom">â 9.49<break/>Â± 0.17</td><td align="char" char="plusmn" valign="bottom">â 14.32<break/>Â± 1.41</td><td align="char" char="plusmn" valign="bottom">â12.87<break/>Â±0.33</td><td align="char" char="plusmn" valign="bottom">â20.28<break/>Â±1.32</td></tr><tr><td align="left" valign="bottom" rowspan="2">Perhexiline</td><td align="left" valign="bottom">Neutral 0%</td><td align="char" char="plusmn" valign="bottom">â 10.47<break/>Â± 0.22</td><td align="char" char="plusmn" valign="bottom">â 12.33<break/>Â± 0.72</td><td align="char" char="plusmn" valign="bottom">â11.66<break/>Â±0.74</td><td align="char" char="plusmn" valign="bottom">â24.39<break/>Â±0.56</td><td align="char" char="." valign="bottom" rowspan="2">37.57%</td><td align="char" char="." valign="bottom" rowspan="2">60.59%</td><td align="char" char="." valign="bottom" rowspan="2">1.84%</td><td align="char" char="plusmn" valign="bottom" rowspan="2">â16.19<break/>Â±1.26</td><td align="char" char="." valign="bottom" rowspan="2">â6.89</td><td align="char" char="." valign="bottom" rowspan="2">7,800</td><td align="char" char="." valign="bottom" rowspan="2"><xref ref-type="bibr" rid="bib128">Walker et al., 1999</xref></td></tr><tr><td align="left" valign="bottom">Cationic 100%</td><td align="char" char="plusmn" valign="bottom">â 11.20<break/>Â± 0.70</td><td align="char" char="plusmn" valign="bottom">â 12.46<break/>Â± 0.02</td><td align="char" char="plusmn" valign="bottom">â19.05<break/>Â±2.04</td><td align="char" char="plusmn" valign="bottom">â23.90<break/>Â±0.66</td></tr><tr><td align="left" valign="bottom" rowspan="2">Nifekalant</td><td align="left" valign="bottom">Neutral 3.80%</td><td align="char" char="plusmn" valign="bottom">â 9.68<break/>Â± 1.47</td><td align="char" char="plusmn" valign="bottom">â 12.28<break/>Â± 0.29</td><td align="char" char="plusmn" valign="bottom">â15.40<break/>Â±0.95</td><td align="char" char="plusmn" valign="bottom">â14.89<break/>Â±1.56</td><td align="char" char="." valign="bottom" rowspan="2">67.65%</td><td align="char" char="." valign="bottom" rowspan="2">27.91%</td><td align="char" char="." valign="bottom" rowspan="2">4.44%</td><td align="char" char="plusmn" valign="bottom" rowspan="2">â14.23<break/>Â±0.99</td><td align="char" char="." valign="bottom" rowspan="2">â6.89</td><td align="char" char="." valign="bottom" rowspan="2">7,900</td><td align="left" valign="bottom" rowspan="2"><xref ref-type="bibr" rid="bib62">Kushida et al., 2002</xref></td></tr><tr><td align="left" valign="bottom">Cationic 96.20%</td><td align="char" char="plusmn" valign="bottom">â 10.93<break/>Â± 1.45</td><td align="char" char="plusmn" valign="bottom">â13.46 Â±0.05</td><td align="char" char="plusmn" valign="bottom">â22.74<break/>Â±0.99</td><td align="char" char="plusmn" valign="bottom">â13.52<break/>Â±3.39</td></tr></tbody></table><table-wrap-foot><fn><p>Simulated binding affinities are shown as averages Â± standard deviations. In the <italic>Ionization states</italic> column, the microspecies distribution percentages were calculated using the ChemAxon software suite and its computed p<italic>K</italic><sub>a</sub> values (<xref ref-type="bibr" rid="bib102">Pirok et al., 2006</xref>). The asterisk (*) indicates that the value has been adjusted by a few percentage points to account for species with alternative ionization states that were not tested. Cells with values separated by a semicolon (;) and shown by different colors represent data from different studies, listed in the âstudies referencedâ column in the same order.</p></fn></table-wrap-foot></table-wrap><p>We compared the experimental drug potencies with the simulated binding affinities, starting with the traditional approach of using only open-state docking simulations (<xref ref-type="fig" rid="fig7">Figure 7a, c</xref>), commonly employed in ion channel pharmacology due to a scarcity of multi-state models, and then extended our analysis to include drug binding to different states (<xref ref-type="fig" rid="fig7">Figure 7b, d</xref>). Using only the open-state model (PDB 5VA2) yielded a moderate correlation with experimental data (<italic>R</italic>Â² = 0.43, <italic>r</italic> = 0.66, <xref ref-type="fig" rid="fig7">Figure 7a</xref>). Incorporating multi-state binding (weighted by their experimental distributions) improved the correlation substantially (<italic>R</italic>Â² = 0.63, <italic>r</italic> = 0.79, <xref ref-type="fig" rid="fig7">Figure 7b</xref>), boosting predictive power by 47% and underscoring the value of multi-state modeling. Importantly, this improvement was achieved without considering potential drug-induced allosteric effects on hERG channel conformation and gating, which will be addressed in future work.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Correlation of simulated hERG drug-binding affinities with experimental drug potencies under different modeling scenarios.</title><p>Single- and multi-state simulated drug-binding affinities (in Rosetta energy units, R.E.U.) are plotted against experimental drug potencies (ICââ converted to free energies in kcal/mol). Lower (more negative) values indicate stronger binding. Horizontal error bars reflect uncertainty from experimental IC<sub>50</sub> measurements, while vertical bars reflect standard deviations in simulated drug-binding affinities (<italic>n</italic> = 100), propagated across ionization states and channel state distributions. A total of 23 measurements representing 16 unique drugs were analyzed. Linear regression was performed using the least-squares method, and exact values for Pearsonâs <italic>r</italic>, R<sup>2</sup>, and p-values are reported within the figure. (<bold>a</bold>) Single-state docking using the experimentally derived open-state structure (PDB 5VA2) yields a moderate correlation (the coefficient of determination <italic>R</italic><sup>2</sup> = 0.43, Pearson correlation coefficient <italic>r</italic> = 0.66). (<bold>b</bold>) Multi-state docking incorporating open (PDB 5VA2), inactivated, and closed-state conformations weighted by experimentally observed state distributions further improve the correlation (<italic>R</italic><sup>2</sup> = 0.63, <italic>r</italic> = 0.79). (<bold>c</bold>) Single-state docking using an alternative AlphaFold-predicted open state (inactivated-state-sampling Cluster 3, ic3) (<italic>R</italic><sup>2</sup> = 0.44, <italic>r</italic> = 0.66). (<bold>d</bold>) Multi-state docking combining the AlphaFold-predicted open- (inactivated-state-sampling Cluster 3, ic3), inactivated-, and closed-state models also results in a notable improvement (<italic>R</italic><sup>2</sup> = 0.64, <italic>r</italic> = 0.80) compared to single-state docking in panel (<bold>c</bold>) and comparable performance to multi-state docking in panel (<bold>b</bold>). These results highlight the enhanced predictive power of multi-state modeling and suggest that structural diversity within ensembles can compensate for individual model limitations, yielding more accurate predictions of drugâion channel interactions and their effect on ion channel function.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104901-fig7-v1.tif"/></fig><p>Next, we substituted the PDB 5VA2-based open-state model with the AF ic3 open-state model. Docking to this alternative model alone produced similar performance (<italic>R</italic><sup>2</sup> = 0.44, <italic>r</italic> = 0.66, <xref ref-type="fig" rid="fig7">Figure 7c</xref>), and incorporating it into the multi-state ensemble further improved the correlation with experiments (<italic>R</italic>Â² = 0.64, <italic>r</italic> = 0.80, <xref ref-type="fig" rid="fig7">Figure 7d</xref>), representing a 45% gain in <italic>R</italic>Â² and matching the performance of multi-state docking results based on the PDB 5VA2-derived model.</p><p>These findings suggest that the predictive power of computational drug docking is enhanced not merely by the accuracy of individual models, but by the structural diversity and complementarity provided by an ensemble of conformations. Rather than relying solely on a single experimentally determined structure, the ensemble benefits from incorporating AlphaFold-predicted models that capture alternative conformations identified through our state-specific sampling approach. These diverse models reflect different structural features, which together offer a more comprehensive representation of the channelâs binding landscape and enhance the predictive performance of computational drug docking. Overall, these results reinforce that multi-state modeling offers a more realistic and predictive framework for understanding drug-channel interactions than traditional single-state approaches, emphasizing the value of both individual model evaluation and their collective integration.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><sec id="s3-1"><title>AlphaFold2 predicts physiologically relevant hERG channel states</title><p>In this study, we introduced a methodology to extend AlphaFold2âs predictive capabilities by guiding it to sample multiple protein conformations reminiscent of different ion channel states, using the hERG potassium channel as a proof of concept. While other studies have focused on generating diverse protein conformations using AlphaFold (<xref ref-type="bibr" rid="bib26">Del Alamo et al., 2022</xref>; <xref ref-type="bibr" rid="bib55">Kalakoti and Wallner, 2024</xref>; <xref ref-type="bibr" rid="bib75">Lidbrink et al., 2024</xref>; <xref ref-type="bibr" rid="bib108">Sala et al., 2023</xref>), we aimed to take this further by validating the physiological relevance of these predicted states for ion channels through computational simulations and experimental data. By incorporating multiple structural templates and refined input parameters, we directed AlphaFold2 to predict distinct functional states, including the closed and inactivated forms of hERG. This approach is significant for pharmacology, particularly for the hERG channel, an anti-target notorious for state-specific drug interactions linked to cardiotoxicity (<xref ref-type="bibr" rid="bib71">Li and Ramos, 2017</xref>; <xref ref-type="bibr" rid="bib98">Perrin et al., 2008</xref>; <xref ref-type="bibr" rid="bib110">Sanguinetti and Tristani-Firouzi, 2006</xref>; <xref ref-type="bibr" rid="bib125">Vandenberg et al., 2012</xref>; <xref ref-type="bibr" rid="bib137">Yang et al., 2020</xref>).</p><p>We employed two complementary strategies to guide AlphaFold2 in predicting physiologically relevant hERG channel conformations. In the first, we used structural fragments representative of specific functional states as templates, prompting AlphaFold2 to reconstruct the full hERG channel accordingly, successfully yielding models with features characteristic of the closed state, such as a constricted pore and deactivated voltage-sensing domains. In the second, we allowed AlphaFold2 to explore a broader conformational space, particularly useful in scenarios where structural knowledge is limited. Remarkably, AlphaFold2 managed to generate conformations that had been previously documented in the literature but not included in the training dataset, showcasing its broad predictive capacity. Among the most compelling findings is the strong correspondence between our AlphaFold2-predicted inactivated-state conformations and those previously proposed through experimental and simulation studies (<xref ref-type="bibr" rid="bib65">Lau et al., 2024</xref>; <xref ref-type="bibr" rid="bib73">Li et al., 2021b</xref>). These structures were identifiable in discrete protein clusters (<xref ref-type="fig" rid="fig2">Figure 2a</xref>) with high prediction confidence metrics and likely together constitute components of the hERG inactivation mechanism. In this way, AlphaFold2 provided a strong method to reconcile apparently disparate previous experimental and computational data.</p><p>Together, these strategies produced models that captured key features of closed, open, and inactivated channel states. Our study goes beyond modeling distinct hERG channel conformations; it also provides extensive validation of their functional and pharmacological relevance through MD simulations and integrated docking analyses. The closed-state model exhibits a constricted pore and deactivated voltage-sensing domains, providing a structural basis for hERG channel deactivation. The open-state model displays a widened, conductive pore consistent with physiological ion flow during cardiac repolarization. The inactivated-state model features a non-conductive SF primarily characterized by SF residue V625 carbonyl flipping away from the conduction pathway. It also reveals notable rearrangements in the pore cavity that enhance drug binding, which is consistent with experimentally measured increases in drug affinity and arrhythmia risk (<xref ref-type="bibr" rid="bib33">Ficker et al., 1998</xref>; <xref ref-type="bibr" rid="bib98">Perrin et al., 2008</xref>; <xref ref-type="bibr" rid="bib98">Perrin et al., 2008</xref>; <xref ref-type="bibr" rid="bib137">Yang et al., 2020</xref>), yet previously lacking a defined structural explanation. Nonetheless, these alterations may not occur concurrently under physiological conditions and could represent only a subset of the broader conformational changes that accompany channel inactivation.</p><p>To demonstrate the broader feasibility of this approach, we applied it to another ion channel system, Na<sub>V</sub>1.5, as illustrated in <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref>. In this example, a deactivated VSD II from the cryo-EM structure of Na<sub>V</sub>1.7 (PDB 6N4R) (<xref ref-type="bibr" rid="bib135">Xu et al., 2019</xref>), which was trapped in a deactivated state by a bound toxin, was used as a structural template. This guided AlphaFold to generate an Na<sub>V</sub>1.5 model in which all four voltage sensor domains (VSD IâIV) exhibit S4 helices in varying degrees of deactivation. Compared to the cryo-EM open-state Na<sub>V</sub>1.5 structure (PDB 6LQA) (<xref ref-type="bibr" rid="bib72">Li et al., 2021a</xref>), the predicted model displays a visibly narrower pore, representing a plausible closed state. This example underscores the versatility of our strategy in modeling alternative conformational states across diverse ion channels.</p></sec><sec id="s3-2"><title>Molecular basis linking hERG inactivation to enhanced drug-binding affinity</title><p>While previous studies have proposed potential molecular mechanisms for hERG C-type inactivation (<xref ref-type="bibr" rid="bib65">Lau et al., 2024</xref>; <xref ref-type="bibr" rid="bib73">Li et al., 2021b</xref>), they have primarily concentrated on conformational shifts leading to a non-conductive SF. Our study takes a step further and sheds light on how these alterations extend to the pore region and subsequently impact drug binding as seen in experiments, which is an outstanding issue in safety pharmacology and drug development as hERG channel is a notorious drug anti-target (<xref ref-type="bibr" rid="bib98">Perrin et al., 2008</xref>; <xref ref-type="bibr" rid="bib110">Sanguinetti and Tristani-Firouzi, 2006</xref>; <xref ref-type="bibr" rid="bib125">Vandenberg et al., 2012</xref>; <xref ref-type="bibr" rid="bib137">Yang et al., 2020</xref>).</p><p>Our results suggest that specific structural rearrangements occurring during the open-to-inactivated transition of the hERG channel may fine-tune the geometry of the central cavity in ways that enhance ligand binding. In particular, the movement of the canonical drug-binding residue Y652, together with the reorientation of the S624 sidechain hydroxyl groups, slightly expands the hydrophobic pockets beneath the SF (<xref ref-type="fig" rid="fig3">Figure 3a, b</xref>, at <italic>Z</italic> = 21 Ã), allowing certain drugs to bind more deeply. Additionally, a slight inward rotation of the S6 helix repositions F656 toward the pore axis, which likely enhances drug interactions through Ï-stacking and hydrophobic contacts and helps to reduce the likelihood of drug dissociation from the cavity. These changes may not occur simultaneously or uniformly and may vary in magnitude, as suggested by the range of conformations observed in the AlphaFold models. Importantly, this local remodeling likely represents just one aspect of the broader inactivation process predicted by AlphaFold and validated in our study, contributing to drug stabilization without necessarily capturing the full inactivated state.</p><p>Together, these structural changes may account for the increased binding affinity observed for some compounds in the hERG channel inactivated state (<xref ref-type="fig" rid="fig6s1">Figure 6âfigure supplement 1</xref>), offering a structural mechanism that links this enhanced binding to elevated arrhythmogenic potential (<xref ref-type="bibr" rid="bib33">Ficker et al., 1998</xref>; <xref ref-type="bibr" rid="bib49">Jaiswal and Goldbarg, 2014</xref>; <xref ref-type="bibr" rid="bib98">Perrin et al., 2008</xref>; <xref ref-type="bibr" rid="bib137">Yang et al., 2020</xref>). It is important to note that drug interaction with other cardiac ion channels may modulate or offset this risk in vivo, and the net proarrhythmic liability is determined by a more complex interplay of multi-channel effects (<xref ref-type="bibr" rid="bib22">Colatsky et al., 2016</xref>). Nevertheless, given the exceptional sensitivity of the hERG channel to a wide range of compounds, understanding its state-dependent binding mechanisms remains critical for predicting and mitigating cardiac safety risks during drug development.</p></sec><sec id="s3-3"><title>Multi-state drug docking with AlphaFold-derived conformations outperforms reliance on a single-state experimental structure in predicting drug potency</title><p>An additional novelty of our study was the development of a new computational modeling and simulation approach that allowed us to use the predicted affinities of drug binding from docking simulations and compare them directly to measured hERG channel inhibition potencies from electrophysiology experiments. We employed a simulated hERG functional model comprising five functional states that we have extensively validated in our earlier studies (<xref ref-type="bibr" rid="bib105">Romero et al., 2015</xref>) and performed in silico electrophysiological experiments under the same conditions as reported in the experimental papers. In doing so, we could compute the relative hERG channel state probabilities during the experimental protocol. The channel state probabilities were then used to scale the computed affinities in each state from the docking simulations, allowing comparison of the overall computed relative affinity with experimentally reported relative potencies. Such an analysis created an opportunity for an âapples-to-applesâ comparison between structurally derived affinity predictions and abundant functional measurements that have been conducted for half a century. This novel linkage can be readily expanded to other protein targets and any variety of drugs. The intersection of structural modeling, molecular docking, functional simulations, and supporting experimental data offers a comprehensive approach to understanding protein structures and their links to biological functions.</p></sec><sec id="s3-4"><title>Comparative mechanisms of inactivation in hERG and other K<sup>+</sup> channels</title><p>For other K<sup>+</sup> channels, dilation in the SF has been proposed to be potential C-type inactivation mechanisms (<xref ref-type="bibr" rid="bib18">Chandy et al., 2023</xref>; <xref ref-type="bibr" rid="bib24">Cuello et al., 2010</xref>; <xref ref-type="bibr" rid="bib114">Selvakumar et al., 2022</xref>; <xref ref-type="bibr" rid="bib120">Tan et al., 2022</xref>; <xref ref-type="bibr" rid="bib124">Tyagi et al., 2022</xref>). While inactivation processes across various K<sup>+</sup> channels may share some similarities, the associated conformational changes can adopt distinct differences due to small variations in the SF sequences, which could explain the observed variability in inactivation rates among hERG and other ion channels (<xref ref-type="bibr" rid="bib125">Vandenberg et al., 2012</xref>). As an example, a study on Shaker-family channels suggested that a two-step widening process in the upper SF could be a mechanism for C-type inactivation (<xref ref-type="bibr" rid="bib134">Wu et al., 2025</xref>). The SF of the Shaker-family channel has the sequence âTVGYGDâ. The first step involves a partial twist of the P-loop backbone, particularly involving the upmost SF residue D30â (D379 in K<sub>V</sub>1.2), which originally stabilizes itself by interacting with W17â (W336 in K<sub>V</sub>1.2). The second step is the reorientation of the upper-middle SF residue Y28â (Y377 in K<sub>V</sub>1.2) upward, which normally participates in hydrogen bonds with nearby pore-helix residues, to fill some of the original volume occupied by D30â.</p><p>In contrast, the hERG SF is characterized by the sequence âSVGFGNâ. In the upper SF of the hERG channel, phenylalanine (F) replaces the tyrosine (Y) found in many K<sup>+</sup> channels including Shaker and K<sub>V</sub>1.2. Phenylalanine has a non-polar benzyl side chain, whereas tyrosine has a polar hydroxyl group attached to its benzene ring. The hydroxyl group in tyrosine can form additional hydrogen bonds, which may stabilize different SF conformations in other K<sup>+</sup> channels compared to hERG. Similarly, at the outermost end of the SF of hERG, asparagine (N) replaces the aspartate (D) found in many other K<sup>+</sup> channels. Asparagine is uncharged, while aspartate introduces a negative charge through its carboxylate group, which could explain the differences in ion coordination and gating dynamics. These structural differences may explain why the hERG channel adopts a similar but distinct SF rearrangement compared to other K<sup>+</sup> channels (such as Shaker and K<sub>V</sub>1.2) and can have a slightly different structural mechanism of the C-type inactivation.</p></sec><sec id="s3-5"><title>Limitations, opportunities, and broader implications</title><p>Despite the promising results, our study is not without limitations. While AlphaFold has demonstrated remarkable accuracy in numerous instances (<xref ref-type="bibr" rid="bib4">AlQuraishi, 2019</xref>; <xref ref-type="bibr" rid="bib54">Jumper et al., 2021b</xref>; <xref ref-type="bibr" rid="bib126">Varadi and Velankar, 2023</xref>), it is important to note that the predicted models may not always be reliably accurate to assess drug binding (<xref ref-type="bibr" rid="bib58">Karelina et al., 2023</xref>). Moreover, hERG channel inactivation and closure might encompass a range of states, as was shown for other ion channels (<xref ref-type="bibr" rid="bib16">Catterall et al., 2020</xref>; <xref ref-type="bibr" rid="bib35">Goldschen-Ohm et al., 2013</xref>; <xref ref-type="bibr" rid="bib45">Hite and MacKinnon, 2017</xref>; <xref ref-type="bibr" rid="bib74">Li et al., 2024</xref>; <xref ref-type="bibr" rid="bib138">Yao et al., 2024</xref>), and the conformations we have identified could potentially represent just a few possibilities within this broad spectrum. Our models excluded the N-terminal PAS domain due to GPU memory limitations, despite its inclusion in initial templates. This omission may overlook its potential roles in gating kinetics and allosteric effects on drug binding (<xref ref-type="bibr" rid="bib1">Abi-Gerges et al., 2011</xref>; <xref ref-type="bibr" rid="bib37">Goversen et al., 2019</xref>; <xref ref-type="bibr" rid="bib39">Gustina and Trudeau, 2013</xref>; <xref ref-type="bibr" rid="bib41">Harchi et al., 2018</xref>; <xref ref-type="bibr" rid="bib97">Perissinotti et al., 2018</xref>). Future research will explore the full-length hERG channel with enhanced computational resources to assess these regionsâ contributions to conformational state transitions and pharmacology.</p><p>As noted in recent studies, pLDDT scores are not reliable indicators for selecting alternative conformations (<xref ref-type="bibr" rid="bib10">Bryant and NoÃ©, 2024</xref>; <xref ref-type="bibr" rid="bib17">Chakravarty et al., 2024</xref>). To address this, we performed a protein backbone dihedral angle analysis in the regions of interest to ensure that our evaluation captured a representative range of sampled conformations. GALigandDock docking results, while insightful, are provisional (<xref ref-type="bibr" rid="bib79">Maly et al., 2022</xref>) and limited by a rigid protein backbone assumption, thus preventing observation of drug-binding-induced allosteric modifications (<xref ref-type="bibr" rid="bib42">Harris et al., 2024</xref>). As such, the results presented here should be interpreted as qualitative indicators of state-dependent binding trends rather than definitive quantitative predictions. To achieve more accurate binding affinity estimates, future studies could leverage MD simulations, incorporating methods like Molecular Mechanics/PoissonâBoltzmann Surface Area to assess relative ligand-binding energies during MD trajectories (<xref ref-type="bibr" rid="bib82">Miller et al., 2012</xref>; <xref ref-type="bibr" rid="bib89">Ngo et al., 2024</xref>; <xref ref-type="bibr" rid="bib130">Wang et al., 2016</xref>). These insights could be further extended by integrating MD results with multiscale functional modeling approaches, as demonstrated in our earlier work (<xref ref-type="bibr" rid="bib27">DeMarco et al., 2021</xref>; <xref ref-type="bibr" rid="bib137">Yang et al., 2020</xref>).</p><p>Our approach currently relies on well-characterized systems with ample static structures, MD simulation data, and mutagenesis insights, as demonstrated with the hERG channel, which may limit its applicability to less-studied proteins. Recently, AlphaFold3 was released, incorporating a diffusion model that enables the prediction of proteins in complex with other proteins, small molecules, nucleic acids, and ions (<xref ref-type="bibr" rid="bib2">Abramson et al., 2024</xref>). We plan to explore the applicability of our template-guided methodology in a follow-up study, leveraging AlphaFold3âs advanced diffusion-based architecture to enhance protein conformational state predictions and state-specific drug docking, particularly given its improved capabilities for modeling small moleculeâprotein interactions.</p><p>Correlating simulated drug-binding affinities with experimental results remains inherently challenging. As demonstrated in multiple studies, drug-binding potency is highly dependent on the measurement technique used, resulting in different IC<sub>50</sub> values being reported for the same channelâdrug pairing (<xref ref-type="bibr" rid="bib3">Alexandrou et al., 2006</xref>; <xref ref-type="bibr" rid="bib5">Asai et al., 2021</xref>; <xref ref-type="bibr" rid="bib13">Cameron et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Chiu et al., 2004</xref>; <xref ref-type="bibr" rid="bib33">Ficker et al., 1998</xref>; <xref ref-type="bibr" rid="bib40">Hansen et al., 2006</xref>; <xref ref-type="bibr" rid="bib51">Johnson and Trudeau, 2023</xref>; <xref ref-type="bibr" rid="bib62">Kushida et al., 2002</xref>; <xref ref-type="bibr" rid="bib93">Orvos et al., 2019</xref>; <xref ref-type="bibr" rid="bib96">Paul et al., 2002</xref>; <xref ref-type="bibr" rid="bib98">Perrin et al., 2008</xref>; <xref ref-type="bibr" rid="bib104">Rampe et al., 1997</xref>; <xref ref-type="bibr" rid="bib119">Suessbrich et al., 1997</xref>; <xref ref-type="bibr" rid="bib121">Tanaka et al., 2014</xref>; <xref ref-type="bibr" rid="bib128">Walker et al., 1999</xref>; <xref ref-type="bibr" rid="bib139">Zhang et al., 1999</xref>; <xref ref-type="bibr" rid="bib142">Zhou et al., 1998</xref>) as was explored in detail in our recent study (<xref ref-type="bibr" rid="bib36">Gomis-Tena et al., 2020</xref>). Additionally, knowing the binding free energies of a drug is not the complete story; binding rates such as <italic>k<sub>on</sub></italic> (association rate) and <italic>k<sub>off</sub></italic> (dissociation rate) are also crucial for a quantitative evaluation of drug binding to the channel.</p><p>In conclusion, this study advances our understanding of hERG channel structural dynamics and state-dependent drug binding, while also demonstrating the broader potential of AlphaFold2-based modeling workflows. Our findings provide a foundation for integrating deep learning-based structure prediction with simulation and functional modeling to study other ion channels and membrane proteins. As computational methods continue to evolve, including alternatives like RoseTTAFold (<xref ref-type="bibr" rid="bib6">Baek et al., 2021</xref>) and ESMFold (<xref ref-type="bibr" rid="bib76">Lin et al., 2023</xref>), such integrated approaches will be increasingly valuable for addressing complex questions in ion channel physiology and pharmacology, with important implications for cardiac drug safety and therapeutic development.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Introduction to AlphaFold2</title><p>AlphaFold2 employs a deep learning architecture that integrates several innovative components, including residue pair representation comprising an architecture module that represents each possible pair of amino acid residues in the sequence. This pairwise representation captures the interactions between residues that determine protein folding. AlphaFold2 also applies an attention mechanism, which constitutes a transformer-based model (similar to the architecture used in natural language processing) to weigh the influence of different parts of the input data differently (<xref ref-type="bibr" rid="bib53">Jumper et al., 2021a</xref>). In AlphaFold2, the effect is to emphasize interactions between certain amino acid residues more than others based on how they might impact folding. There is also a so-called Evoformer block within the learning model that specifically processes the evolutionary data from MSAs, enabling the model to effectively incorporate evolutionary information (<xref ref-type="bibr" rid="bib53">Jumper et al., 2021a</xref>). After processing through the Evoformer, intermediate representations are used to predict the distances and angles between residues as part of an iterative feedback process. A critical feature of AlphaFold2 is its iterative refinement, where pairwise residue representations, MSAs, and initial structural predictions are recycled through the model multiple times, improving accuracy with each iteration.</p><p>Due to the time-intensive process of creating MSAs for AlphaFold2, the ColabFold (<xref ref-type="bibr" rid="bib85">Mirdita et al., 2022</xref>) webserver was made to streamline protein structure prediction by combining MMseqs2 (<xref ref-type="bibr" rid="bib84">Mirdita et al., 2019</xref>) sequence search toolkit with AlphaFold2, enhancing runtime efficiency while preserving high prediction accuracy. ColabFold is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/sokrypton/ColabFold">https://github.com/sokrypton/ColabFold</ext-link> (<xref ref-type="bibr" rid="bib94">Ovchinnikov and Steinegger, 2025</xref>).</p></sec><sec id="s4-2"><title>hERG channel model generation with ColabFold</title><p>We modeled the hERG potassium channel in three functional states (closed, open, and inactivated) using ColabFold with tailored structural templates and configurations. The structural templates were assembled by first using ChimeraX (<xref ref-type="bibr" rid="bib99">Pettersen et al., 2021</xref>) to superimpose all relevant PDB entries with the âmatchmakerâ command. Unnecessary regions were then removed from the aligned models, leaving only the fragments intended for use as templates. These remaining segments were merged into a single model using the âcombineâ command. This approach preserves the spatial arrangement of template regions as they are expected to appear in the AlphaFold prediction, which can be important for guiding the model toward a specific conformation. The following sections describe the template selection process for each conformational state.</p><sec id="s4-2-1"><title>Closed-state template</title><p>For modeling the closed state, we used a structural fragment from an experimental structure of a homologous protein that exhibits the desired characteristics of the target state. Specifically, for modeling the closed state of the hERG channel, we require the voltage sensor to be in a deactivated conformation.</p><p>We selected the deactivated VSD from the closed-state rat EAG channel cryo-EM structure (PDB 8EP1, residues H208âH343) (<xref ref-type="bibr" rid="bib80">Mandala and MacKinnon, 2022</xref>) as the template to guide AlphaFold2 toward predicting a deactivated VSD conformation.</p><p>We combined this with the SF and adjacent pore helix from the open-state hERG cryo-EM structure (PDB 5VA2, residues I607âT634) (<xref ref-type="bibr" rid="bib131">Wang and MacKinnon, 2017</xref>) to maintain its conductive conformation, as it is generally understood that K<sup>+</sup> channel closure primarily involves the intracellular gate rather than significant SF distortion. Including additional helices (e.g., S5âS6) or the entire membrane domain from PDB 8EP1 risked biasing the model toward the EAG channelâs pore structure, which differs from hERGâs, while omitting the cytosolic domain ensured focus on the VSD-driven closure without over-constraining cytoplasmic domain interactions.</p></sec><sec id="s4-2-2"><title>Open-state template</title><p>For modeling the open state of the hERG channel, we utilized the existing cryo-EM structure of the hERG channel (PDB 5VA2) (<xref ref-type="bibr" rid="bib131">Wang and MacKinnon, 2017</xref>). This structure was shown in our previous studies to be open and conducting (<xref ref-type="bibr" rid="bib83">Miranda et al., 2020</xref>; <xref ref-type="bibr" rid="bib137">Yang et al., 2020</xref>). We rebuilt the missing extracellular loops using the Rosetta LoopRemodel protocol (<xref ref-type="bibr" rid="bib46">Huang et al., 2011</xref>; <xref ref-type="bibr" rid="bib69">Leman et al., 2020</xref>) to generate a complete model that serves as the basis for MD and drug docking simulations.</p><p>However, we also wanted to test the potential for AlphaFold2 to emulate the open-state model. To do so, specific regions of the putative open state hERG model (PDB 5VA2) (<xref ref-type="bibr" rid="bib131">Wang and MacKinnon, 2017</xref>), namely the VSD (W398âV549), the SF with adjacent pore helix (I607âT634), a part of S6 helix and the cytosolic domain (S660âR863), were provided to ColabFold as structural templates. Then, 100 diverse models were generated for further analysis.</p></sec><sec id="s4-2-3"><title>Inactivated-state template</title><p>In situations where structural information about state transitions is limited or inconsistent, we adopt a second strategy. We erase regions expected to undergo conformational changes during state transition from an existing protein structure. For hERG inactivation in particular, where we know the SF shifts from an open, conductive conformation to a distorted, non-conductive state (<xref ref-type="bibr" rid="bib83">Miranda et al., 2020</xref>), we initially used only the cytosolic domain from the open-state PDB 5VA2 (residues S660âR863) as a template. Excluding the SF or attached helices at this stage avoided locking the model into the open-state SF, and the cytosolic domain alone provided a minimal scaffold to maintain hERGâs intracellular architecture without dictating pore dynamics. Following the initial prediction, we initiated more extensive sampling by using one of the predicted SFs that differs from the traditional open-state SF (PDB 5VA2) (<xref ref-type="bibr" rid="bib131">Wang and MacKinnon, 2017</xref>) as a structural seed, aiming to guide predictions away from the open-state configuration. The VSD and cytosolic domain were also included in this state to discourage pore closure during prediction.</p></sec><sec id="s4-2-4"><title>ColabFold configuration</title><p>Structural templates were converted to CIF format and renamed â5va2â (after hERG cryo-EM structure) to meet ColabFoldâs four-letter code requirement. We optimized the following settings based on prior studies (<xref ref-type="bibr" rid="bib9">Brown et al., 2024</xref>; <xref ref-type="bibr" rid="bib26">Del Alamo et al., 2022</xref>; <xref ref-type="bibr" rid="bib85">Mirdita et al., 2022</xref>; <xref ref-type="bibr" rid="bib108">Sala et al., 2023</xref>) to sample diverse conformations:</p><list list-type="bullet" id="list6"><list-item><p><italic>max_msa =</italic> â256:512â: limit to 256 cluster centers and 512 sequences (down from 512:1024).</p></list-item><list-item><p><italic>num_seeds</italic> = 20: generate 5 models per seed, yielding 100 models per state, except for the initial inactivated-state phase (1 seed, 5 models).</p></list-item><list-item><p><italic>use_dropout</italic> = True: enable stochastic sampling for ambiguous regions.</p></list-item><list-item><p><italic>num_recycles</italic> = 20, <italic>recycle_early_stop_tolerance</italic> = 0.5: recycle up to 20 iterations, stop if pLDDT deviation fell below 0.5 after previous recycle.</p></list-item></list><p>It is important to note that the length of the structural template often affects the diversity of the predictions. Using a template that is too long or positioned differently may cause AlphaFold to generate models that do not reflect the templateâs features, and this behavior can vary depending on the system. AlphaFoldâs behavior is shaped by nonlinear patterns learned from vast structural data, making its internal logic not fully transparent. However, through careful tuning and testing, it is possible to influence its outputs by experimenting with input templates that vary in both length and position, as demonstrated in this study. As an example, <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref> demonstrates how this approach can be applied to model the closed, resting state of Na<sub>V</sub>1.5 using a structural template derived from the Na<sub>V</sub>1.7 channel.</p><p>For our study, the N-terminal PAS domain (residues M1âR397) was not included in the final prediction due to graphics card memory limitation making the resultant model (W398âR863) resemble hERG 1b isoform (<xref ref-type="bibr" rid="bib101">Phartiyal et al., 2007</xref>).</p></sec><sec id="s4-2-5"><title>Clustering of predicted models</title><p>The resulting 100 models for each structural state were categorized into clusters based on all-atom RMSD between those models. Closed-state models were clustered with a threshold of 0.75 Ã across the entire channel, whereas inactivated- and open-state models focused on the SF (residues S624âG628), with a more stringent threshold of 0.35 Ã.</p><p>We ranked the models in the cluster by their average per-residue confidence metric (pLDDT), which assesses the likelihood that the predicted structure aligns with an experimentally determined structure (<xref ref-type="bibr" rid="bib53">Jumper et al., 2021a</xref>). pLDDT value above 90 is considered to be highly reliable, and those between 70 and 90 as reliable with generally good protein backbone structure prediction (<xref ref-type="bibr" rid="bib53">Jumper et al., 2021a</xref>). Lower scores indicate regions of lower confidence and may be unstructured. Cluster 1 is defined in this study to be the cluster with the highest average pLDDT among all the clusters.</p></sec><sec id="s4-2-6"><title>Structural refinement</title><p>Afterward, we refined the preliminary atomistic structural models putatively representing each functional state of the hERG channel (open, inactivated, and closed) using the Rosetta FastRelax protocol (<xref ref-type="bibr" rid="bib34">Fleishman et al., 2011</xref>; <xref ref-type="bibr" rid="bib69">Leman et al., 2020</xref>) with an implicit membrane to optimize each residue conformation and resolve any steric clashes. The protocol was set to repeat 15 times and included an implicit POPC membrane environment. For each final model, 10 separate relaxation runs were executed, and the highest scoring model from these runs was selected for further simulations and analyses.</p></sec></sec><sec id="s4-3"><title>Atomistic MD simulations to evaluate hERG channel conduction</title><sec id="s4-3-1"><title>System assembly</title><p>The CHARMM-GUI web server (<xref ref-type="bibr" rid="bib50">Jo et al., 2008</xref>) was employed to embed hERG channel structural models within tetragonal patches of phospholipid bilayers, each comprising approximately 230â240 POPC lipid molecules. The resulting assemblies were immersed in a 0.3 M KCl aqueous solution, yielding molecular systems with an approximate total of 138,000â144,000 atoms. Residue protonation reflected a pH of 7.4, with subunits terminated with standard charged N- and C-termini.</p></sec><sec id="s4-3-2"><title>Simulation setup</title><p>MD simulations were conducted using the Amber22 (<xref ref-type="bibr" rid="bib14">Case et al., 2005</xref>) software suite. The simulations utilized standard all-atom Chemistry at Harvard Macromolecular Mechanics (CHARMM) force fields such as CHARMM36m (<xref ref-type="bibr" rid="bib47">Huang et al., 2017</xref>) for proteins, C36 (<xref ref-type="bibr" rid="bib60">Klauda et al., 2010</xref>) for lipids, and standard ion parameters (<xref ref-type="bibr" rid="bib7">Beglov and Roux, 1994</xref>), in conjunction with the TIP3P water model (<xref ref-type="bibr" rid="bib52">Jorgensen et al., 1983</xref>).</p><p>The systems were maintained at 310.15 K and 1 atm pressure in the isobaricâisothermal (<italic>NPT</italic>) ensemble, facilitated by Langevin thermostat and the Berendsen barostat. Non-bonded interactions were calculated with a cutoff of 12 Ã. Long-range electrostatic forces were computed using the Particle Mesh Ewald method (<xref ref-type="bibr" rid="bib25">Darden et al., 1993</xref>), and van der Waals interactions were not subjected to long-range correction as per recommendations for the C36 lipid force field (<xref ref-type="bibr" rid="bib60">Klauda et al., 2010</xref>). All hydrogen-connected covalent bonds were constrained using the SHAKE algorithm to enable a 2-fs MD simulation time step (<xref ref-type="bibr" rid="bib107">Ryckaert et al., 1977</xref>).</p></sec><sec id="s4-3-3"><title>MD equilibration protocol and production run</title><p>Equilibration began with harmonic restraints imposed on all protein atoms and lipid tail dihedral angles, initially set at 20 kcal/mol/ÃÂ² and reduced to 2.5 kcal/mol/ÃÂ² over ~2 ns. A subsequent 90 ns equilibration phase further decreased the restraints to 0.1 kcal/mol/ÃÂ², initially encompassing all atoms in the protein and eventually focusing solely on the backbone atoms of pore-domain residues (G546 to F720). In selected MD simulations, an electric field was applied along the <italic>Z</italic> direction to mimic membrane voltage (<xref ref-type="bibr" rid="bib38">Gumbart et al., 2012</xref>), increasing linearly over the final 10 ns of equilibration to reach either 500 or 750 mV. This setup prefaced a production phase lasting 910 ns, totaling 1 Î¼s of total simulation time per each case.</p></sec></sec><sec id="s4-4"><title>Docking of small-molecule drugs to hERG channel models</title><sec id="s4-4-1"><title>Ligand preparation</title><p>Ligand structures (i.e., drugs) were retrieved from the PubChem (<xref ref-type="bibr" rid="bib59">Kim et al., 2016</xref>) and ZINC (<xref ref-type="bibr" rid="bib123">Tingle et al., 2023</xref>) databases. In this study, we considered the protonation states of the top two most dominant species at the physiological pH of 7.4, computed using the HendersonâHasselbalch equation. After these initial modifications, each ligand's partial atomic charges, as well as atom and bond types, were refined using AM1-BCC correction via the Antechamber module in AmberTools22 (<xref ref-type="bibr" rid="bib15">Case et al., 2023</xref>; <xref ref-type="bibr" rid="bib14">Case et al., 2005</xref>).</p><p>Prior to the docking process, each ligand was individually positioned within the pore of the hERG channel, specifically between the key drug-binding residues, Y652 and F656, located on the pore-lining S6 helices using ChimeraX (<xref ref-type="bibr" rid="bib99">Pettersen et al., 2021</xref>).</p></sec><sec id="s4-4-2"><title>Drug docking</title><p>Docking was executed using the GALigandDock (<xref ref-type="bibr" rid="bib95">Park et al., 2021</xref>) Rosetta mover, a component of the Rosetta software suite (<xref ref-type="bibr" rid="bib69">Leman et al., 2020</xref>). The <italic>DockFlex</italic> mode was utilized for this purpose with a spatial padding of 6 Ã. For every individual hERG channelâligand pair, a substantial collection of 25,000 docking poses was generated for each ligandâhERG channel complex. This extensive array of poses was intended to ensure a comprehensive exploration of potential ligand-binding configurations and orientations within the hERG channel pore.</p></sec><sec id="s4-4-3"><title>Clustering the results</title><p>The top 100 lowest energy poses were selected and clustered based on the structural similarity of ligand positions, using all-atom RMSD while accounting for the fourfold symmetry of the hERG channel. To identify the most representative binding mode, we applied a hybrid scoring approach that considers both binding energy and cluster size. Clusters with similar average binding energies (within a defined tolerance of Â± 0.25 kcal/mol from the best-scoring cluster) were compared, and preference was given to non-outlier clusters with larger numbers of poses. The cluster with the most favorable balance of energy and convergence was considered the best and selected for further analysis, and its mean binding energy and standard deviation were used to represent the drugâchannel interaction. This approach was designed to reduce sensitivity to isolated low-energy poses that may not reflect stable binding modes and to favor interactions that are both energetically favorable and structurally well-converged.</p></sec><sec id="s4-4-4"><title>Visualization</title><p>Within the selected cluster, we chose the top scoring pose as the representative pose for further analysis. This pose was then subjected to a detailed analysis of proteinâligand interactions utilizing the Grapheme Toolkit from the OpenEye software suite (<ext-link ext-link-type="uri" xlink:href="https://www.eyesopen.com/">https://www.eyesopen.com/</ext-link>). The criteria for detecting interactions are outlined in the OEChem Toolkit manual (<ext-link ext-link-type="uri" xlink:href="https://docs.eyesopen.com/toolkits/python/oechemtk/OEBioClasses/OEPerceiveInteractionOptions.html">https://docs.eyesopen.com/toolkits/python/oechemtk/OEBioClasses/OEPerceiveInteractionOptions.html</ext-link>), with two modifications to minimize clutter: the <italic>MaxContactFraction</italic> is set to 1 (default: 1.2), and the <italic>MaxCationPiAngle</italic> is adjusted to 30Â° (default: 40Â°). The interaction patterns and binding sites were subsequently rendered as a two-dimensional image for comprehensive visual interpretation. Additionally, for a more detailed understanding of the spatial arrangement, three-dimensional visualization of the protein-ligand complexes was conducted using the ChimeraX (<xref ref-type="bibr" rid="bib99">Pettersen et al., 2021</xref>) software.</p></sec></sec><sec id="s4-5"><title>Comparing simulated and experimental drug-binding affinities</title><sec id="s4-5-1"><title>Five-state hERG Markov model for state probability prediction</title><p>Over the time course of experimental recordings of hERG inhibition by various drugs, the channel can be in different functional states, each bound by drugs with different ionization states, making it difficult to compare experimental and simulated binding affinities. Moreover, different studies utilize different electrophysiological protocols to measure state-dependent ligand binding, further complicating comparisons.</p><p>To address this complication, we used a five-state hERG Markov model to predict the probabilities of the channel in each state (open, closed, and inactivated) during a given experimental protocol (<xref ref-type="bibr" rid="bib105">Romero et al., 2015</xref>). Transition rate constants are provided in <xref ref-type="table" rid="table5">Table 5</xref>. The protocols that were used in the model to calculate each state probabilities (closed states: C3 + C2 + C1, inactivated state: I, and open state: O) are shown in <xref ref-type="table" rid="table6">Table 6</xref>. To simulate the inhibitory effects of the drug on the hERG channel current, <italic>I</italic><sub>Kr</sub>, we decreased the peak conductance, <italic>G</italic><sub>Kr</sub>, in a concentration-dependent fashion using a concentration response relationship with a Hill coefficient of 1 (<italic>n</italic> = 1) as follows:<disp-formula id="equ1"><alternatives><mml:math id="m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mtext>Kr</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mtext>Kr,max</mml:mtext></mml:mrow></mml:msub><mml:mo>â</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mtext>Drug</mml:mtext><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:msub><mml:mtext>IC</mml:mtext><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mi>n</mml:mi></mml:msup></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math><tex-math id="t1">\begin{document}$$\displaystyle G_{\text{Kr}} = G_{\text{Kr,max}} \cdot \left( \frac{1}{1 + \left( \frac{[\text{Drug}]}{\text{IC}_{50}} \right)^n} \right) $$\end{document}</tex-math></alternatives></disp-formula></p><p>where <italic>G</italic><sub>Kr,max</sub> is the nominal conductance value obtained from each ventricular myocyte model, [Drug] is a molar drug concentration, and the IC<sub>50</sub> is the concentration of drug that produces a 50% inhibition of the targeted transmembrane current, that is, <italic>I</italic><sub>Kr</sub> in this case (see <xref ref-type="table" rid="table6">Table 6</xref>).</p><table-wrap id="table5" position="float"><label>Table 5.</label><caption><title>Transition rates in the hERG channel (I<sub>Kr</sub>) Markov model.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="bottom" colspan="2">Transition rates (ms<sup>â1</sup>)Drug free Kr channel</th></tr></thead><tbody><tr><td align="left" valign="bottom">C3âC2</td><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>a</mml:mi><mml:mi>e</mml:mi><mml:mo>=</mml:mo><mml:mtext>Â </mml:mtext><mml:mfrac><mml:mi>T</mml:mi><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>24.335</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mi>T</mml:mi></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>0.0112</mml:mn><mml:mo>Ã</mml:mo><mml:mi>V</mml:mi><mml:mo>â</mml:mo><mml:mn>25.914</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math><tex-math id="inft1">\begin{document}$ae=\ \frac{T}{T_{base}}e^{\left (24.335+\frac{T_{base}}{T}\left (0.0112\times V-25.914\right)\right)}$\end{document}</tex-math></alternatives></inline-formula></td></tr><tr><td align="left" valign="bottom">C2âC3</td><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mo>=</mml:mo><mml:mtext>Â </mml:mtext><mml:mfrac><mml:mi>T</mml:mi><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>13.688</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mi>T</mml:mi></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>â</mml:mo><mml:mn>0.0603</mml:mn><mml:mo>Ã</mml:mo><mml:mi>V</mml:mi><mml:mo>â</mml:mo><mml:mn>15.707</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math><tex-math id="inft2">\begin{document}$be=\ \frac{T}{T_{base}}e^{\left (13.688+\frac{T_{base}}{T}\left (-0.0603\times V-15.707\right)\right)}$\end{document}</tex-math></alternatives></inline-formula></td></tr><tr><td align="left" valign="bottom">C2âC1</td><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mtext>Â </mml:mtext><mml:mfrac><mml:mi>T</mml:mi><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>22.746</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mi>T</mml:mi></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>â</mml:mo><mml:mn>25.914</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math><tex-math id="inft3">\begin{document}$ain=\ \frac{T}{T_{base}}e^{\left (22.746+\frac{T_{base}}{T}\left (-25.914\right)\right)}$\end{document}</tex-math></alternatives></inline-formula></td></tr><tr><td align="left" valign="bottom">C1âC2</td><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>b</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mtext>Â </mml:mtext><mml:mfrac><mml:mi>T</mml:mi><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>13.193</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mi>T</mml:mi></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>â</mml:mo><mml:mn>15.707</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math><tex-math id="inft4">\begin{document}$bin=\ \frac{T}{T_{base}}e^{\left (13.193+\frac{T_{base}}{T}\left (-15.707\right)\right)}$\end{document}</tex-math></alternatives></inline-formula></td></tr><tr><td align="left" valign="bottom">C1âO</td><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>a</mml:mi><mml:mi>a</mml:mi><mml:mo>=</mml:mo><mml:mtext>Â </mml:mtext><mml:mfrac><mml:mi>T</mml:mi><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>22.098</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mi>T</mml:mi></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>0.0365</mml:mn><mml:mo>Ã</mml:mo><mml:mi>V</mml:mi><mml:mo>â</mml:mo><mml:mn>25.914</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math><tex-math id="inft5">\begin{document}$aa=\ \frac{T}{T_{base}}e^{\left (22.098+\frac{T_{base}}{T}\left (0.0365\times V-25.914\right)\right)}$\end{document}</tex-math></alternatives></inline-formula></td></tr><tr><td align="left" valign="bottom">OâC1</td><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>b</mml:mi><mml:mi>b</mml:mi><mml:mo>=</mml:mo><mml:mtext>Â </mml:mtext><mml:mfrac><mml:mi>T</mml:mi><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>7.313</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mi>T</mml:mi></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>â</mml:mo><mml:mn>0.0399</mml:mn><mml:mo>Ã</mml:mo><mml:mi>V</mml:mi><mml:mo>â</mml:mo><mml:mn>15.707</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math><tex-math id="inft6">\begin{document}$bb=\ \frac{T}{T_{base}}e^{\left (7.313+\frac{T_{base}}{T}\left (-0.0399\times V-15.707\right)\right)}$\end{document}</tex-math></alternatives></inline-formula></td></tr><tr><td align="left" valign="bottom">OâI</td><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>Î²</mml:mi><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mi>T</mml:mi><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>30.016</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mi>T</mml:mi></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>0.0223</mml:mn><mml:mo>Ã</mml:mo><mml:mi>V</mml:mi><mml:mo>â</mml:mo><mml:mn>30.88</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup><mml:mo>Ã</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mn>5.4</mml:mn><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mi>K</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>o</mml:mi></mml:mrow></mml:msup></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>0.4</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math><tex-math id="inft7">\begin{document}$\beta i= \frac{T}{T_{base}}e^{\left (30.016+\frac{T_{base}}{T}\left (0.0223\times V-30.88\right)\right)}\times \left (\frac{5.4}{\left [K\right ]^{o}}\right)^{0.4}$\end{document}</tex-math></alternatives></inline-formula></td></tr><tr><td align="left" valign="bottom">IâO</td><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf8"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>Î±</mml:mi><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mtext>Â </mml:mtext><mml:mfrac><mml:mi>T</mml:mi><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>30.061</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mi>T</mml:mi></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>â</mml:mo><mml:mn>0.0312</mml:mn><mml:mo>Ã</mml:mo><mml:mi>V</mml:mi><mml:mo>â</mml:mo><mml:mn>33.243</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math><tex-math id="inft8">\begin{document}$\alpha i=\ \frac{T}{T_{base}}e^{\left (30.061+\frac{T_{base}}{T}\left (-0.0312\times V-33.243\right)\right)}$\end{document}</tex-math></alternatives></inline-formula></td></tr><tr><td align="left" valign="bottom">Base temperature (<italic>T</italic><sub>base</sub>)</td><td align="char" char="." valign="bottom">310 K</td></tr><tr><td align="left" valign="bottom">Temperature (<italic>T</italic>)</td><td align="left" valign="bottom">Please see <xref ref-type="table" rid="table6">Table 6</xref></td></tr></tbody></table></table-wrap><table-wrap id="table6" position="float"><label>Table 6.</label><caption><title>Voltage stimulation protocols and IC<sub>50</sub> for drugs used in the <italic>I</italic><sub>kr</sub> Markov model.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Drugs</th><th align="left" valign="bottom">IC<sub>50</sub> (nM)</th><th align="left" valign="bottom">Dose (nM)</th><th align="left" valign="bottom">Temperature (K)</th><th align="left" valign="bottom">Voltage protocols</th><th align="left" valign="bottom">Refs</th></tr></thead><tbody><tr><td align="left" valign="bottom">Astemizole</td><td align="char" char="." valign="bottom">26</td><td align="char" char="." valign="bottom">80</td><td align="char" char="." valign="bottom">310</td><td align="left" valign="bottom"><inline-graphic mimetype="image" mime-subtype="tif" xlink:href="elife-104901-inf001-v1.tif"/> </td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib20">Chiu et al., 2004</xref></td></tr><tr><td align="left" valign="bottom" rowspan="2">Terfenadine</td><td align="char" char="." valign="bottom">31</td><td align="char" char="." valign="bottom">100</td><td align="char" char="." valign="bottom">310</td><td align="left" valign="bottom"><inline-graphic mimetype="image" mime-subtype="tif" xlink:href="elife-104901-inf002-v1.tif"/> </td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib93">Orvos et al., 2019</xref></td></tr><tr><td align="char" char="." valign="bottom">30.6</td><td align="char" char="." valign="bottom">30</td><td align="char" char="." valign="bottom">310</td><td align="left" valign="bottom"><inline-graphic mimetype="image" mime-subtype="tif" xlink:href="elife-104901-inf003-v1.tif"/> </td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib121">Tanaka et al., 2014</xref></td></tr><tr><td align="left" valign="bottom" rowspan="2">Cisapride</td><td align="char" char="." valign="bottom">44.5</td><td align="char" char="." valign="bottom">100</td><td align="char" char="." valign="bottom">295</td><td align="left" valign="bottom"><inline-graphic mimetype="image" mime-subtype="tif" xlink:href="elife-104901-inf004-v1.tif"/> </td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib104">Rampe et al., 1997</xref></td></tr><tr><td align="char" char="." valign="bottom">6.9</td><td align="char" char="." valign="bottom">20</td><td align="char" char="." valign="bottom">310</td><td align="left" valign="bottom"><inline-graphic mimetype="image" mime-subtype="tif" xlink:href="elife-104901-inf005-v1.tif"/> </td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib20">Chiu et al., 2004</xref></td></tr><tr><td align="left" valign="bottom" rowspan="2">Verapamil</td><td align="char" char="." valign="bottom">143</td><td align="char" char="." valign="bottom">500</td><td align="char" char="." valign="bottom">295</td><td align="left" valign="bottom"><inline-graphic mimetype="image" mime-subtype="tif" xlink:href="elife-104901-inf006-v1.tif"/> </td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib139">Zhang et al., 1999</xref></td></tr><tr><td align="char" char="." valign="bottom">180.4</td><td align="char" char="." valign="bottom">300</td><td align="char" char="." valign="bottom">310</td><td align="left" valign="bottom"><inline-graphic mimetype="image" mime-subtype="tif" xlink:href="elife-104901-inf007-v1.tif"/> </td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib51">Johnson and Trudeau, 2023</xref></td></tr><tr><td align="left" valign="bottom">dl-Sotalol</td><td align="char" char="." valign="bottom">515,500</td><td align="char" char="." valign="bottom">300,000</td><td align="char" char="." valign="bottom">310</td><td align="left" valign="bottom"><inline-graphic mimetype="image" mime-subtype="tif" xlink:href="elife-104901-inf008-v1.tif"/> </td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib98">Perrin et al., 2008</xref></td></tr><tr><td align="left" valign="bottom" rowspan="2">Dofetilide</td><td align="char" char="." valign="bottom">320</td><td align="char" char="." valign="bottom">1000</td><td align="char" char="." valign="bottom">295</td><td align="left" valign="bottom"><inline-graphic mimetype="image" mime-subtype="tif" xlink:href="elife-104901-inf009-v1.tif"/> </td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib33">Ficker et al., 1998</xref></td></tr><tr><td align="char" char="." valign="bottom">17.9</td><td align="char" char="." valign="bottom">10</td><td align="char" char="." valign="bottom">295</td><td align="left" valign="bottom"><inline-graphic mimetype="image" mime-subtype="tif" xlink:href="elife-104901-inf010-v1.tif"/> </td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib70">Li et al., 2012</xref></td></tr><tr><td align="left" valign="bottom">Haloperidol</td><td align="char" char="." valign="bottom">1000</td><td align="char" char="." valign="bottom">3000</td><td align="char" char="." valign="bottom">295</td><td align="left" valign="bottom"><inline-graphic mimetype="image" mime-subtype="tif" xlink:href="elife-104901-inf011-v1.tif"/> </td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib119">Suessbrich et al., 1997</xref></td></tr><tr><td align="left" valign="bottom">Amiodarone</td><td align="char" char="." valign="bottom">45</td><td align="char" char="." valign="bottom">100</td><td align="char" char="." valign="bottom">310</td><td align="left" valign="bottom"><inline-graphic mimetype="image" mime-subtype="tif" xlink:href="elife-104901-inf012-v1.tif"/> </td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib140">Zhang et al., 2016</xref></td></tr><tr><td align="left" valign="bottom">E-4031</td><td align="char" char="." valign="bottom">7.7</td><td align="char" char="." valign="bottom">10</td><td align="char" char="." valign="bottom">310</td><td align="left" valign="bottom"><inline-graphic mimetype="image" mime-subtype="tif" xlink:href="elife-104901-inf013-v1.tif"/></td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib142">Zhou et al., 1998</xref></td></tr><tr><td align="left" valign="bottom" rowspan="2">Clozapine</td><td align="char" char="." valign="bottom">28,300</td><td align="char" char="." valign="bottom">20,000</td><td align="char" char="." valign="bottom">295</td><td align="left" valign="bottom" rowspan="2"><inline-graphic mimetype="image" mime-subtype="tif" xlink:href="elife-104901-inf014-v1.tif"/></td><td align="char" char="." valign="bottom" rowspan="2"><xref ref-type="bibr" rid="bib66">Lee et al., 2006</xref></td></tr><tr><td align="char" char="." valign="bottom">22,900</td><td align="char" char="." valign="bottom">20,000</td><td align="char" char="." valign="bottom">295</td></tr><tr><td align="left" valign="bottom">NS1643</td><td align="char" char="." valign="bottom">10,500</td><td align="char" char="." valign="bottom">30,000</td><td align="char" char="." valign="bottom">310</td><td align="left" valign="bottom"><inline-graphic mimetype="image" mime-subtype="tif" xlink:href="elife-104901-inf015-v1.tif"/></td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib40">Hansen et al., 2006</xref></td></tr><tr><td align="left" valign="bottom" rowspan="2">Moxifloxacin</td><td align="char" char="." valign="bottom">65,000</td><td align="char" char="." valign="bottom">60,000</td><td align="char" char="." valign="bottom">295</td><td align="left" valign="bottom"><inline-graphic mimetype="image" mime-subtype="tif" xlink:href="elife-104901-inf016-v1.tif"/></td><td align="left" valign="bottom" rowspan="2"><xref ref-type="bibr" rid="bib3">Alexandrou et al., 2006</xref></td></tr><tr><td align="char" char="." valign="bottom">35,700</td><td align="char" char="." valign="bottom">600,000</td><td align="char" char="." valign="bottom">310</td><td align="left" valign="bottom"><inline-graphic mimetype="image" mime-subtype="tif" xlink:href="elife-104901-inf017-v1.tif"/></td></tr><tr><td align="left" valign="bottom" rowspan="2">Quinidine</td><td align="char" char="." valign="bottom">800</td><td align="char" char="." valign="bottom">500</td><td align="char" char="." valign="bottom">295</td><td align="left" valign="bottom"><inline-graphic mimetype="image" mime-subtype="tif" xlink:href="elife-104901-inf018-v1.tif"/></td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib136">Yan et al., 2016</xref></td></tr><tr><td align="char" char="." valign="bottom">410</td><td align="char" char="." valign="bottom">500</td><td align="char" char="." valign="bottom">310</td><td align="left" valign="bottom"><inline-graphic mimetype="image" mime-subtype="tif" xlink:href="elife-104901-inf019-v1.tif"/></td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib96">Paul et al., 2002</xref></td></tr><tr><td align="left" valign="bottom">Perhexiline</td><td align="char" char="." valign="bottom">7800</td><td align="char" char="." valign="bottom">1000</td><td align="char" char="." valign="bottom">295</td><td align="left" valign="bottom"><inline-graphic mimetype="image" mime-subtype="tif" xlink:href="elife-104901-inf020-v1.tif"/></td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib128">Walker et al., 1999</xref></td></tr><tr><td align="left" valign="bottom">Nifekalant</td><td align="char" char="." valign="bottom">7900</td><td align="char" char="." valign="bottom">1000</td><td align="char" char="." valign="bottom">295</td><td align="left" valign="bottom"><inline-graphic mimetype="image" mime-subtype="tif" xlink:href="elife-104901-inf021-v1.tif"/></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib62">Kushida et al., 2002</xref></td></tr></tbody></table></table-wrap></sec><sec id="s4-5-2"><title>Calculation of simulated drug-binding affinities</title><p>To obtain the simulated binding affinity of a drug, Î<italic>G</italic><sub>bind, sim</sub>, we multiplied the binding affinity for each state by the probability of the channel being in that state and combined these values for both neutral and cationic forms of the drug, as represented by the following equation:<disp-formula id="equ2"><alternatives><mml:math id="m2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mtable columnalign="right left right left right left right left right left right left" rowspacing="3pt" columnspacing="0em 2em 0em 2em 0em 2em 0em 2em 0em 2em 0em" displaystyle="true"><mml:mtr><mml:mtd><mml:mi mathvariant="normal">Î</mml:mi><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mi/><mml:mo>=</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo maxsize="1.2em" minsize="1.2em">(</mml:mo></mml:mrow><mml:mi mathvariant="normal">Î</mml:mi><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">O</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:msub><mml:mo>Ã</mml:mo><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">G</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">O</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Î</mml:mi><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">I</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:msub><mml:mspace width="thinmathspace"/><mml:mo>Ã</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">G</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">I</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mi/><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Î</mml:mi><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">C</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:msub><mml:mo>Ã</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">G</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo maxsize="1.2em" minsize="1.2em">)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo maxsize="1.2em" minsize="1.2em">(</mml:mo></mml:mrow><mml:mi mathvariant="normal">Î</mml:mi><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">O</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi></mml:mrow></mml:msub><mml:mo>Ã</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">G</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">O</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mi/><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Î</mml:mi><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">I</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi></mml:mrow></mml:msub><mml:mo>Ã</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">G</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">I</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Î</mml:mi><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">C</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi></mml:mrow></mml:msub><mml:mo>Ã</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">G</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo maxsize="1.2em" minsize="1.2em">)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t2">\begin{document}$$\displaystyle  \begin {aligned}\Delta G_{\rm bind,\, sim} &amp; = P_{\rm drug,\, neutral}\big(\Delta G_{\rm bind,\, O,\, neutral}\times \, P_{\rm hERG,\, O}+ \Delta G_{\rm bind,\, I,\, neutral} \, \times P_{\rm hERG,\, I} \\ &amp;+\Delta G_{\rm bind,\, C,\, neutral}\times P_{\rm hERG,\, C} \big) +P_{\rm drug,\, cationic}\big(\Delta G_{\rm bind,\, O,\, cationic}\times P_{\rm hERG, \, O} \\ &amp;+\Delta G_{\rm bind,\, I,\, cationic} \times P_{\rm hERG,\, I}+\Delta G_{\rm bind,\, C,\, cationic}\times P_{\rm hERG,\, C}\big) $$\end{document}</tex-math></alternatives></disp-formula></p><p>Here,</p><list list-type="bullet" id="list7"><list-item><p><inline-formula><alternatives><mml:math id="inf9"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Î</mml:mi><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">O</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi mathvariant="normal">Î</mml:mi><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">I</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi mathvariant="normal">Î</mml:mi><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math><tex-math id="inft9">\begin{document}$\Delta G_{\rm bind,\, O}, \Delta G_{\rm bind, \, I}, \Delta G_{\rm bind,\, C}$\end{document}</tex-math></alternatives></inline-formula> represent simulated binding affinities for the open, inactivated, and closed state, respectively, to either the neutral or the cationic form of the drug.</p></list-item><list-item><p><inline-formula><alternatives><mml:math id="inf10"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mtext>hERG,O</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mtext>hERG,I</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mtext>hERG,C</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math><tex-math id="inft10">\begin{document}$P_{\text{hERG,O}}, P_{\text{hERG,I}}, P_{\text{hERG,C}} $\end{document}</tex-math></alternatives></inline-formula> represent the fraction of channels that are in the open, inactivated, and closed state, at the time when the tail current was observed in electrophysiological recordings to calculate drug fractional block, determined for the specific voltage protocol employed.</p></list-item><list-item><p><inline-formula><alternatives><mml:math id="inf11"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mtext>drug,neutral</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math><tex-math id="inft11">\begin{document}$P_{\text{drug,neutral}} $\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf12"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math><tex-math id="inft12">\begin{document}$P_{\rm drug,\, cationic}$\end{document}</tex-math></alternatives></inline-formula> represent the fraction of neutral and cationic species of each drug at physiological pH 7.4 as calculated using the HendersonâHasselbalch equation using drug p<italic>K</italic><sub>a</sub> values from Chemaxon. The zwitterionic species of moxifloxacin instead of cationic was included. These data are recorded in <xref ref-type="table" rid="table4">Table 4</xref>.</p></list-item></list><p>Experimental IC<sub>50</sub> values (in units of M) were converted to equivalent binding free energies using the equation <inline-formula><alternatives><mml:math id="inf13"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Î</mml:mi><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo>â</mml:mo><mml:mi>R</mml:mi><mml:mi>T</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi mathvariant="normal">l</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math><tex-math id="inft13">\begin{document}$\Delta G_{pot,\, exp}=-RT\rm ln(1/lC_{50})$\end{document}</tex-math></alternatives></inline-formula> where <italic>R</italic> = 0.0019872036 kcal K<sup>â1</sup> mol<sup>â1</sup> is the gas constant and <italic>T</italic> is the experimental temperature in K.</p></sec></sec><sec id="s4-6"><title>Molecular graphics and interaction analysis</title><p>Molecular graphics visualization was performed using ChimeraX (<xref ref-type="bibr" rid="bib99">Pettersen et al., 2021</xref>). MD trajectory and simulation images were visualized using VMD (<xref ref-type="bibr" rid="bib48">Humphrey et al., 1996</xref>). Interaction network analysis was performed using the Protein-Ligand Interaction Profiler (PLIP) (<xref ref-type="bibr" rid="bib109">Salentin et al., 2015</xref>) with criteria outlined in <xref ref-type="table" rid="table1">Table 1</xref>.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing â original draft, Project administration, Writing â review and editing</p></fn><fn fn-type="con" id="con2"><p>Resources, Data curation, Software, Formal analysis, Validation, Investigation, Methodology, Writing â original draft, Writing â review and editing</p></fn><fn fn-type="con" id="con3"><p>Resources, Software, Supervision, Funding acquisition, Writing â original draft, Project administration, Writing â review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Resources, Supervision, Funding acquisition, Investigation, Methodology, Writing â original draft, Project administration, Writing â review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Resources, Software, Supervision, Funding acquisition, Investigation, Methodology, Writing â original draft, Project administration, Writing â review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Open-state hERG channel structural model (PDB 5VA2-based).</title></caption><media xlink:href="elife-104901-supp1-v1.pdb" mimetype="chemical" mime-subtype="x-pdb"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Inactivated-state AlphaFold hERG channel structural model.</title></caption><media xlink:href="elife-104901-supp2-v1.pdb" mimetype="chemical" mime-subtype="x-pdb"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Closed-state AlphaFold hERG channel structural model.</title></caption><media xlink:href="elife-104901-supp3-v1.pdb" mimetype="chemical" mime-subtype="x-pdb"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Open-state AlphaFold hERG channel structural model (ic3).</title></caption><media xlink:href="elife-104901-supp4-v1.pdb" mimetype="chemical" mime-subtype="x-pdb"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-104901-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All final study data are included in the article and/or supplementary files, with key molecular modeling, docking, molecular dynamics simulation, analysis data files, and scripts available to download from <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.18931zd5x">Dryad Digital Repository</ext-link>. Scripts developed in this study for analyzing AlphaFold-predicted protein structure models are also available on <ext-link ext-link-type="uri" xlink:href="https://github.com/k-ngo/AlphaFold_Analysis">GitHub</ext-link> (copy archived at <xref ref-type="bibr" rid="bib90">Ngo, 2025</xref>).</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Ngo</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Yarov-Yarovoy</surname><given-names>V</given-names></name><name><surname>Clancy</surname><given-names>CE</given-names></name><name><surname>Vorobyov</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>Data from: Harnessing AlphaFold to reveal hERG channel conformational state secrets</data-title><source>Dryad Digital Repository</source><pub-id pub-id-type="doi">10.5061/dryad.18931zd5x</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We would like to thank all members of the IV, CEC, and VY-Y laboratories and KNâs cats, Momo and Orange, for helpful discussions and support. This work was supported by National Institutes of Health Common Fund Grant OT2OD026580 (to CEC and IV), National Heart, Lung, and Blood Institute (NHLBI) grants R01HL128537, R01HL174001, R01HL085844, R01HL152681, and U01HL126273 (to CEC, VY-Y, and IV), American Heart Association Career Development Award grant 19CDA34770101 (to IV), National Science Foundation travel grant 2032486 (to IV), UC Davis Department of Physiology and Membrane Biology Research Partnership Fund (to CEC and IV) as well as UC Davis T32 Predoctoral Training in Basic and Translational Cardiovascular Medicine fellowship supported in part by NHLBI Institutional Training Grant T32HL086350 (to KN). Computer allocations were provided through Advanced Cyberinfrastructure Coordination Ecosystem: Services &amp; Support (ACCESS) grant MCB170095 (to IV, CEC, and VY-Y), Texas Advanced Computing Center (TACC) Leadership Resource and Pathways Allocations MCB20010 (IV, CEC, and VY-Y), Oracle for Research fellowship and cloud credits award (to IV, CEC), Pittsburgh Supercomputing Center (PSC) Anton 2 allocations PSCA17085P, MCB160089P, PSCA18077P, PSCA17085P, and PSCA16108P (to IV, CEC, and VY-Y). Anton 2 computer time was provided by the Pittsburgh Supercomputing Center (PSC) through Grant R01GM116961 from the National Institutes of Health. The Anton 2 machine at PSC was generously made available by DE. Shaw Research. OpenEye academic license was provided by OpenEye Scientific.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abi-Gerges</surname><given-names>N</given-names></name><name><surname>Holkham</surname><given-names>H</given-names></name><name><surname>Jones</surname><given-names>EMC</given-names></name><name><surname>Pollard</surname><given-names>CE</given-names></name><name><surname>Valentin</surname><given-names>JP</given-names></name><name><surname>Robertson</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>hERG subunit composition determines differential drug sensitivity</article-title><source>British Journal of Pharmacology</source><volume>164</volume><fpage>419</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01378.x</pub-id><pub-id pub-id-type="pmid">21449979</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abramson</surname><given-names>J</given-names></name><name><surname>Adler</surname><given-names>J</given-names></name><name><surname>Dunger</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>R</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Pritzel</surname><given-names>A</given-names></name><name><surname>Ronneberger</surname><given-names>O</given-names></name><name><surname>Willmore</surname><given-names>L</given-names></name><name><surname>Ballard</surname><given-names>AJ</given-names></name><name><surname>Bambrick</surname><given-names>J</given-names></name><name><surname>Bodenstein</surname><given-names>SW</given-names></name><name><surname>Evans</surname><given-names>DA</given-names></name><name><surname>Hung</surname><given-names>C-C</given-names></name><name><surname>OâNeill</surname><given-names>M</given-names></name><name><surname>Reiman</surname><given-names>D</given-names></name><name><surname>Tunyasuvunakool</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Å½emgulytÄ</surname><given-names>A</given-names></name><name><surname>Arvaniti</surname><given-names>E</given-names></name><name><surname>Beattie</surname><given-names>C</given-names></name><name><surname>Bertolli</surname><given-names>O</given-names></name><name><surname>Bridgland</surname><given-names>A</given-names></name><name><surname>Cherepanov</surname><given-names>A</given-names></name><name><surname>Congreve</surname><given-names>M</given-names></name><name><surname>Cowen-Rivers</surname><given-names>AI</given-names></name><name><surname>Cowie</surname><given-names>A</given-names></name><name><surname>Figurnov</surname><given-names>M</given-names></name><name><surname>Fuchs</surname><given-names>FB</given-names></name><name><surname>Gladman</surname><given-names>H</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Khan</surname><given-names>YA</given-names></name><name><surname>Low</surname><given-names>CMR</given-names></name><name><surname>Perlin</surname><given-names>K</given-names></name><name><surname>Potapenko</surname><given-names>A</given-names></name><name><surname>Savy</surname><given-names>P</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Stecula</surname><given-names>A</given-names></name><name><surname>Thillaisundaram</surname><given-names>A</given-names></name><name><surname>Tong</surname><given-names>C</given-names></name><name><surname>Yakneen</surname><given-names>S</given-names></name><name><surname>Zhong</surname><given-names>ED</given-names></name><name><surname>Zielinski</surname><given-names>M</given-names></name><name><surname>Å½Ã­dek</surname><given-names>A</given-names></name><name><surname>Bapst</surname><given-names>V</given-names></name><name><surname>Kohli</surname><given-names>P</given-names></name><name><surname>Jaderberg</surname><given-names>M</given-names></name><name><surname>Hassabis</surname><given-names>D</given-names></name><name><surname>Jumper</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Accurate structure prediction of biomolecular interactions with AlphaFold 3</article-title><source>Nature</source><volume>630</volume><fpage>493</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-07487-w</pub-id><pub-id pub-id-type="pmid">38718835</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrou</surname><given-names>AJ</given-names></name><name><surname>Duncan</surname><given-names>RS</given-names></name><name><surname>Sullivan</surname><given-names>A</given-names></name><name><surname>Hancox</surname><given-names>JC</given-names></name><name><surname>Leishman</surname><given-names>DJ</given-names></name><name><surname>Witchel</surname><given-names>HJ</given-names></name><name><surname>Leaney</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin</article-title><source>British Journal of Pharmacology</source><volume>147</volume><fpage>905</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0706678</pub-id><pub-id pub-id-type="pmid">16474415</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>AlQuraishi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>AlphaFold at CASP13</article-title><source>Bioinformatics</source><volume>35</volume><fpage>4862</fpage><lpage>4865</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btz422</pub-id><pub-id pub-id-type="pmid">31116374</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asai</surname><given-names>T</given-names></name><name><surname>Adachi</surname><given-names>N</given-names></name><name><surname>Moriya</surname><given-names>T</given-names></name><name><surname>Oki</surname><given-names>H</given-names></name><name><surname>Maru</surname><given-names>T</given-names></name><name><surname>Kawasaki</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Ishii</surname><given-names>R</given-names></name><name><surname>Yonemori</surname><given-names>K</given-names></name><name><surname>Igaki</surname><given-names>S</given-names></name><name><surname>Yasuda</surname><given-names>S</given-names></name><name><surname>Ogasawara</surname><given-names>S</given-names></name><name><surname>Senda</surname><given-names>T</given-names></name><name><surname>Murata</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cryo-EM Structure of K<sup>+</sup>-Bound hERG channel complexed with the Blocker Astemizole</article-title><source>Structure</source><volume>29</volume><fpage>203</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/j.str.2020.12.007</pub-id><pub-id pub-id-type="pmid">33450182</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baek</surname><given-names>M</given-names></name><name><surname>DiMaio</surname><given-names>F</given-names></name><name><surname>Anishchenko</surname><given-names>I</given-names></name><name><surname>Dauparas</surname><given-names>J</given-names></name><name><surname>Ovchinnikov</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>GR</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cong</surname><given-names>Q</given-names></name><name><surname>Kinch</surname><given-names>LN</given-names></name><name><surname>Schaeffer</surname><given-names>RD</given-names></name><name><surname>MillÃ¡n</surname><given-names>C</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Adams</surname><given-names>C</given-names></name><name><surname>Glassman</surname><given-names>CR</given-names></name><name><surname>DeGiovanni</surname><given-names>A</given-names></name><name><surname>Pereira</surname><given-names>JH</given-names></name><name><surname>Rodrigues</surname><given-names>AV</given-names></name><name><surname>van Dijk</surname><given-names>AA</given-names></name><name><surname>Ebrecht</surname><given-names>AC</given-names></name><name><surname>Opperman</surname><given-names>DJ</given-names></name><name><surname>Sagmeister</surname><given-names>T</given-names></name><name><surname>Buhlheller</surname><given-names>C</given-names></name><name><surname>Pavkov-Keller</surname><given-names>T</given-names></name><name><surname>Rathinaswamy</surname><given-names>MK</given-names></name><name><surname>Dalwadi</surname><given-names>U</given-names></name><name><surname>Yip</surname><given-names>CK</given-names></name><name><surname>Burke</surname><given-names>JE</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name><name><surname>Grishin</surname><given-names>NV</given-names></name><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Accurate prediction of protein structures and interactions using a three-track neural network</article-title><source>Science</source><volume>373</volume><fpage>871</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1126/science.abj8754</pub-id><pub-id pub-id-type="pmid">34282049</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beglov</surname><given-names>D</given-names></name><name><surname>Roux</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Finite representation of an infinite bulk system: Solvent boundary potential for computer simulations</article-title><source>The Journal of Chemical Physics</source><volume>100</volume><fpage>9050</fpage><lpage>9063</lpage><pub-id pub-id-type="doi">10.1063/1.466711</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Branduardi</surname><given-names>D</given-names></name><name><surname>Faraldo-GÃ³mez</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>String method for calculation of minimum free-energy paths in Cartesian space in freely-tumbling systems</article-title><source>Journal of Chemical Theory and Computation</source><volume>9</volume><fpage>4140</fpage><lpage>4154</lpage><pub-id pub-id-type="doi">10.1021/ct400469w</pub-id><pub-id pub-id-type="pmid">24729762</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>BP</given-names></name><name><surname>Stein</surname><given-names>RA</given-names></name><name><surname>Meiler</surname><given-names>J</given-names></name><name><surname>Mchaourab</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Approximating projections of conformational boltzmann distributions with AlphaFold2 predictions: opportunities and limitations</article-title><source>Journal of Chemical Theory and Computation</source><volume>20</volume><fpage>1434</fpage><lpage>1447</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.3c01081</pub-id><pub-id pub-id-type="pmid">38215214</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryant</surname><given-names>P</given-names></name><name><surname>NoÃ©</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Structure prediction of alternative protein conformations</article-title><source>Nature Communications</source><volume>15</volume><elocation-id>7328</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-024-51507-2</pub-id><pub-id pub-id-type="pmid">39187507</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Stuart</surname><given-names>AG</given-names></name><name><surname>Dempsey</surname><given-names>CE</given-names></name><name><surname>Hancox</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Action potential clamp characterization of the S631A hERG mutation associated with short QT syndrome</article-title><source>Physiological Reports</source><volume>6</volume><elocation-id>e13845</elocation-id><pub-id pub-id-type="doi">10.14814/phy2.13845</pub-id><pub-id pub-id-type="pmid">30175559</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Helliwell</surname><given-names>MV</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Hancox</surname><given-names>JC</given-names></name><name><surname>Dempsey</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>An Update on the Structure of hERG</article-title><source>Frontiers in Pharmacology</source><volume>10</volume><elocation-id>1572</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2019.01572</pub-id><pub-id pub-id-type="pmid">32038248</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>LP</given-names></name><name><surname>Tombari</surname><given-names>RJ</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Pell</surname><given-names>AJ</given-names></name><name><surname>Hurley</surname><given-names>ZQ</given-names></name><name><surname>Ehinger</surname><given-names>Y</given-names></name><name><surname>Vargas</surname><given-names>MV</given-names></name><name><surname>McCarroll</surname><given-names>MN</given-names></name><name><surname>Taylor</surname><given-names>JC</given-names></name><name><surname>Myers-Turnbull</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Yaghoobi</surname><given-names>B</given-names></name><name><surname>Laskowski</surname><given-names>LJ</given-names></name><name><surname>Anderson</surname><given-names>EI</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Viswanathan</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>BM</given-names></name><name><surname>Tjia</surname><given-names>M</given-names></name><name><surname>Dunlap</surname><given-names>LE</given-names></name><name><surname>Rabow</surname><given-names>ZT</given-names></name><name><surname>Fiehn</surname><given-names>O</given-names></name><name><surname>Wulff</surname><given-names>H</given-names></name><name><surname>McCorvy</surname><given-names>JD</given-names></name><name><surname>Lein</surname><given-names>PJ</given-names></name><name><surname>Kokel</surname><given-names>D</given-names></name><name><surname>Ron</surname><given-names>D</given-names></name><name><surname>Peters</surname><given-names>J</given-names></name><name><surname>Zuo</surname><given-names>Y</given-names></name><name><surname>Olson</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A non-hallucinogenic psychedelic analogue with therapeutic potential</article-title><source>Nature</source><volume>589</volume><fpage>474</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-3008-z</pub-id><pub-id pub-id-type="pmid">33299186</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Case</surname><given-names>DA</given-names></name><name><surname>Cheatham</surname><given-names>TE</given-names></name><name><surname>Darden</surname><given-names>T</given-names></name><name><surname>Gohlke</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>R</given-names></name><name><surname>Merz</surname><given-names>KM</given-names></name><name><surname>Onufriev</surname><given-names>A</given-names></name><name><surname>Simmerling</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Woods</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The Amber biomolecular simulation programs</article-title><source>Journal of Computational Chemistry</source><volume>26</volume><fpage>1668</fpage><lpage>1688</lpage><pub-id pub-id-type="doi">10.1002/jcc.20290</pub-id><pub-id pub-id-type="pmid">16200636</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Case</surname><given-names>DA</given-names></name><name><surname>Aktulga</surname><given-names>HM</given-names></name><name><surname>Belfon</surname><given-names>K</given-names></name><name><surname>Cerutti</surname><given-names>DS</given-names></name><name><surname>Cisneros</surname><given-names>GA</given-names></name><name><surname>Cruzeiro</surname><given-names>VWD</given-names></name><name><surname>Forouzesh</surname><given-names>N</given-names></name><name><surname>Giese</surname><given-names>TJ</given-names></name><name><surname>GÃ¶tz</surname><given-names>AW</given-names></name><name><surname>Gohlke</surname><given-names>H</given-names></name><name><surname>Izadi</surname><given-names>S</given-names></name><name><surname>Kasavajhala</surname><given-names>K</given-names></name><name><surname>Kaymak</surname><given-names>MC</given-names></name><name><surname>King</surname><given-names>E</given-names></name><name><surname>Kurtzman</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>TS</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Luchko</surname><given-names>T</given-names></name><name><surname>Luo</surname><given-names>R</given-names></name><name><surname>Manathunga</surname><given-names>M</given-names></name><name><surname>Machado</surname><given-names>MR</given-names></name><name><surname>Nguyen</surname><given-names>HM</given-names></name><name><surname>OâHearn</surname><given-names>KA</given-names></name><name><surname>Onufriev</surname><given-names>AV</given-names></name><name><surname>Pan</surname><given-names>F</given-names></name><name><surname>Pantano</surname><given-names>S</given-names></name><name><surname>Qi</surname><given-names>R</given-names></name><name><surname>Rahnamoun</surname><given-names>A</given-names></name><name><surname>Risheh</surname><given-names>A</given-names></name><name><surname>Schott-Verdugo</surname><given-names>S</given-names></name><name><surname>Shajan</surname><given-names>A</given-names></name><name><surname>Swails</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Cheatham</surname><given-names>TE</given-names></name><name><surname>Roe</surname><given-names>DR</given-names></name><name><surname>Roitberg</surname><given-names>A</given-names></name><name><surname>Simmerling</surname><given-names>C</given-names></name><name><surname>York</surname><given-names>DM</given-names></name><name><surname>Nagan</surname><given-names>MC</given-names></name><name><surname>Merz</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>AmberTools</article-title><source>Journal of Chemical Information and Modeling</source><volume>63</volume><fpage>6183</fpage><lpage>6191</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.3c01153</pub-id><pub-id pub-id-type="pmid">37805934</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catterall</surname><given-names>WA</given-names></name><name><surname>Wisedchaisri</surname><given-names>G</given-names></name><name><surname>Zheng</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The conformational cycle of a prototypical voltage-gated sodium channel</article-title><source>Nature Chemical Biology</source><volume>16</volume><fpage>1314</fpage><lpage>1320</lpage><pub-id pub-id-type="doi">10.1038/s41589-020-0644-4</pub-id><pub-id pub-id-type="pmid">33199904</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakravarty</surname><given-names>D</given-names></name><name><surname>Schafer</surname><given-names>JW</given-names></name><name><surname>Chen</surname><given-names>EA</given-names></name><name><surname>Thole</surname><given-names>JF</given-names></name><name><surname>Ronish</surname><given-names>LA</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Porter</surname><given-names>LL</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>AlphaFold predictions of fold-switched conformations are driven by structure memorization</article-title><source>Nature Communications</source><volume>15</volume><elocation-id>7296</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-024-51801-z</pub-id><pub-id pub-id-type="pmid">39181864</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandy</surname><given-names>KG</given-names></name><name><surname>Sanches</surname><given-names>K</given-names></name><name><surname>Norton</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Structure of the voltage-gated potassium channel K<sub>V</sub>1.3: Insights into the inactivated conformation and binding to therapeutic leads</article-title><source>Channels</source><volume>17</volume><elocation-id>2253104</elocation-id><pub-id pub-id-type="doi">10.1080/19336950.2023.2253104</pub-id><pub-id pub-id-type="pmid">37695839</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Cass</surname><given-names>JD</given-names></name><name><surname>Bradley</surname><given-names>JA</given-names></name><name><surname>Dahm</surname><given-names>CM</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Kadyszewski</surname><given-names>E</given-names></name><name><surname>Engwall</surname><given-names>MJ</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome</article-title><source>British Journal of Pharmacology</source><volume>146</volume><fpage>792</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0706389</pub-id><pub-id pub-id-type="pmid">16158069</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>PJS</given-names></name><name><surname>Marcoe</surname><given-names>KF</given-names></name><name><surname>Bounds</surname><given-names>SE</given-names></name><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Feng</surname><given-names>JJ</given-names></name><name><surname>Lin</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>FC</given-names></name><name><surname>Crumb</surname><given-names>WJ</given-names></name><name><surname>Mitchell</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels</article-title><source>Journal of Pharmacological Sciences</source><volume>95</volume><fpage>311</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1254/jphs.fpe0040101</pub-id><pub-id pub-id-type="pmid">15272206</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>CE</given-names></name><name><surname>Hill</surname><given-names>AP</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Kondo</surname><given-names>M</given-names></name><name><surname>Subbiah</surname><given-names>RN</given-names></name><name><surname>Campbell</surname><given-names>TJ</given-names></name><name><surname>Vandenberg</surname><given-names>JI</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Effect of S5P alpha-helix charge mutants on inactivation of hERG K+ channels</article-title><source>The Journal of Physiology</source><volume>573</volume><fpage>291</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2006.108332</pub-id><pub-id pub-id-type="pmid">16556651</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colatsky</surname><given-names>T</given-names></name><name><surname>Fermini</surname><given-names>B</given-names></name><name><surname>Gintant</surname><given-names>G</given-names></name><name><surname>Pierson</surname><given-names>JB</given-names></name><name><surname>Sager</surname><given-names>P</given-names></name><name><surname>Sekino</surname><given-names>Y</given-names></name><name><surname>Strauss</surname><given-names>DG</given-names></name><name><surname>Stockbridge</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The comprehensive in vitro proarrhythmia assay (CiPA) initiative - update on progress</article-title><source>Journal of Pharmacological and Toxicological Methods</source><volume>81</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.vascn.2016.06.002</pub-id><pub-id pub-id-type="pmid">27282641</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordeiro</surname><given-names>JM</given-names></name><name><surname>Brugada</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>YS</given-names></name><name><surname>Hong</surname><given-names>K</given-names></name><name><surname>Dumaine</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Modulation of I(Kr) inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome</article-title><source>Cardiovascular Research</source><volume>67</volume><fpage>498</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1016/j.cardiores.2005.02.018</pub-id><pub-id pub-id-type="pmid">16039272</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuello</surname><given-names>LG</given-names></name><name><surname>Jogini</surname><given-names>V</given-names></name><name><surname>Cortes</surname><given-names>DM</given-names></name><name><surname>Perozo</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Structural mechanism of C-type inactivation in K(+) channels</article-title><source>Nature</source><volume>466</volume><fpage>203</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1038/nature09153</pub-id><pub-id pub-id-type="pmid">20613835</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darden</surname><given-names>T</given-names></name><name><surname>York</surname><given-names>D</given-names></name><name><surname>Pedersen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Particle mesh Ewald: An Nâlog(N) method for Ewald sums in large systems</article-title><source>The Journal of Chemical Physics</source><volume>98</volume><fpage>10089</fpage><lpage>10092</lpage><pub-id pub-id-type="doi">10.1063/1.464397</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Alamo</surname><given-names>D</given-names></name><name><surname>Sala</surname><given-names>D</given-names></name><name><surname>Mchaourab</surname><given-names>HS</given-names></name><name><surname>Meiler</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Sampling alternative conformational states of transporters and receptors with AlphaFold2</article-title><source>eLife</source><volume>11</volume><elocation-id>e75751</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.75751</pub-id><pub-id pub-id-type="pmid">35238773</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeMarco</surname><given-names>KR</given-names></name><name><surname>Yang</surname><given-names>PC</given-names></name><name><surname>Singh</surname><given-names>V</given-names></name><name><surname>Furutani</surname><given-names>K</given-names></name><name><surname>Dawson</surname><given-names>JRD</given-names></name><name><surname>Jeng</surname><given-names>MT</given-names></name><name><surname>Fettinger</surname><given-names>JC</given-names></name><name><surname>Bekker</surname><given-names>S</given-names></name><name><surname>Ngo</surname><given-names>VA</given-names></name><name><surname>Noskov</surname><given-names>SY</given-names></name><name><surname>Yarov-Yarovoy</surname><given-names>V</given-names></name><name><surname>Sack</surname><given-names>JT</given-names></name><name><surname>Wulff</surname><given-names>H</given-names></name><name><surname>Clancy</surname><given-names>CE</given-names></name><name><surname>Vorobyov</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Molecular determinants of pro-arrhythmia proclivity of d- and l-sotalol via a multi-scale modeling pipeline</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>158</volume><fpage>163</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2021.05.015</pub-id><pub-id pub-id-type="pmid">34062207</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doyle</surname><given-names>DA</given-names></name><name><surname>Morais Cabral</surname><given-names>J</given-names></name><name><surname>Pfuetzner</surname><given-names>RA</given-names></name><name><surname>Kuo</surname><given-names>A</given-names></name><name><surname>Gulbis</surname><given-names>JM</given-names></name><name><surname>Cohen</surname><given-names>SL</given-names></name><name><surname>Chait</surname><given-names>BT</given-names></name><name><surname>MacKinnon</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The structure of the potassium channel: molecular basis of K+ conduction and selectivity</article-title><source>Science</source><volume>280</volume><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1126/science.280.5360.69</pub-id><pub-id pub-id-type="pmid">9525859</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zou</surname><given-names>A</given-names></name><name><surname>Tu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain</article-title><source>Acta Pharmacologica Sinica</source><volume>28</volume><fpage>959</fpage><lpage>967</lpage><pub-id pub-id-type="doi">10.1111/j.1745-7254.2007.00562.x</pub-id><pub-id pub-id-type="pmid">17588331</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dun</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Tseng</surname><given-names>GN</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Allosteric effects of mutations in the extracellular S5-P loop on the gating and ion permeation properties of the hERG potassium channel</article-title><source>Pflugers Archiv</source><volume>439</volume><fpage>141</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1007/s004249900101</pub-id><pub-id pub-id-type="pmid">10651011</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>JS</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Dun</surname><given-names>W</given-names></name><name><surname>McDonald</surname><given-names>TV</given-names></name><name><surname>Tseng</surname><given-names>GN</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Effects of outer mouth mutations on hERG channel function: a comparison with similar mutations in the Shaker channel</article-title><source>Biophysical Journal</source><volume>76</volume><fpage>3128</fpage><lpage>3140</lpage><pub-id pub-id-type="doi">10.1016/S0006-3495(99)77464-3</pub-id><pub-id pub-id-type="pmid">10354437</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferri</surname><given-names>N</given-names></name><name><surname>Siegl</surname><given-names>P</given-names></name><name><surname>Corsini</surname><given-names>A</given-names></name><name><surname>Herrmann</surname><given-names>J</given-names></name><name><surname>Lerman</surname><given-names>A</given-names></name><name><surname>Benghozi</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity</article-title><source>Pharmacology &amp; Therapeutics</source><volume>138</volume><fpage>470</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2013.03.005</pub-id><pub-id pub-id-type="pmid">23507039</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ficker</surname><given-names>E</given-names></name><name><surname>Jarolimek</surname><given-names>W</given-names></name><name><surname>Kiehn</surname><given-names>J</given-names></name><name><surname>Baumann</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Molecular determinants of dofetilide block of HERG K+ channels</article-title><source>Circulation Research</source><volume>82</volume><fpage>386</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1161/01.res.82.3.386</pub-id><pub-id pub-id-type="pmid">9486667</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleishman</surname><given-names>SJ</given-names></name><name><surname>Leaver-Fay</surname><given-names>A</given-names></name><name><surname>Corn</surname><given-names>JE</given-names></name><name><surname>Strauch</surname><given-names>EM</given-names></name><name><surname>Khare</surname><given-names>SD</given-names></name><name><surname>Koga</surname><given-names>N</given-names></name><name><surname>Ashworth</surname><given-names>J</given-names></name><name><surname>Murphy</surname><given-names>P</given-names></name><name><surname>Richter</surname><given-names>F</given-names></name><name><surname>Lemmon</surname><given-names>G</given-names></name><name><surname>Meiler</surname><given-names>J</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>RosettaScripts: a scripting language interface to the Rosetta macromolecular modeling suite</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e20161</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0020161</pub-id><pub-id pub-id-type="pmid">21731610</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldschen-Ohm</surname><given-names>MP</given-names></name><name><surname>Capes</surname><given-names>DL</given-names></name><name><surname>Oelstrom</surname><given-names>KM</given-names></name><name><surname>Chanda</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Multiple pore conformations driven by asynchronous movements of voltage sensors in a eukaryotic sodium channel</article-title><source>Nature Communications</source><volume>4</volume><elocation-id>1350</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms2356</pub-id><pub-id pub-id-type="pmid">23322038</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomis-Tena</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>BM</given-names></name><name><surname>Cano</surname><given-names>J</given-names></name><name><surname>Trenor</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>PC</given-names></name><name><surname>Saiz</surname><given-names>J</given-names></name><name><surname>Clancy</surname><given-names>CE</given-names></name><name><surname>Romero</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>When does the IC50 accurately assess the blocking potency of a drug</article-title><source>Journal of Chemical Information and Modeling</source><volume>60</volume><fpage>1779</fpage><lpage>1790</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.9b01085</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goversen</surname><given-names>B</given-names></name><name><surname>Jonsson</surname><given-names>MK</given-names></name><name><surname>van den Heuvel</surname><given-names>NH</given-names></name><name><surname>Rijken</surname><given-names>R</given-names></name><name><surname>Vos</surname><given-names>MA</given-names></name><name><surname>van Veen</surname><given-names>TA</given-names></name><name><surname>de Boer</surname><given-names>TP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The influence of hERG1a and hERG1b isoforms on drug safety screening in iPSC-CMs</article-title><source>Progress in Biophysics and Molecular Biology</source><volume>149</volume><fpage>86</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.pbiomolbio.2019.02.003</pub-id><pub-id pub-id-type="pmid">30826123</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gumbart</surname><given-names>J</given-names></name><name><surname>Khalili-Araghi</surname><given-names>F</given-names></name><name><surname>Sotomayor</surname><given-names>M</given-names></name><name><surname>Roux</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Constant electric field simulations of the membrane potential illustrated with simple systems</article-title><source>Biochim Biophys Acta BBA - Biomembr, Membrane Protein Structure and Function</source><volume>1818</volume><fpage>294</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2011.09.030</pub-id><pub-id pub-id-type="pmid">22001851</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gustina</surname><given-names>AS</given-names></name><name><surname>Trudeau</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The eag domain regulates hERG channel inactivation gating via a direct interaction</article-title><source>The Journal of General Physiology</source><volume>141</volume><fpage>229</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1085/jgp.201210870</pub-id><pub-id pub-id-type="pmid">23319729</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>RS</given-names></name><name><surname>Diness</surname><given-names>TG</given-names></name><name><surname>Christ</surname><given-names>T</given-names></name><name><surname>Demnitz</surname><given-names>J</given-names></name><name><surname>Ravens</surname><given-names>U</given-names></name><name><surname>Olesen</surname><given-names>SP</given-names></name><name><surname>Grunnet</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643)</article-title><source>Molecular Pharmacology</source><volume>69</volume><fpage>266</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1124/mol.105.015859</pub-id><pub-id pub-id-type="pmid">16219910</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harchi</surname><given-names>AE</given-names></name><name><surname>Melgari</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Hancox</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Investigation of hERG1b Influence on hERG channel pharmacology at physiological temperature</article-title><source>Journal of Pharmacology and Pharmacotherapeutics</source><volume>9</volume><fpage>92</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.4103/jpp.JPP_158_17</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>BJ</given-names></name><name><surname>Nguyen</surname><given-names>PT</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Wulff</surname><given-names>H</given-names></name><name><surname>DiMaio</surname><given-names>F</given-names></name><name><surname>Yarov-Yarovoy</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Toward high-resolution modeling of small molecule-ion channel interactions</article-title><source>Frontiers in Pharmacology</source><volume>15</volume><elocation-id>1411428</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2024.1411428</pub-id><pub-id pub-id-type="pmid">38919257</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helliwell</surname><given-names>MV</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>El Harchi</surname><given-names>A</given-names></name><name><surname>Du</surname><given-names>C</given-names></name><name><surname>Hancox</surname><given-names>JC</given-names></name><name><surname>Dempsey</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structural implications of hERG K<sup>+</sup> channel block by a high-affinity minimally structured blocker</article-title><source>The Journal of Biological Chemistry</source><volume>293</volume><fpage>7040</fpage><lpage>7057</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA117.000363</pub-id><pub-id pub-id-type="pmid">29545312</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helliwell</surname><given-names>MV</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>El Harchi</surname><given-names>A</given-names></name><name><surname>Dempsey</surname><given-names>CE</given-names></name><name><surname>Hancox</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Inhibition of the hERG potassium channel by a methanesulphonate-free E-4031 Analogue</article-title><source>Pharmaceuticals</source><volume>16</volume><elocation-id>1204</elocation-id><pub-id pub-id-type="doi">10.3390/ph16091204</pub-id><pub-id pub-id-type="pmid">37765012</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hite</surname><given-names>RK</given-names></name><name><surname>MacKinnon</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structural titration of Slo2.2, a Na<sup>+</sup>-dependent K<sup>+</sup> channel</article-title><source>Cell</source><volume>168</volume><fpage>390</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.12.030</pub-id><pub-id pub-id-type="pmid">28111072</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>PS</given-names></name><name><surname>Ban</surname><given-names>YEA</given-names></name><name><surname>Richter</surname><given-names>F</given-names></name><name><surname>Andre</surname><given-names>I</given-names></name><name><surname>Vernon</surname><given-names>R</given-names></name><name><surname>Schief</surname><given-names>WR</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>RosettaRemodel: a generalized framework for flexible backbone protein design</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e24109</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0024109</pub-id><pub-id pub-id-type="pmid">21909381</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Rauscher</surname><given-names>S</given-names></name><name><surname>Nawrocki</surname><given-names>G</given-names></name><name><surname>Ran</surname><given-names>T</given-names></name><name><surname>Feig</surname><given-names>M</given-names></name><name><surname>de Groot</surname><given-names>BL</given-names></name><name><surname>GrubmÃ¼ller</surname><given-names>H</given-names></name><name><surname>MacKerell</surname><given-names>AD</given-names><suffix>Jr</suffix></name></person-group><year iso-8601-date="2017">2017</year><article-title>CHARMM36m: an improved force field for folded and intrinsically disordered proteins</article-title><source>Nature Methods</source><volume>14</volume><fpage>71</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4067</pub-id><pub-id pub-id-type="pmid">27819658</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphrey</surname><given-names>W</given-names></name><name><surname>Dalke</surname><given-names>A</given-names></name><name><surname>Schulten</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>VMD: visual molecular dynamics</article-title><source>Journal of Molecular Graphics</source><volume>14</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/0263-7855(96)00018-5</pub-id><pub-id pub-id-type="pmid">8744570</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaiswal</surname><given-names>A</given-names></name><name><surname>Goldbarg</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Dofetilide induced torsade de pointes: mechanism, risk factors and management strategies</article-title><source>Indian Heart Journal</source><volume>66</volume><fpage>640</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1016/j.ihj.2013.12.021</pub-id><pub-id pub-id-type="pmid">25634399</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Iyer</surname><given-names>VG</given-names></name><name><surname>Im</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>CHARMM-GUI: a web-based graphical user interface for CHARMM</article-title><source>Journal of Computational Chemistry</source><volume>29</volume><fpage>1859</fpage><lpage>1865</lpage><pub-id pub-id-type="doi">10.1002/jcc.20945</pub-id><pub-id pub-id-type="pmid">18351591</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>AA</given-names></name><name><surname>Trudeau</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Inhibition of hERG K Channels by Verapamil at Physiological Temperature: Implications for the CiPA Initiative</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2023.12.12.571313</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorgensen</surname><given-names>WL</given-names></name><name><surname>Chandrasekhar</surname><given-names>J</given-names></name><name><surname>Madura</surname><given-names>JD</given-names></name><name><surname>Impey</surname><given-names>RW</given-names></name><name><surname>Klein</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Comparison of simple potential functions for simulating liquid water</article-title><source>The Journal of Chemical Physics</source><volume>79</volume><fpage>926</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1063/1.445869</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jumper</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>R</given-names></name><name><surname>Pritzel</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Figurnov</surname><given-names>M</given-names></name><name><surname>Ronneberger</surname><given-names>O</given-names></name><name><surname>Tunyasuvunakool</surname><given-names>K</given-names></name><name><surname>Bates</surname><given-names>R</given-names></name><name><surname>Å½Ã­dek</surname><given-names>A</given-names></name><name><surname>Potapenko</surname><given-names>A</given-names></name><name><surname>Bridgland</surname><given-names>A</given-names></name><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Kohl</surname><given-names>SAA</given-names></name><name><surname>Ballard</surname><given-names>AJ</given-names></name><name><surname>Cowie</surname><given-names>A</given-names></name><name><surname>Romera-Paredes</surname><given-names>B</given-names></name><name><surname>Nikolov</surname><given-names>S</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Adler</surname><given-names>J</given-names></name><name><surname>Back</surname><given-names>T</given-names></name><name><surname>Petersen</surname><given-names>S</given-names></name><name><surname>Reiman</surname><given-names>D</given-names></name><name><surname>Clancy</surname><given-names>E</given-names></name><name><surname>Zielinski</surname><given-names>M</given-names></name><name><surname>Steinegger</surname><given-names>M</given-names></name><name><surname>Pacholska</surname><given-names>M</given-names></name><name><surname>Berghammer</surname><given-names>T</given-names></name><name><surname>Bodenstein</surname><given-names>S</given-names></name><name><surname>Silver</surname><given-names>D</given-names></name><name><surname>Vinyals</surname><given-names>O</given-names></name><name><surname>Senior</surname><given-names>AW</given-names></name><name><surname>Kavukcuoglu</surname><given-names>K</given-names></name><name><surname>Kohli</surname><given-names>P</given-names></name><name><surname>Hassabis</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Highly accurate protein structure prediction with AlphaFold</article-title><source>Nature</source><volume>596</volume><fpage>583</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id><pub-id pub-id-type="pmid">34265844</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jumper</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>R</given-names></name><name><surname>Pritzel</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Figurnov</surname><given-names>M</given-names></name><name><surname>Ronneberger</surname><given-names>O</given-names></name><name><surname>Tunyasuvunakool</surname><given-names>K</given-names></name><name><surname>Bates</surname><given-names>R</given-names></name><name><surname>Å½Ã­dek</surname><given-names>A</given-names></name><name><surname>Potapenko</surname><given-names>A</given-names></name><name><surname>Bridgland</surname><given-names>A</given-names></name><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Kohl</surname><given-names>SAA</given-names></name><name><surname>Ballard</surname><given-names>AJ</given-names></name><name><surname>Cowie</surname><given-names>A</given-names></name><name><surname>Romera-Paredes</surname><given-names>B</given-names></name><name><surname>Nikolov</surname><given-names>S</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Adler</surname><given-names>J</given-names></name><name><surname>Back</surname><given-names>T</given-names></name><name><surname>Petersen</surname><given-names>S</given-names></name><name><surname>Reiman</surname><given-names>D</given-names></name><name><surname>Clancy</surname><given-names>E</given-names></name><name><surname>Zielinski</surname><given-names>M</given-names></name><name><surname>Steinegger</surname><given-names>M</given-names></name><name><surname>Pacholska</surname><given-names>M</given-names></name><name><surname>Berghammer</surname><given-names>T</given-names></name><name><surname>Silver</surname><given-names>D</given-names></name><name><surname>Vinyals</surname><given-names>O</given-names></name><name><surname>Senior</surname><given-names>AW</given-names></name><name><surname>Kavukcuoglu</surname><given-names>K</given-names></name><name><surname>Kohli</surname><given-names>P</given-names></name><name><surname>Hassabis</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Applying and improving AlphaFold at CASP14</article-title><source>Proteins</source><volume>89</volume><fpage>1711</fpage><lpage>1721</lpage><pub-id pub-id-type="doi">10.1002/prot.26257</pub-id><pub-id pub-id-type="pmid">34599769</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Kalakoti</surname><given-names>Y</given-names></name><name><surname>Wallner</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>AFsample2: Predicting Multiple Conformations and Ensembles with AlphaFold2</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2024.05.28.596195</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamiya</surname><given-names>K</given-names></name><name><surname>Niwa</surname><given-names>R</given-names></name><name><surname>Mitcheson</surname><given-names>JS</given-names></name><name><surname>Sanguinetti</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Molecular determinants of HERG channel block</article-title><source>Molecular Pharmacology</source><volume>69</volume><fpage>1709</fpage><lpage>1716</lpage><pub-id pub-id-type="doi">10.1124/mol.105.020990</pub-id><pub-id pub-id-type="pmid">16474003</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamiya</surname><given-names>K</given-names></name><name><surname>Niwa</surname><given-names>R</given-names></name><name><surname>Morishima</surname><given-names>M</given-names></name><name><surname>Honjo</surname><given-names>H</given-names></name><name><surname>Sanguinetti</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Molecular determinants of hERG channel block by terfenadine and cisapride</article-title><source>Journal of Pharmacological Sciences</source><volume>108</volume><fpage>301</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1254/jphs.08102fp</pub-id><pub-id pub-id-type="pmid">18987434</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karelina</surname><given-names>M</given-names></name><name><surname>Noh</surname><given-names>JJ</given-names></name><name><surname>Dror</surname><given-names>RO</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>How accurately can one predict drug binding modes using AlphaFold models?</article-title><source>eLife</source><volume>12</volume><elocation-id>RP89386</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.89386</pub-id><pub-id pub-id-type="pmid">38131311</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Thiessen</surname><given-names>PA</given-names></name><name><surname>Bolton</surname><given-names>EE</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>G</given-names></name><name><surname>Gindulyte</surname><given-names>A</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>Shoemaker</surname><given-names>BA</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Bryant</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>PubChem substance and compound databases</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>D1202</fpage><lpage>D1213</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv951</pub-id><pub-id pub-id-type="pmid">26400175</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klauda</surname><given-names>JB</given-names></name><name><surname>Venable</surname><given-names>RM</given-names></name><name><surname>Freites</surname><given-names>JA</given-names></name><name><surname>OâConnor</surname><given-names>JW</given-names></name><name><surname>Tobias</surname><given-names>DJ</given-names></name><name><surname>Mondragon-Ramirez</surname><given-names>C</given-names></name><name><surname>Vorobyov</surname><given-names>I</given-names></name><name><surname>MacKerell</surname><given-names>AD</given-names><suffix>Jr</suffix></name><name><surname>Pastor</surname><given-names>RW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types</article-title><source>The Journal of Physical Chemistry. B</source><volume>114</volume><fpage>7830</fpage><lpage>7843</lpage><pub-id pub-id-type="doi">10.1021/jp101759q</pub-id><pub-id pub-id-type="pmid">20496934</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kocadal</surname><given-names>K</given-names></name><name><surname>Saygi</surname><given-names>S</given-names></name><name><surname>Alkas</surname><given-names>FB</given-names></name><name><surname>Sardas</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Drug-associated cardiovascular risks: a retrospective evaluation of withdrawn drugs</article-title><source>Northern Clinics of Istanbul</source><volume>6</volume><fpage>196</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.14744/nci.2018.44977</pub-id><pub-id pub-id-type="pmid">31297490</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kushida</surname><given-names>S</given-names></name><name><surname>Ogura</surname><given-names>T</given-names></name><name><surname>Komuro</surname><given-names>I</given-names></name><name><surname>Nakaya</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Inhibitory effect of the class III antiarrhythmic drug nifekalant on HERG channels: mode of action</article-title><source>European Journal of Pharmacology</source><volume>457</volume><fpage>19</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/s0014-2999(02)02666-3</pub-id><pub-id pub-id-type="pmid">12460639</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>CK</given-names></name><name><surname>de Groot</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Ion conduction mechanisms in potassium channels revealed by permeation cycles</article-title><source>Journal of Chemical Theory and Computation</source><volume>19</volume><fpage>2574</fpage><lpage>2589</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.3c00061</pub-id><pub-id pub-id-type="pmid">37040262</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Protein structure prediction has reached the single-structure frontier</article-title><source>Nature Methods</source><volume>20</volume><fpage>170</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1038/s41592-022-01760-4</pub-id><pub-id pub-id-type="pmid">36639584</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>CHY</given-names></name><name><surname>Flood</surname><given-names>E</given-names></name><name><surname>Hunter</surname><given-names>MJ</given-names></name><name><surname>Williams-Noonan</surname><given-names>BJ</given-names></name><name><surname>Corbett</surname><given-names>KM</given-names></name><name><surname>Ng</surname><given-names>CA</given-names></name><name><surname>Bouwer</surname><given-names>JC</given-names></name><name><surname>Stewart</surname><given-names>AG</given-names></name><name><surname>Perozo</surname><given-names>E</given-names></name><name><surname>Allen</surname><given-names>TW</given-names></name><name><surname>Vandenberg</surname><given-names>JI</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Potassium dependent structural changes in the selectivity filter of HERG potassium channels</article-title><source>Nature Communications</source><volume>15</volume><elocation-id>7470</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-024-51208-w</pub-id><pub-id pub-id-type="pmid">39209832</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>KT</given-names></name><name><surname>Choe</surname><given-names>H</given-names></name><name><surname>Jo</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Blockade of HERG human K+ channels and IKr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine</article-title><source>British Journal of Pharmacology</source><volume>148</volume><fpage>499</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0706744</pub-id><pub-id pub-id-type="pmid">16633353</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lees-Miller</surname><given-names>JP</given-names></name><name><surname>Duan</surname><given-names>Y</given-names></name><name><surname>Teng</surname><given-names>GQ</given-names></name><name><surname>Duff</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2000">2000a</year><article-title>Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in <italic>Xenopus</italic> oocytes: involvement of S6 sites</article-title><source>Molecular Pharmacology</source><volume>57</volume><fpage>367</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1016/S0026-895X(24)23209-0</pub-id><pub-id pub-id-type="pmid">10648647</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lees-Miller</surname><given-names>JP</given-names></name><name><surname>Duan</surname><given-names>Y</given-names></name><name><surname>Teng</surname><given-names>GQ</given-names></name><name><surname>Thorstad</surname><given-names>K</given-names></name><name><surname>Duff</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2000">2000b</year><article-title>Novel gain-of-function mechanism in K(+) channel-related long-QT syndrome: altered gating and selectivity in the HERG1 N629D mutant</article-title><source>Circulation Research</source><volume>86</volume><fpage>507</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1161/01.res.86.5.507</pub-id><pub-id pub-id-type="pmid">10720411</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leman</surname><given-names>JK</given-names></name><name><surname>Weitzner</surname><given-names>BD</given-names></name><name><surname>Lewis</surname><given-names>SM</given-names></name><name><surname>Adolf-Bryfogle</surname><given-names>J</given-names></name><name><surname>Alam</surname><given-names>N</given-names></name><name><surname>Alford</surname><given-names>RF</given-names></name><name><surname>Aprahamian</surname><given-names>M</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name><name><surname>Barlow</surname><given-names>KA</given-names></name><name><surname>Barth</surname><given-names>P</given-names></name><name><surname>Basanta</surname><given-names>B</given-names></name><name><surname>Bender</surname><given-names>BJ</given-names></name><name><surname>Blacklock</surname><given-names>K</given-names></name><name><surname>Bonet</surname><given-names>J</given-names></name><name><surname>Boyken</surname><given-names>SE</given-names></name><name><surname>Bradley</surname><given-names>P</given-names></name><name><surname>Bystroff</surname><given-names>C</given-names></name><name><surname>Conway</surname><given-names>P</given-names></name><name><surname>Cooper</surname><given-names>S</given-names></name><name><surname>Correia</surname><given-names>BE</given-names></name><name><surname>Coventry</surname><given-names>B</given-names></name><name><surname>Das</surname><given-names>R</given-names></name><name><surname>De Jong</surname><given-names>RM</given-names></name><name><surname>DiMaio</surname><given-names>F</given-names></name><name><surname>Dsilva</surname><given-names>L</given-names></name><name><surname>Dunbrack</surname><given-names>R</given-names></name><name><surname>Ford</surname><given-names>AS</given-names></name><name><surname>Frenz</surname><given-names>B</given-names></name><name><surname>Fu</surname><given-names>DY</given-names></name><name><surname>Geniesse</surname><given-names>C</given-names></name><name><surname>Goldschmidt</surname><given-names>L</given-names></name><name><surname>Gowthaman</surname><given-names>R</given-names></name><name><surname>Gray</surname><given-names>JJ</given-names></name><name><surname>Gront</surname><given-names>D</given-names></name><name><surname>Guffy</surname><given-names>S</given-names></name><name><surname>Horowitz</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>P-S</given-names></name><name><surname>Huber</surname><given-names>T</given-names></name><name><surname>Jacobs</surname><given-names>TM</given-names></name><name><surname>Jeliazkov</surname><given-names>JR</given-names></name><name><surname>Johnson</surname><given-names>DK</given-names></name><name><surname>Kappel</surname><given-names>K</given-names></name><name><surname>Karanicolas</surname><given-names>J</given-names></name><name><surname>Khakzad</surname><given-names>H</given-names></name><name><surname>Khar</surname><given-names>KR</given-names></name><name><surname>Khare</surname><given-names>SD</given-names></name><name><surname>Khatib</surname><given-names>F</given-names></name><name><surname>Khramushin</surname><given-names>A</given-names></name><name><surname>King</surname><given-names>IC</given-names></name><name><surname>Kleffner</surname><given-names>R</given-names></name><name><surname>Koepnick</surname><given-names>B</given-names></name><name><surname>Kortemme</surname><given-names>T</given-names></name><name><surname>Kuenze</surname><given-names>G</given-names></name><name><surname>Kuhlman</surname><given-names>B</given-names></name><name><surname>Kuroda</surname><given-names>D</given-names></name><name><surname>Labonte</surname><given-names>JW</given-names></name><name><surname>Lai</surname><given-names>JK</given-names></name><name><surname>Lapidoth</surname><given-names>G</given-names></name><name><surname>Leaver-Fay</surname><given-names>A</given-names></name><name><surname>Lindert</surname><given-names>S</given-names></name><name><surname>Linsky</surname><given-names>T</given-names></name><name><surname>London</surname><given-names>N</given-names></name><name><surname>Lubin</surname><given-names>JH</given-names></name><name><surname>Lyskov</surname><given-names>S</given-names></name><name><surname>Maguire</surname><given-names>J</given-names></name><name><surname>MalmstrÃ¶m</surname><given-names>L</given-names></name><name><surname>Marcos</surname><given-names>E</given-names></name><name><surname>Marcu</surname><given-names>O</given-names></name><name><surname>Marze</surname><given-names>NA</given-names></name><name><surname>Meiler</surname><given-names>J</given-names></name><name><surname>Moretti</surname><given-names>R</given-names></name><name><surname>Mulligan</surname><given-names>VK</given-names></name><name><surname>Nerli</surname><given-names>S</given-names></name><name><surname>Norn</surname><given-names>C</given-names></name><name><surname>ÃâConchÃºir</surname><given-names>S</given-names></name><name><surname>Ollikainen</surname><given-names>N</given-names></name><name><surname>Ovchinnikov</surname><given-names>S</given-names></name><name><surname>Pacella</surname><given-names>MS</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Pavlovicz</surname><given-names>RE</given-names></name><name><surname>Pethe</surname><given-names>M</given-names></name><name><surname>Pierce</surname><given-names>BG</given-names></name><name><surname>Pilla</surname><given-names>KB</given-names></name><name><surname>Raveh</surname><given-names>B</given-names></name><name><surname>Renfrew</surname><given-names>PD</given-names></name><name><surname>Burman</surname><given-names>SSR</given-names></name><name><surname>Rubenstein</surname><given-names>A</given-names></name><name><surname>Sauer</surname><given-names>MF</given-names></name><name><surname>Scheck</surname><given-names>A</given-names></name><name><surname>Schief</surname><given-names>W</given-names></name><name><surname>Schueler-Furman</surname><given-names>O</given-names></name><name><surname>Sedan</surname><given-names>Y</given-names></name><name><surname>Sevy</surname><given-names>AM</given-names></name><name><surname>Sgourakis</surname><given-names>NG</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Siegel</surname><given-names>JB</given-names></name><name><surname>Silva</surname><given-names>D-A</given-names></name><name><surname>Smith</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Stein</surname><given-names>A</given-names></name><name><surname>Szegedy</surname><given-names>M</given-names></name><name><surname>Teets</surname><given-names>FD</given-names></name><name><surname>Thyme</surname><given-names>SB</given-names></name><name><surname>Wang</surname><given-names>RY-R</given-names></name><name><surname>Watkins</surname><given-names>A</given-names></name><name><surname>Zimmerman</surname><given-names>L</given-names></name><name><surname>Bonneau</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Macromolecular modeling and design in Rosetta: recent methods and frameworks</article-title><source>Nature Methods</source><volume>17</volume><fpage>665</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/s41592-020-0848-2</pub-id><pub-id pub-id-type="pmid">32483333</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Comparison of the effects of DC031050, a class III antiarrhythmic agent, on hERG channel and three neuronal potassium channels</article-title><source>Acta Pharmacologica Sinica</source><volume>33</volume><fpage>728</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1038/aps.2012.41</pub-id><pub-id pub-id-type="pmid">22609836</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Ramos</surname><given-names>LG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Drug-induced QT prolongation and torsades de pointes</article-title><source>Pharm Ther</source><volume>42</volume><fpage>473</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">28674475</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name><name><surname>Lei</surname><given-names>J</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Structural basis for pore blockade of the human cardiac sodium channel Na <sub>v</sub> 1.5 by the antiarrhythmic drug quinidine**</article-title><source>Angewandte Chemie International Edition</source><volume>60</volume><fpage>11474</fpage><lpage>11480</lpage><pub-id pub-id-type="doi">10.1002/anie.202102196</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>R</given-names></name><name><surname>Reddy</surname><given-names>B</given-names></name><name><surname>Perozo</surname><given-names>E</given-names></name><name><surname>Roux</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Mechanism of C-type inactivation in the hERG potassium channel</article-title><source>Science Advances</source><volume>7</volume><elocation-id>eabd6203</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abd6203</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Dissection of the structure-function relationship of Nav channels</article-title><source>PNAS</source><volume>121</volume><elocation-id>e2322899121</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2322899121</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Lidbrink</surname><given-names>SE</given-names></name><name><surname>Howard</surname><given-names>R</given-names></name><name><surname>Haloi</surname><given-names>N</given-names></name><name><surname>Lindahl</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Resolving the Conformational Ensemble of a Membrane Protein by Integrating Small-Angle Scattering with AlphaFold</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2024.09.05.611464</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Akin</surname><given-names>H</given-names></name><name><surname>Rao</surname><given-names>R</given-names></name><name><surname>Hie</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Smetanin</surname><given-names>N</given-names></name><name><surname>Verkuil</surname><given-names>R</given-names></name><name><surname>Kabeli</surname><given-names>O</given-names></name><name><surname>Shmueli</surname><given-names>Y</given-names></name><name><surname>Dos Santos Costa</surname><given-names>A</given-names></name><name><surname>Fazel-Zarandi</surname><given-names>M</given-names></name><name><surname>Sercu</surname><given-names>T</given-names></name><name><surname>Candido</surname><given-names>S</given-names></name><name><surname>Rives</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Evolutionary-scale prediction of atomic-level protein structure with a language model</article-title><source>Science</source><volume>379</volume><fpage>1123</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1126/science.ade2574</pub-id><pub-id pub-id-type="pmid">36927031</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Tseng</surname><given-names>GN</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Structural and functional role of the extracellular S5-p linker in the HERG potassium channel</article-title><source>The Journal of General Physiology</source><volume>120</volume><fpage>723</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1085/jgp.20028687</pub-id><pub-id pub-id-type="pmid">12407082</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>SB</given-names></name><name><surname>Campbell</surname><given-names>EB</given-names></name><name><surname>Mackinnon</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Crystal structure of a mammalian voltage-dependent Shaker family K+ channel</article-title><source>Science</source><volume>309</volume><fpage>897</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1126/science.1116269</pub-id><pub-id pub-id-type="pmid">16002581</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maly</surname><given-names>J</given-names></name><name><surname>Emigh</surname><given-names>AM</given-names></name><name><surname>DeMarco</surname><given-names>KR</given-names></name><name><surname>Furutani</surname><given-names>K</given-names></name><name><surname>Sack</surname><given-names>JT</given-names></name><name><surname>Clancy</surname><given-names>CE</given-names></name><name><surname>Vorobyov</surname><given-names>I</given-names></name><name><surname>Yarov-Yarovoy</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Structural modeling of the hERG potassium channel and associated drug interactions</article-title><source>Frontiers in Pharmacology</source><volume>13</volume><elocation-id>966463</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2022.966463</pub-id><pub-id pub-id-type="pmid">36188564</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandala</surname><given-names>VS</given-names></name><name><surname>MacKinnon</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Voltage-sensor movements in the Eag Kv channel under an applied electric field</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2214151119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2214151119</pub-id><pub-id pub-id-type="pmid">36331999</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>Y</given-names></name><name><surname>Bhattarai</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Ligand gaussian accelerated molecular dynamics (LiGaMD): characterization of ligand binding thermodynamics and kinetics</article-title><source>Journal of Chemical Theory and Computation</source><volume>16</volume><fpage>5526</fpage><lpage>5547</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.0c00395</pub-id><pub-id pub-id-type="pmid">32692556</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>BR</given-names><suffix>III</suffix></name><name><surname>McGee</surname><given-names>TD</given-names></name><name><surname>Swails</surname><given-names>JM</given-names></name><name><surname>Homeyer</surname><given-names>N</given-names></name><name><surname>Gohlke</surname><given-names>H</given-names></name><name><surname>Roitberg</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>MMPBSA.py: an efficient program for end-state free energy calculations</article-title><source>Journal of Chemical Theory and Computation</source><volume>8</volume><fpage>3314</fpage><lpage>3321</lpage><pub-id pub-id-type="doi">10.1021/ct300418h</pub-id><pub-id pub-id-type="pmid">26605738</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miranda</surname><given-names>WE</given-names></name><name><surname>DeMarco</surname><given-names>KR</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Duff</surname><given-names>HJ</given-names></name><name><surname>Vorobyov</surname><given-names>I</given-names></name><name><surname>Clancy</surname><given-names>CE</given-names></name><name><surname>Noskov</surname><given-names>SY</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Selectivity filter modalities and rapid inactivation of the hERG1 channel</article-title><source>PNAS</source><volume>117</volume><fpage>2795</fpage><lpage>2804</lpage><pub-id pub-id-type="doi">10.1073/pnas.1909196117</pub-id><pub-id pub-id-type="pmid">31980532</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirdita</surname><given-names>M</given-names></name><name><surname>Steinegger</surname><given-names>M</given-names></name><name><surname>SÃ¶ding</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>MMseqs2 desktop and local web server app for fast, interactive sequence searches</article-title><source>Bioinformatics</source><volume>35</volume><fpage>2856</fpage><lpage>2858</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bty1057</pub-id><pub-id pub-id-type="pmid">30615063</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirdita</surname><given-names>M</given-names></name><name><surname>SchÃ¼tze</surname><given-names>K</given-names></name><name><surname>Moriwaki</surname><given-names>Y</given-names></name><name><surname>Heo</surname><given-names>L</given-names></name><name><surname>Ovchinnikov</surname><given-names>S</given-names></name><name><surname>Steinegger</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>ColabFold: making protein folding accessible to all</article-title><source>Nature Methods</source><volume>19</volume><fpage>679</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/s41592-022-01488-1</pub-id><pub-id pub-id-type="pmid">35637307</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyashita</surname><given-names>Y</given-names></name><name><surname>Moriya</surname><given-names>T</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Kawasaki</surname><given-names>M</given-names></name><name><surname>Yasuda</surname><given-names>S</given-names></name><name><surname>Adachi</surname><given-names>N</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Ogasawara</surname><given-names>S</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Senda</surname><given-names>T</given-names></name><name><surname>Murata</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Improved higher resolution cryo-EM structures reveal the binding modes of hERG channel inhibitors</article-title><source>Structure</source><volume>32</volume><fpage>1926</fpage><lpage>1935</lpage><pub-id pub-id-type="doi">10.1016/j.str.2024.08.021</pub-id><pub-id pub-id-type="pmid">39321803</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monahan</surname><given-names>BP</given-names></name><name><surname>Ferguson</surname><given-names>CL</given-names></name><name><surname>Killeavy</surname><given-names>ES</given-names></name><name><surname>Lloyd</surname><given-names>BK</given-names></name><name><surname>Troy</surname><given-names>J</given-names></name><name><surname>Cantilena</surname><given-names>LR</given-names><suffix>Jr</suffix></name></person-group><year iso-8601-date="1990">1990</year><article-title>Torsades de pointes occurring in association with terfenadine use</article-title><source>JAMA</source><volume>264</volume><fpage>2788</fpage><lpage>2790</lpage><pub-id pub-id-type="doi">10.1001/jama.1990.03450210088038</pub-id><pub-id pub-id-type="pmid">1977935</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Furukawa</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Katayama</surname><given-names>Y</given-names></name><name><surname>Nagai</surname><given-names>R</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Hiraoka</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Novel mechanism of HERG current suppression in LQT2: shift in voltage dependence of HERG inactivation</article-title><source>Circulation Research</source><volume>83</volume><fpage>415</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1161/01.RES.83.4.415</pub-id><pub-id pub-id-type="pmid">9721698</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngo</surname><given-names>K</given-names></name><name><surname>Lopez Mateos</surname><given-names>D</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Rouen</surname><given-names>KC</given-names></name><name><surname>Ahn</surname><given-names>SH</given-names></name><name><surname>Wulff</surname><given-names>H</given-names></name><name><surname>Clancy</surname><given-names>CE</given-names></name><name><surname>Yarov-Yarovoy</surname><given-names>V</given-names></name><name><surname>Vorobyov</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Elucidating molecular mechanisms of protoxin-II state-specific binding to the human NaV1.7 channel</article-title><source>The Journal of General Physiology</source><volume>156</volume><elocation-id>e202313368</elocation-id><pub-id pub-id-type="doi">10.1085/jgp.202313368</pub-id><pub-id pub-id-type="pmid">38127314</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Ngo</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>AlphaFold_Analysis</data-title><version designator="swh:1:rev:bc2a52e9f9bc6d483957710eecd7823a72d617b1">swh:1:rev:bc2a52e9f9bc6d483957710eecd7823a72d617b1</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:70660e1b4644118cc78e295e43ffc5f41d5ede98;origin=https://github.com/k-ngo/AlphaFold_Analysis;visit=swh:1:snp:68738fc8f1583276086b98d37338ff38f58bc8b7;anchor=swh:1:rev:bc2a52e9f9bc6d483957710eecd7823a72d617b1">https://archive.softwareheritage.org/swh:1:dir:70660e1b4644118cc78e295e43ffc5f41d5ede98;origin=https://github.com/k-ngo/AlphaFold_Analysis;visit=swh:1:snp:68738fc8f1583276086b98d37338ff38f58bc8b7;anchor=swh:1:rev:bc2a52e9f9bc6d483957710eecd7823a72d617b1</ext-link></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noel</surname><given-names>JK</given-names></name><name><surname>Whitford</surname><given-names>PC</given-names></name><name><surname>Onuchic</surname><given-names>JN</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The shadow map: a general contact definition for capturing the dynamics of biomolecular folding and function</article-title><source>The Journal of Physical Chemistry. B</source><volume>116</volume><fpage>8692</fpage><lpage>8702</lpage><pub-id pub-id-type="doi">10.1021/jp300852d</pub-id><pub-id pub-id-type="pmid">22536820</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Numaguchi</surname><given-names>H</given-names></name><name><surname>Mullins</surname><given-names>FM</given-names></name><name><surname>Johnson</surname><given-names>JP</given-names></name><name><surname>Johns</surname><given-names>DC</given-names></name><name><surname>Po</surname><given-names>SS</given-names></name><name><surname>Yang</surname><given-names>ICH</given-names></name><name><surname>Tomaselli</surname><given-names>GF</given-names></name><name><surname>Balser</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Probing the interaction between inactivation gating and Dd-sotalol block of HERG</article-title><source>Circulation Research</source><volume>87</volume><fpage>1012</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1161/01.res.87.11.1012</pub-id><pub-id pub-id-type="pmid">11090546</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orvos</surname><given-names>P</given-names></name><name><surname>Kohajda</surname><given-names>Z</given-names></name><name><surname>SzlovÃ¡k</surname><given-names>J</given-names></name><name><surname>Gazdag</surname><given-names>P</given-names></name><name><surname>ÃrpÃ¡dffy-Lovas</surname><given-names>T</given-names></name><name><surname>TÃ³th</surname><given-names>D</given-names></name><name><surname>Geramipour</surname><given-names>A</given-names></name><name><surname>TÃ¡losi</surname><given-names>L</given-names></name><name><surname>Jost</surname><given-names>N</given-names></name><name><surname>VarrÃ³</surname><given-names>A</given-names></name><name><surname>VirÃ¡g</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Evaluation of possible proarrhythmic potency: comparison of the effect of dofetilide, cisapride, sotalol</article-title><source>Terfenadine, and Verapamil on hERG and Native IKr Currents and on Cardiac Action Potential. Toxicol Sci Off J Soc Toxicol</source><volume>168</volume><fpage>365</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfy299</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Ovchinnikov</surname><given-names>S</given-names></name><name><surname>Steinegger</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>ColabFold</data-title><version designator="a134f6a">a134f6a</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/sokrypton/ColabFold">https://github.com/sokrypton/ColabFold</ext-link></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Baek</surname><given-names>M</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name><name><surname>DiMaio</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Force field optimization guided by small molecule crystal lattice data enables consistent sub-angstrom protein-ligand docking</article-title><source>Journal of Chemical Theory and Computation</source><volume>17</volume><fpage>2000</fpage><lpage>2010</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.0c01184</pub-id><pub-id pub-id-type="pmid">33577321</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>AA</given-names></name><name><surname>Witchel</surname><given-names>HJ</given-names></name><name><surname>Hancox</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine</article-title><source>British Journal of Pharmacology</source><volume>136</volume><fpage>717</fpage><lpage>729</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0704784</pub-id><pub-id pub-id-type="pmid">12086981</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perissinotti</surname><given-names>LL</given-names></name><name><surname>De Biase</surname><given-names>PM</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>PC</given-names></name><name><surname>Lee</surname><given-names>MC</given-names></name><name><surname>Clancy</surname><given-names>CE</given-names></name><name><surname>Duff</surname><given-names>HJ</given-names></name><name><surname>Noskov</surname><given-names>SY</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Determinants of isoform-specific gating kinetics of hERG1 channel: combined experimental and simulation study</article-title><source>Frontiers in Physiology</source><volume>9</volume><elocation-id>207</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2018.00207</pub-id><pub-id pub-id-type="pmid">29706893</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrin</surname><given-names>MJ</given-names></name><name><surname>Kuchel</surname><given-names>PW</given-names></name><name><surname>Campbell</surname><given-names>TJ</given-names></name><name><surname>Vandenberg</surname><given-names>JI</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-Ã -go-go-related gene channels</article-title><source>Molecular Pharmacology</source><volume>74</volume><fpage>1443</fpage><lpage>1452</lpage><pub-id pub-id-type="doi">10.1124/mol.108.049056</pub-id><pub-id pub-id-type="pmid">18701618</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>EF</given-names></name><name><surname>Goddard</surname><given-names>TD</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Meng</surname><given-names>EC</given-names></name><name><surname>Couch</surname><given-names>GS</given-names></name><name><surname>Croll</surname><given-names>TI</given-names></name><name><surname>Morris</surname><given-names>JH</given-names></name><name><surname>Ferrin</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>UCSF ChimeraX: structure visualization for researchers, educators, and developers</article-title><source>Protein Science</source><volume>30</volume><fpage>70</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1002/pro.3943</pub-id><pub-id pub-id-type="pmid">32881101</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettini</surname><given-names>F</given-names></name><name><surname>Domene</surname><given-names>C</given-names></name><name><surname>Furini</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Early steps in C-type inactivation of the hERG potassium channel</article-title><source>Journal of Chemical Information and Modeling</source><volume>63</volume><fpage>251</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.2c01028</pub-id><pub-id pub-id-type="pmid">36512342</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phartiyal</surname><given-names>P</given-names></name><name><surname>Jones</surname><given-names>EMC</given-names></name><name><surname>Robertson</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Heteromeric assembly of human ether-Ã -go-go-related gene (hERG) 1a/1b channels occurs cotranslationally via N-terminal interactions</article-title><source>The Journal of Biological Chemistry</source><volume>282</volume><fpage>9874</fpage><lpage>9882</lpage><pub-id pub-id-type="doi">10.1074/jbc.M610875200</pub-id><pub-id pub-id-type="pmid">17272276</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pirok</surname><given-names>G</given-names></name><name><surname>MatÃ©</surname><given-names>N</given-names></name><name><surname>Varga</surname><given-names>J</given-names></name><name><surname>Szegezdi</surname><given-names>J</given-names></name><name><surname>Vargyas</surname><given-names>M</given-names></name><name><surname>DÃ³rant</surname><given-names>S</given-names></name><name><surname>Csizmadia</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Making ârealâ molecules in virtual space</article-title><source>Journal of Chemical Information and Modeling</source><volume>46</volume><fpage>563</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1021/ci050373p</pub-id><pub-id pub-id-type="pmid">16562984</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Priest</surname><given-names>BT</given-names></name><name><surname>Bell</surname><given-names>IM</given-names></name><name><surname>Garcia</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Role of hERG potassium channel assays in drug development</article-title><source>Channels</source><volume>2</volume><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.4161/chan.2.2.6004</pub-id><pub-id pub-id-type="pmid">18849661</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rampe</surname><given-names>D</given-names></name><name><surname>Roy</surname><given-names>ML</given-names></name><name><surname>Dennis</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG</article-title><source>FEBS Letters</source><volume>417</volume><fpage>28</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/s0014-5793(97)01249-0</pub-id><pub-id pub-id-type="pmid">9395068</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>L</given-names></name><name><surname>Trenor</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>PC</given-names></name><name><surname>Saiz</surname><given-names>J</given-names></name><name><surname>Clancy</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>87</volume><fpage>271</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2015.08.015</pub-id><pub-id pub-id-type="pmid">26859003</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roux</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Ion channels and ion selectivity</article-title><source>Essays in Biochemistry</source><volume>61</volume><fpage>201</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1042/EBC20160074</pub-id><pub-id pub-id-type="pmid">28487397</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryckaert</surname><given-names>JP</given-names></name><name><surname>Ciccotti</surname><given-names>G</given-names></name><name><surname>Berendsen</surname><given-names>HJC</given-names></name></person-group><year iso-8601-date="1977">1977</year><article-title>Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes</article-title><source>Journal of Computational Physics</source><volume>23</volume><fpage>327</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1016/0021-9991(77)90098-5</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sala</surname><given-names>D</given-names></name><name><surname>Hildebrand</surname><given-names>PW</given-names></name><name><surname>Meiler</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Biasing AlphaFold2 to predict GPCRs and kinases with user-defined functional or structural properties</article-title><source>Frontiers in Molecular Biosciences</source><volume>10</volume><elocation-id>1121962</elocation-id><pub-id pub-id-type="doi">10.3389/fmolb.2023.1121962</pub-id><pub-id pub-id-type="pmid">36876042</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salentin</surname><given-names>S</given-names></name><name><surname>Schreiber</surname><given-names>S</given-names></name><name><surname>Haupt</surname><given-names>VJ</given-names></name><name><surname>Adasme</surname><given-names>MF</given-names></name><name><surname>Schroeder</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>PLIP: fully automated protein-ligand interaction profiler</article-title><source>Nucleic Acids Research</source><volume>43</volume><fpage>W443</fpage><lpage>W447</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv315</pub-id><pub-id pub-id-type="pmid">25873628</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanguinetti</surname><given-names>MC</given-names></name><name><surname>Tristani-Firouzi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>hERG potassium channels and cardiac arrhythmia</article-title><source>Nature</source><volume>440</volume><fpage>463</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1038/nature04710</pub-id><pub-id pub-id-type="pmid">16554806</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satler</surname><given-names>CA</given-names></name><name><surname>Vesely</surname><given-names>MR</given-names></name><name><surname>Duggal</surname><given-names>P</given-names></name><name><surname>Ginsburg</surname><given-names>GS</given-names></name><name><surname>Beggs</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Multiple different missense mutations in the pore region of HERG in patients with long QT syndrome</article-title><source>Human Genetics</source><volume>102</volume><fpage>265</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1007/s004390050690</pub-id><pub-id pub-id-type="pmid">9544837</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxena</surname><given-names>P</given-names></name><name><surname>Zangerl-Plessl</surname><given-names>EM</given-names></name><name><surname>Linder</surname><given-names>T</given-names></name><name><surname>Windisch</surname><given-names>A</given-names></name><name><surname>Hohaus</surname><given-names>A</given-names></name><name><surname>Timin</surname><given-names>E</given-names></name><name><surname>Hering</surname><given-names>S</given-names></name><name><surname>Stary-Weinzinger</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>New potential binding determinant for hERG channel inhibitors</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>24182</elocation-id><pub-id pub-id-type="doi">10.1038/srep24182</pub-id><pub-id pub-id-type="pmid">27067805</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>SchÃ¶nherr</surname><given-names>R</given-names></name><name><surname>Heinemann</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Molecular determinants for activation and inactivation of HERG, a human inward rectifier potassium channel</article-title><source>The Journal of Physiology</source><volume>493 (Pt 3)</volume><fpage>635</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.1996.sp021410</pub-id><pub-id pub-id-type="pmid">8799887</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvakumar</surname><given-names>P</given-names></name><name><surname>FernÃ¡ndez-MariÃ±o</surname><given-names>AI</given-names></name><name><surname>Khanra</surname><given-names>N</given-names></name><name><surname>He</surname><given-names>C</given-names></name><name><surname>Paquette</surname><given-names>AJ</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Smider</surname><given-names>VV</given-names></name><name><surname>Rice</surname><given-names>WJ</given-names></name><name><surname>Swartz</surname><given-names>KJ</given-names></name><name><surname>Meyerson</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Structures of the T cell potassium channel Kv1.3 with immunoglobulin modulators</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>3854</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-31285-5</pub-id><pub-id pub-id-type="pmid">35788586</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>YP</given-names></name><name><surname>Thouta</surname><given-names>S</given-names></name><name><surname>Claydon</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Modulation of hERG K<sup>+</sup> channel deactivation by voltage sensor relaxation</article-title><source>Frontiers in Pharmacology</source><volume>11</volume><elocation-id>139</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2020.00139</pub-id><pub-id pub-id-type="pmid">32184724</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shinozawa</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Shoji</surname><given-names>M</given-names></name><name><surname>Morita</surname><given-names>M</given-names></name><name><surname>Kimura</surname><given-names>M</given-names></name><name><surname>Furukawa</surname><given-names>H</given-names></name><name><surname>Ueda</surname><given-names>H</given-names></name><name><surname>Shiramoto</surname><given-names>M</given-names></name><name><surname>Matsuguma</surname><given-names>K</given-names></name><name><surname>Kaji</surname><given-names>Y</given-names></name><name><surname>Ikushima</surname><given-names>I</given-names></name><name><surname>Yono</surname><given-names>M</given-names></name><name><surname>Liou</surname><given-names>SY</given-names></name><name><surname>Nagai</surname><given-names>H</given-names></name><name><surname>Nakanishi</surname><given-names>A</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Izumo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Recapitulation of clinical individual susceptibility to drug-induced QT prolongation in healthy subjects using iPSC-derived cardiomyocytes</article-title><source>Stem Cell Reports</source><volume>8</volume><fpage>226</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2016.12.014</pub-id><pub-id pub-id-type="pmid">28111276</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stepanovic</surname><given-names>SZ</given-names></name><name><surname>Potet</surname><given-names>F</given-names></name><name><surname>Petersen</surname><given-names>CI</given-names></name><name><surname>Smith</surname><given-names>JA</given-names></name><name><surname>Meiler</surname><given-names>J</given-names></name><name><surname>Balser</surname><given-names>JR</given-names></name><name><surname>Kupershmidt</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The evolutionarily conserved residue A653 plays a key role in HERG channel closing</article-title><source>The Journal of Physiology</source><volume>587</volume><fpage>2555</fpage><lpage>2566</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2008.166694</pub-id><pub-id pub-id-type="pmid">19406877</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stork</surname><given-names>D</given-names></name><name><surname>Timin</surname><given-names>EN</given-names></name><name><surname>Berjukow</surname><given-names>S</given-names></name><name><surname>Huber</surname><given-names>C</given-names></name><name><surname>Hohaus</surname><given-names>A</given-names></name><name><surname>Auer</surname><given-names>M</given-names></name><name><surname>Hering</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>State dependent dissociation of HERG channel inhibitors</article-title><source>British Journal of Pharmacology</source><volume>151</volume><fpage>1368</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0707356</pub-id><pub-id pub-id-type="pmid">17592502</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suessbrich</surname><given-names>H</given-names></name><name><surname>SchÃ¶nherr</surname><given-names>R</given-names></name><name><surname>Heinemann</surname><given-names>SH</given-names></name><name><surname>Attali</surname><given-names>B</given-names></name><name><surname>Lang</surname><given-names>F</given-names></name><name><surname>Busch</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in <italic>Xenopus</italic> oocytes</article-title><source>British Journal of Pharmacology</source><volume>120</volume><fpage>968</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0700989</pub-id><pub-id pub-id-type="pmid">9138706</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>XF</given-names></name><name><surname>Bae</surname><given-names>C</given-names></name><name><surname>Stix</surname><given-names>R</given-names></name><name><surname>FernÃ¡ndez-MariÃ±o</surname><given-names>AI</given-names></name><name><surname>Huffer</surname><given-names>K</given-names></name><name><surname>Chang</surname><given-names>TH</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Faraldo-GÃ³mez</surname><given-names>JD</given-names></name><name><surname>Swartz</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Structure of the Shaker Kv channel and mechanism of slow C-type inactivation</article-title><source>Science Advances</source><volume>8</volume><elocation-id>eabm7814</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abm7814</pub-id><pub-id pub-id-type="pmid">35302848</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Hamaguchi</surname><given-names>S</given-names></name><name><surname>Iida-Tanaka</surname><given-names>N</given-names></name><name><surname>Oka</surname><given-names>T</given-names></name><name><surname>Nishio</surname><given-names>M</given-names></name><name><surname>Ohtsuki</surname><given-names>A</given-names></name><name><surname>Namekata</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Effect of terfenadine and pentamidine on the HERG channel and its intracellular trafficking: combined analysis with automated voltage clamp and confocal microscopy</article-title><source>Biological &amp; Pharmaceutical Bulletin</source><volume>37</volume><fpage>1826</fpage><lpage>1830</lpage><pub-id pub-id-type="doi">10.1248/bpb.b14-00417</pub-id><pub-id pub-id-type="pmid">25366487</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thouta</surname><given-names>S</given-names></name><name><surname>Sokolov</surname><given-names>S</given-names></name><name><surname>Abe</surname><given-names>Y</given-names></name><name><surname>Clark</surname><given-names>SJ</given-names></name><name><surname>Cheng</surname><given-names>YM</given-names></name><name><surname>Claydon</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Proline scan of the HERG channel S6 helix reveals the location of the intracellular pore gate</article-title><source>Biophysical Journal</source><volume>106</volume><fpage>1057</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2014.01.035</pub-id><pub-id pub-id-type="pmid">24606930</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tingle</surname><given-names>BI</given-names></name><name><surname>Tang</surname><given-names>KG</given-names></name><name><surname>Castanon</surname><given-names>M</given-names></name><name><surname>Gutierrez</surname><given-names>JJ</given-names></name><name><surname>Khurelbaatar</surname><given-names>M</given-names></name><name><surname>Dandarchuluun</surname><given-names>C</given-names></name><name><surname>Moroz</surname><given-names>YS</given-names></name><name><surname>Irwin</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>ZINC-22âA free multi-billion-scale database of tangible compounds for ligand discovery</article-title><source>Journal of Chemical Information and Modeling</source><volume>63</volume><fpage>1166</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.2c01253</pub-id><pub-id pub-id-type="pmid">36790087</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyagi</surname><given-names>A</given-names></name><name><surname>Ahmed</surname><given-names>T</given-names></name><name><surname>Jian</surname><given-names>S</given-names></name><name><surname>Bajaj</surname><given-names>S</given-names></name><name><surname>Ong</surname><given-names>ST</given-names></name><name><surname>Goay</surname><given-names>SSM</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Vorobyov</surname><given-names>I</given-names></name><name><surname>Tian</surname><given-names>C</given-names></name><name><surname>Chandy</surname><given-names>KG</given-names></name><name><surname>Bhushan</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Rearrangement of a unique Kv1.3 selectivity filter conformation upon binding of a drug</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2113536119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2113536119</pub-id><pub-id pub-id-type="pmid">35091471</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandenberg</surname><given-names>JI</given-names></name><name><surname>Perry</surname><given-names>MD</given-names></name><name><surname>Perrin</surname><given-names>MJ</given-names></name><name><surname>Mann</surname><given-names>SA</given-names></name><name><surname>Ke</surname><given-names>Y</given-names></name><name><surname>Hill</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>hERG K(+) channels: structure, function, and clinical significance</article-title><source>Physiological Reviews</source><volume>92</volume><fpage>1393</fpage><lpage>1478</lpage><pub-id pub-id-type="doi">10.1152/physrev.00036.2011</pub-id><pub-id pub-id-type="pmid">22988594</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varadi</surname><given-names>M</given-names></name><name><surname>Velankar</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The impact of alphafold protein structure database on the fields of life sciences</article-title><source>Proteomics</source><volume>23</volume><elocation-id>e2200128</elocation-id><pub-id pub-id-type="doi">10.1002/pmic.202200128</pub-id><pub-id pub-id-type="pmid">36382391</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waldo</surname><given-names>AL</given-names></name><name><surname>Camm</surname><given-names>AJ</given-names></name><name><surname>deRuyter</surname><given-names>H</given-names></name><name><surname>Friedman</surname><given-names>PL</given-names></name><name><surname>MacNeil</surname><given-names>DJ</given-names></name><name><surname>Pauls</surname><given-names>JF</given-names></name><name><surname>Pitt</surname><given-names>B</given-names></name><name><surname>Pratt</surname><given-names>CM</given-names></name><name><surname>Schwartz</surname><given-names>PJ</given-names></name><name><surname>Veltri</surname><given-names>EP</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction</article-title><source>The Lancet</source><volume>348</volume><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(96)02149-6</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>BD</given-names></name><name><surname>Valenzuela</surname><given-names>SM</given-names></name><name><surname>Singleton</surname><given-names>CB</given-names></name><name><surname>Tie</surname><given-names>H</given-names></name><name><surname>Bursill</surname><given-names>JA</given-names></name><name><surname>Wyse</surname><given-names>KR</given-names></name><name><surname>Qiu</surname><given-names>MR</given-names></name><name><surname>Breit</surname><given-names>SN</given-names></name><name><surname>Campbell</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleate</article-title><source>British Journal of Pharmacology</source><volume>127</volume><fpage>243</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0702502</pub-id><pub-id pub-id-type="pmid">10369479</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Morales</surname><given-names>MJ</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Strauss</surname><given-names>HC</given-names></name><name><surname>Rasmusson</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Modulation of HERG affinity for E-4031 by [K+]o and C-type inactivation</article-title><source>FEBS Letters</source><volume>417</volume><fpage>43</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/s0014-5793(97)01245-3</pub-id><pub-id pub-id-type="pmid">9395071</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Nguyen</surname><given-names>PH</given-names></name><name><surname>Pham</surname><given-names>K</given-names></name><name><surname>Huynh</surname><given-names>D</given-names></name><name><surname>Le</surname><given-names>TBN</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Ren</surname><given-names>P</given-names></name><name><surname>Luo</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Calculating protein-ligand binding affinities with MMPBSA: Method and error analysis</article-title><source>Journal of Computational Chemistry</source><volume>37</volume><fpage>2436</fpage><lpage>2446</lpage><pub-id pub-id-type="doi">10.1002/jcc.24467</pub-id><pub-id pub-id-type="pmid">27510546</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>MacKinnon</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cryo-EM structure of the open human ether-Ã -go-go-related K<sup>+</sup> Channel hERG</article-title><source>Cell</source><volume>169</volume><fpage>422</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.03.048</pub-id><pub-id pub-id-type="pmid">28431243</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Windisch</surname><given-names>A</given-names></name><name><surname>Timin</surname><given-names>EN</given-names></name><name><surname>Schwarz</surname><given-names>T</given-names></name><name><surname>Stork-Riedler</surname><given-names>D</given-names></name><name><surname>Erker</surname><given-names>T</given-names></name><name><surname>Ecker</surname><given-names>GF</given-names></name><name><surname>Hering</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Trapping and dissociation of propafenone derivatives in HERG channels</article-title><source>British Journal of Pharmacology</source><volume>162</volume><fpage>1542</fpage><lpage>1552</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.01159.x</pub-id><pub-id pub-id-type="pmid">21175572</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Windley</surname><given-names>MJ</given-names></name><name><surname>Abi-Gerges</surname><given-names>N</given-names></name><name><surname>Fermini</surname><given-names>B</given-names></name><name><surname>Hancox</surname><given-names>JC</given-names></name><name><surname>Vandenberg</surname><given-names>JI</given-names></name><name><surname>Hill</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Measuring kinetics and potency of hERG block for CiPA</article-title><source>Journal of Pharmacological and Toxicological Methods</source><volume>87</volume><fpage>99</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.vascn.2017.02.017</pub-id><pub-id pub-id-type="pmid">28192183</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Bian</surname><given-names>S</given-names></name><name><surname>Rivetta</surname><given-names>A</given-names></name><name><surname>Allen</surname><given-names>K</given-names></name><name><surname>Sigworth</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>CryoEM structures of Kv1.2 potassium channels, conducting and non-conducting</article-title><source>eLife</source><volume>12</volume><elocation-id>RP89459</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.89459</pub-id><pub-id pub-id-type="pmid">39945513</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Rohou</surname><given-names>A</given-names></name><name><surname>Arthur</surname><given-names>CP</given-names></name><name><surname>Tzakoniati</surname><given-names>F</given-names></name><name><surname>Wong</surname><given-names>E</given-names></name><name><surname>Estevez</surname><given-names>A</given-names></name><name><surname>Kugel</surname><given-names>C</given-names></name><name><surname>Franke</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Ciferri</surname><given-names>C</given-names></name><name><surname>Hackos</surname><given-names>DH</given-names></name><name><surname>Koth</surname><given-names>CM</given-names></name><name><surname>Payandeh</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Structural basis of Nav1.7 inhibition by a gating-modifier spider toxin</article-title><source>Cell</source><volume>176</volume><fpage>702</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.12.018</pub-id><pub-id pub-id-type="pmid">30661758</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>M</given-names></name><name><surname>Fan</surname><given-names>P</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhan</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Stereoselective blockage of quinidine and quinine in the hERG channel and the effect of their rescue potency on drug-induced hERG trafficking defect</article-title><source>International Journal of Molecular Sciences</source><volume>17</volume><elocation-id>1648</elocation-id><pub-id pub-id-type="doi">10.3390/ijms17101648</pub-id><pub-id pub-id-type="pmid">27690007</pub-id></element-citation></ref><ref id="bib137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>PC</given-names></name><name><surname>DeMarco</surname><given-names>KR</given-names></name><name><surname>Aghasafari</surname><given-names>P</given-names></name><name><surname>Jeng</surname><given-names>MT</given-names></name><name><surname>Dawson</surname><given-names>JRD</given-names></name><name><surname>Bekker</surname><given-names>S</given-names></name><name><surname>Noskov</surname><given-names>SY</given-names></name><name><surname>Yarov-Yarovoy</surname><given-names>V</given-names></name><name><surname>Vorobyov</surname><given-names>I</given-names></name><name><surname>Clancy</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A computational pipeline to predict Cardiotoxicity: from the atom to the rhythm</article-title><source>Circulation Research</source><volume>126</volume><fpage>947</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.119.316404</pub-id><pub-id pub-id-type="pmid">32091972</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Yan</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Structural biology of voltage-gated calcium channels</article-title><source>Channels</source><volume>18</volume><elocation-id>2290807</elocation-id><pub-id pub-id-type="doi">10.1080/19336950.2023.2290807</pub-id><pub-id pub-id-type="pmid">38062897</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Gong</surname><given-names>Q</given-names></name><name><surname>Makielski</surname><given-names>JC</given-names></name><name><surname>January</surname><given-names>CT</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Mechanism of block and identification of the verapamil binding domain to HERG potassium channels</article-title><source>Circulation Research</source><volume>84</volume><fpage>989</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.1161/01.res.84.9.989</pub-id><pub-id pub-id-type="pmid">10325236</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Colenso</surname><given-names>CK</given-names></name><name><surname>El Harchi</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>H</given-names></name><name><surname>Witchel</surname><given-names>HJ</given-names></name><name><surname>Dempsey</surname><given-names>CE</given-names></name><name><surname>Hancox</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking</article-title><source>Biochemical Pharmacology</source><volume>113</volume><fpage>24</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2016.05.013</pub-id><pub-id pub-id-type="pmid">27256139</pub-id></element-citation></ref><ref id="bib141"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>JT</given-names></name><name><surname>Hill</surname><given-names>AP</given-names></name><name><surname>Varghese</surname><given-names>A</given-names></name><name><surname>Cooper</surname><given-names>AA</given-names></name><name><surname>Swan</surname><given-names>H</given-names></name><name><surname>Laitinen-Forsblom</surname><given-names>PJ</given-names></name><name><surname>Rees</surname><given-names>MI</given-names></name><name><surname>Skinner</surname><given-names>JR</given-names></name><name><surname>Campbell</surname><given-names>TJ</given-names></name><name><surname>Vandenberg</surname><given-names>JI</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Not all hERG pore domain mutations have a severe phenotype: G584S has an inactivation gating defect with mild phenotype compared to G572S, which has a dominant negative trafficking defect and a severe phenotype</article-title><source>Journal of Cardiovascular Electrophysiology</source><volume>20</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1111/j.1540-8167.2009.01468.x</pub-id><pub-id pub-id-type="pmid">19490267</pub-id></element-citation></ref><ref id="bib142"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Gong</surname><given-names>Q</given-names></name><name><surname>Ye</surname><given-names>B</given-names></name><name><surname>Fan</surname><given-names>Z</given-names></name><name><surname>Makielski</surname><given-names>JC</given-names></name><name><surname>Robertson</surname><given-names>GA</given-names></name><name><surname>January</surname><given-names>CT</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature</article-title><source>Biophysical Journal</source><volume>74</volume><fpage>230</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1016/S0006-3495(98)77782-3</pub-id><pub-id pub-id-type="pmid">9449325</pub-id></element-citation></ref><ref id="bib143"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>QP</given-names></name><name><surname>Sanguinetti</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A mutation in the pore region of HERG K+ channels expressed in <italic>Xenopus</italic> oocytes reduces rectification by shifting the voltage dependence of inactivation</article-title><source>The Journal of Physiology</source><volume>509 (Pt 1)</volume><fpage>129</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1111/j.1469-7793.1998.129bo.x</pub-id><pub-id pub-id-type="pmid">9547387</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.104901.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Panchenko</surname><given-names>Anna</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Queen's University</institution><country>Canada</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This <bold>valuable</bold> study uses AlphaFold2 to guide the structural modelling of different states of the human voltage-gated potassium channel K<sub>V</sub>11.1, a key pharmacological drug target. Follow-up molecular dynamics and drug-docking simulations, combined with experimental characterization, offer <bold>convincing</bold> evidence supporting the models. The work shows potential for improving drug potency predictions in ion channel pharmacology.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.104901.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Ngo et. al use several computational methods to determine and characterize structures defining the three major states sampled by the human voltage-gated potassium channel hERG: the open, closed and inactivated state. Specifically, they use AlphaFold and Rosetta to generate conformations that likely represent key features of the open, closed and inactivated states of this channel. Molecular dynamics simulations confirm that ion conduction for structure models of the open but not the inactivated state. Moreover, drug docking in silico experiments show differential binding of drugs to the conformation of the three states; the inactivated one being preferentially bound by many of them. Docking results are then combined with a Markov model to get state-weighted binding free energies that are compared with experimentally measured ones.</p><p>Strengths:</p><p>The study uses state-of-the-art modeling methods to provide detailed insights into the structure-function relationship of an important human potassium channel. AlphaFold modeling, MD simulations and Markov modeling are nicely combined to investigate the impact of structural changes in the hERG channel on potassium conduction and drug binding.</p><p>Weaknesses:</p><p>(1) Selection of inactivated conformations based on AlphaFold modeling seems a bit biased.</p><p>The authors base their initial selection of the &quot;most likely&quot; inactivated conformation on the expected flipping of V625 and the constriction at G626 carbonyls. This follows a bit the &quot;Streetlight effect&quot;. It would be better to have selection criteria that are independent of what they expect to find for the inactivated state conformations. Using cues that favour sampling/modeling of the inactivated conformation, such as the deactivated conformation of the VSD used in the modeling of the closed state, would be more convincing. There may be other conformations that are more accurately representing the inactivated state. In addition, I am not sure whether pLDDT is a good selection criterion. It reports on structural confidence, but that may not relate to functional relevance.</p><p>(2) The comparison of predicted and experimentally measured binding affinities lacks of appropriate controls. Using binding data from open-state conformations only is not the best control. A much better control is the use of alternative structures predicted by AlphaFold for each state (e.g. from the outlier clusters or not considered clusters) in the docking and energy calculations. Importantly, labels for open, closed and inactivated state should be randomized to check robustness of the findings. Such a control would strengthen the overall findings significantly.</p><p>(3) Figures where multiple datapoints are compared across states generally lack assessment of the statistical significance of observed trends (e,g. Figure 3d).</p><p>The authors have successfully achieved their goal of providing new insights into the structural details of the three major conformational states sampled by the human voltage-gated potassium channel hERG, and linking these states to changes in drug-binding affinities. However, the study would benefit from more robust controls and orthogonal validation. Additionally, the generalizability of the approach remains to be demonstrated.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.104901.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Ngo et al. use AlphaFold2 and Rosetta to model closed, open, and inactive states of the human ion channel hERG. Subsequent MD simulations and comparisons with experiment support the plausibility of their models.</p><p>Strengths:</p><p>Ngo et al. employ various computational methods to enhance AlphaFold2's prediction capabilities for the human voltage-gated potassium channel hERG. They guide AlphaFold2 to explore different protein conformations and states, including its open, closed, and inactivated forms, using targeted templates. Additionally, they applied the Rosetta FastRelax protocol with an implicit membrane to refine the conformation of each residue in the predictions and address steric clashes, along with molecular dynamics (MD) simulations to account for membrane-pore flexibility. The methodology is well-described, and the figures are clear and descriptive.</p><p>The authors have addressed some of the concerns raised during the first round of reviews. For instance, to mitigate potential bias in selecting the inactivated conformation, they evaluated conformational variability via backbone dihedral angles at specific residues in the selectivity filter and the drug binding sites. They also evaluated the top representative model from inactivated-state-sampling Cluster 3 (termed &quot;AF ic3&quot;), which was initially excluded. This model is now included in the revised manuscript as Figure S9a, b. MD simulations confirmed that this state could be a potential alternative open-state conformation. The authors also acknowledged the limitation of their study by not incorporating other enhanced sampling methods and AF3.</p><p>In the revised manuscript, the authors provided more extensive explanations of their methods. For example, they explained that their approach to template selection was guided by their experience-AlphaFold2 with larger templates often overly constraining predictions to the input structure, reducing its flexibility to explore alternative conformations. In contrast, smaller, targeted fragments increase the likelihood that AlphaFold2 will incorporate the desired structural features while predicting the rest of the protein. They also noted that pLDDT scores are not always reliable for selecting new or alternative conformations, citing proper references. They included a model from cluster 3 of the inactivated-state sampling process, which exhibited lower pLDDT scores to illustrate this further.</p><p>Another point raised by the reviewers was the exclusion of the N-terminal PAS domain due to GPU memory limitations and its impact on the study. This omission may overlook the PAS domain's potential roles in gating kinetics and allosteric effects on drug binding. The authors acknowledged these limitations in the main text and highlighted the need for future studies to explore these regions in greater detail. They also alluded to potential future research to address these points. Additionally, they have made some of their analysis scripts and tools available on GitHub as a community resource.</p><p>Weakness:</p><p>The primary issue with the study is the lack of a general pipeline or strategy that can be universally applied to any system, even if limited to ion channels or membrane proteins. A related paper assessed the conformational variability in voltage-sensing domains (VSDs) by applying both the default MSA depth and a range of reduced MSA depths to enhance conformational diversity (please see <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1101/2025.03.12.642934">https://doi.org/10.1101/2025.03.12.642934</ext-link>). They generated 600 models for 32 members of the voltage-gated cation channel superfamily and demonstrated that AlphaFold2 can predict a range of diverse structures of the VSDs, representing activated, deactivated, and intermediate conformations, with more diversity observed for some VSDs compared to others.</p><p>The authors have addressed one of the reviewer's concerns about generalizability by including an example in Figure S14 of the modified text, showing how their approach can be applied to model another ion channel system. However, some outstanding questions remain: Is this method better suited for ion channels or membrane proteins with already solved structures and extensive research available? Can this pipeline be applied to other systems as well? Additionally, how does this method compare to other methods using MSA subsampling and other enhanced AF-based techniques to generate alternative conformations of proteins?</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.104901.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ngo</surname><given-names>Khoa</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, Davis</institution><addr-line><named-content content-type="city">Davis</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Pei-Chi</given-names></name><role specific-use="author">Author</role><aff><institution>University of California Davis</institution><addr-line><named-content content-type="city">Davis</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Yarov-Yarovoy</surname><given-names>Vladimir</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, Davis</institution><addr-line><named-content content-type="city">Davis</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Clancy</surname><given-names>Colleen E</given-names></name><role specific-use="author">Author</role><aff><institution>University of California Davis Medical Center</institution><addr-line><named-content content-type="city">Davis</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Vorobyov</surname><given-names>Igor</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, Davis</institution><addr-line><named-content content-type="city">Davis</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authorsâ response to the original reviews</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public review):</bold></p><p>Weaknesses:</p><p>(1) The selection of inactivated conformations based on AlphaFold modeling seems a bit biased. The authors base their selection of the âmost likelyâ inactivated conformation on the expected flipping of V625 and the constriction at G626 carbonyls. This follows a bit of the âStreetlight effectâ. It would be better to have selection criteria that are independent of what they expect to find for the inactivated state conformations. Using cues that favour sampling/modeling of the inactivated conformation, such as the deactivated conformation of the VSD used in the modeling of the closed state, would be more convincing. There may be other conformations that are more accurately representing the inactivated state. I see no objective criteria that justify the non-consideration of conformations from cluster 3 of the inactivated state modeling. I am not sure whether pLDDT is a good selection criterion. It reports on structural confidence, but that may not relate to functional relevance.</p></disp-quote><p>We sincerely thank the reviewer for their perceptive critique highlighting potential bias in selecting the inactivated conformation. We recognize that over-relying on preconceived traits could limit exploration of diverse inactivated states, and we appreciate the opportunity to address this concern.</p><p>Although we selected the model with the flipped V625 in the selectivity filter (SF) from the first round of inactivated-state sampling as the template for the second round, the resulting models still exhibited substantial diversity in their SF conformations. This selection primarily served to steer predictions away from the open-state configuration observed in the PDB 5VA2 SF, and we have clarified this rationale in the Methodology section. To assess conformational variability, we examined backbone dihedral angles (phi Ï and psi Ï) at key residues in the selectivity filter (S624 â G628) and drugbinding region on the pore-lining S6 segment (Y652, F656), of all 100 models sampled in the subsequent inactivatedstate-sampling attempt. By overlaying the Ï and Ï dihedral angles from different models, including the open state (PDB 5VA2-based), the closed state, and representative models from AlphaFold inactivated-state-sampling Cluster 2 and Cluster 3, we found that these conformations consistently fall within or near high-probability regions of the dihedral angle distributions. This indicates that these structural states are well represented within the ensemble of conformations sampled by AlphaFold within the scope of this study, particularly at functionally critical positions.</p><p>Following the analysis above and consistent with the reviewerâs suggestion, we evaluated the top representative model from inactivated-state-sampling Cluster 3 (named âAF ic3â), which we had initially excluded. This model demonstrated SF residue G626 carbonyl oxygen flipped away from the conduction pathway, hinting at potential impact on ion conduction, yet its pore region structurally resembled the open state (Figure S9a, b). To test this objectively, we ran molecular dynamics (MD) simulations (2 runs, 1 Î¼s long each, with applied 750 mV voltage) with varied initial ion/water configurations in the SF, finding it consistently open and conducting throughout (Figure S9c, d), consistent with our previous observations in Figure S11 that ion conduction can still occur when the upper SF is dilated. Drug docking (Figure S12) further revealed that the model exhibited binding affinities similar to those for the PDB 5VA2-based openstate structure. These findings combined led us to classify it as a possible alternative open-state conformation.</p><p>Models from Cluster 4 were not tested due to extensive steric clashes, where residues in the SF overlapped with neighboring residues from adjacent subunits. The remaining models displayed SF conformations that combined features from earlier clusters. However, due to subunit-to-subunit variability, where individual subunits adopted differing conformations, they were classified as outliers. This combination of features may be valuable to investigate further in a follow-up study.</p><p>We acknowledge that our approach is just one of many ways to sample different states, and alternative strategies, such as generating more models, varying multiple sequence alignment (MSA) subsampling, or testing different templates, might reveal improved models. Given that hERG channel inactivation likely spans a spectrum of conformations, our resource limitations may have restricted us to exploring and validating only part of this diversity. Nevertheless, the putative inactivated (AlphaFold Cluster 2) modelâs non-conductivity and improved affinity for drugs targeting the inactivated state observed in our study suggests that this approach may be capturing relevant features of the inactivated-state conformation. We look forward to investigating deeper other possibilities in a future study and are grateful for the reviewerâs feedback.</p><disp-quote content-type="editor-comment"><p>(2) The comparison of predicted and experimentally measured binding affinities lacks an appropriate control. Using binding data from open-state conformations only is not the best control. A much better control is the use of alternative structures predicted by AlphaFold for each state (e.g. from the outlier clusters or not considered clusters) in the docking and energy calculations. Using these docking results in the calculations would reveal whether the initially selected conformations (e.g. from cluster 2 for the inactivated state) are truly doing a better job in predicting binding affinities. Such a control would strengthen the overall findings significantly.</p></disp-quote><p>We appreciate the reviewerâs insightful suggestion. To address this, we extended our analysis by incorporating an alternative AlphaFold2-predicted model from inactivated-state-sampling cluster 3 as a structural control. This model was established in a previously discussed analysis to be open and conducting as a follow up to comment #1, so we will call it Open (AF ic3) to differentiate it from Open (PDB 5VA2). We evaluated this new model in single-state and multi-state contexts alongside our original open-state model based on the experimental PDB 5VA2 structure. Additionally, we expanded the drug docking procedure to explore a broader region around the putative drug binding site by increasing the sampling space, and we adopted an improved approach for selecting representative docking poses to better capture relevant binding modes.</p><p>Shown in Figure 7 are comparisons of experimental drug potencies with the binding affinities from the molecular docking calculations under the following conditions:</p><p>(a) Single-state docking using the experimentally derived open-state structure (PDB 5VA2)</p><p>(b) Multi-state docking incorporating open (PDB 5VA2), inactivated, and closed-state conformations weighted by experimentally observed state distributions</p><p>(c) Single-state docking using an alternative AlphaFold-predicted open-state (inactivated-state-sampling cluster 3, AF ic3)</p><p>(d) Multi-state docking combining the AlphaFold-predicted open-state (inactivated-state-sampling cluster 3, AF ic3)</p><p>Using only the open-state model (PDB 5VA2) yielded a moderate correlation with experimental data (<italic>R2</italic> = 0.43, <italic>r</italic> = 0.66, Figure 7a). Incorporating multi-state binding (weighted by their experimental distributions) improved the correlation substantially (<italic>R2</italic> = 0.63, <italic>r</italic> = 0.79, Figure 7b), boosting predictive power by 47% and underscoring the value of multi-state modeling. Importantly, this improvement was achieved without considering potential drug-induced allosteric effects on the hERG channel conformation and gating, which will be addressed in future work.</p><p>Next, we substituted the PDB 5VA2-based open-state model with the AF ic3 open-state model. Docking to this alternative model alone produced similar performance (<italic>R2</italic> = 0.44, <italic>r</italic> = 0.66, Figure 7c), and incorporating it into the multi-state ensemble further improved the correlation with experiments (<italic>R2</italic> = 0.64, <italic>r</italic> = 0.80, Figure 7d), representing a 45% gain in <italic>R2</italic> and matching the performance of multi-state docking results based on the PDB 5VA2-derived model.</p><p>These findings suggest that the predictive power of computational drug docking is enhanced not merely by the accuracy of individual models, but by the structural diversity and complementarity provided by an ensemble of protein conformations. Rather than relying solely on a single experimentally determined protein structure, the ensemble benefits from incorporating AlphaFold-predicted models that capture alternative conformations identified through our state-specific sampling approach. These diverse protein models reflect different structural features, which together offer a more comprehensive representation of the ion channelâs binding landscape and enhance the predictive performance of computational drug docking. Overall, these results reinforce that multi-state modeling offers a more realistic and predictive framework for understanding drug â ion channel interactions than traditional single-state approaches, emphasizing the value of both individual model evaluation and their collective integration. We are grateful for the reviewerâs suggestion.</p><disp-quote content-type="editor-comment"><p>(3) Figures where multiple datapoints are compared across states generally lack assessment of the statistical significance of observed trends (e.g. Figure 3d).</p></disp-quote><p>We appreciate the reviewerâs comment on the statistical significance assessment in Figure 3d. To clarify, the comparisons shown in the subpanels are based on three selected representative models for each state, rather than a broader population sample (similarly for Figure 3b). In the closed-state predicted models, the strong convergence of the voltagesensing domain (VSD), with an all-atom RMSD of 0.36 Ã between cluster 1 and 2 closed-state sampling models and 0.95 Ã to the outlier cluster, indicates minimal structural variation. Those RMSD values shown in the manuscript text demonstrates good convergence and by themselves represent statistical significance assessment of those models. This trend extends to open-state and inactivated-state AlphaFold models with similarly limited differences in the VSD regions among them. This convergence suggests that population-based statistical analysis may not reveal meaningful deviations, as the low variability among models limits the insights beyond those obtained from comparing representative structures.</p><p>Nonetheless, we acknowledge this limitation. In future studies, we plan to explore alternative modeling approaches to introduce greater variability, enabling a more robust statistical evaluation of state-specific trends in the predictions.</p><disp-quote content-type="editor-comment"><p>(4) Figure 3 and Figures S1-S4 compare structural differences between states. However, these differences are inferred from the initial models. The collection of conformations generated via the MD runs allow for much more robust comparisons of structural differences.</p></disp-quote><p>We have explored these conformational state dynamics through MD simulations for the Open (5VA2-based), Inactivated (AlphaFold Cluster 2), and Closed-state models, as presented in Figures S7, S8, S10, S11. These figures provide detailed insights: Figure S7-S8 analyzes SF and pore conformation dynamics, including averaged pore radii with and without voltage and superimposed conformational ensembles; Figure S10 tracks cross-subunit distances between protein backbone carbonyl oxygens, revealing sequential SF dilation steps near residues F627 an G628; and Figure S11 illustrates this SF dilation process over time, highlighting residue F627 carbonyl flipping and SF expansion. We appreciate the opportunity to clarify our approach.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>Major concerns:</p><p>(1) Protein fragments are used to model the closed and inactivated states of hERG, but the choices of fragments are not well justified. For instance, in Figure 1a, helices from 8EP1 (deactivated voltage-sensing domain) and a helix+loop from 5VA2 (selectivity filter) are used. Why just the selectivity filter and not the cytosolic domain, for instance? Why not some parts of the helices attached to the selectivity filter, or the whole membrane inserted domain of 8EP1? Same for the inactivated conformation in Figure 1c: why the cytosolic domain only?</p></disp-quote><p>We thank the reviewer for their thoughtful questions regarding our choice of protein fragments for modeling the closed and inactivated states of hERG in Figures 1a and 1c, and we appreciate the opportunity to justify these selections more clearly. Our approach to template selection was guided by our experience that providing AlphaFold2 with larger templates often leads it to overly constrain predictions to the input structure, reducing its flexibility to explore alternative conformations. In contrast, smaller, targeted fragments increase the likelihood that AlphaFold2 will incorporate the desired structural features while predicting the rest of the protein. We have provided a more detailed discussion of this in the methodology section.</p><p>For the closed state (Figure 1a), we chose the deactivated voltage-sensing domain (VSD) from the rat EAG channel (PDB 8EP1) to inspire AlphaFold2 to predict a similarly deactivated VSD conformation characteristic of hERG channel closure, as this domainâs downward shift is a hallmark of potassium channel closure. We paired this with the selectivity filter (SF) and adjacent residues from the open-state hERG structure (PDB 5VA2) to maintain its conductive conformation, as it is generally understood that K<sup>+</sup> channel closure primarily involves the intracellular gate rather than significant SF distortion. Including additional helices (e.g., S5âS6) or the entire membrane domain from PDB 8EP1 risked biasing the model toward the EAG channelâs pore structure, which differs from hERGâs, while omitting the cytosolic domain ensured focus on the VSD-driven closure without over-constraining cytoplasmic domain interactions.</p><p>For the inactivated state (Figure 1c), we initially used only the cytosolic domain from PDB 5VA2 to anchor the prediction while allowing AlphaFold2 to freely sample transmembrane domain conformations, particularly the SF, where the inactivation occurs via its distortion. Excluding the SF or attached helices at this stage avoided locking the model into the open-state SF, and the cytosolic domain alone provided a minimal scaffold to maintain hERGâs intracellular architecture without dictating pore dynamics. Following the initial prediction, we initiated more extensive sampling by using one of the predicted SFs that differs from the open-state SF (PDB 5VA2) as a structural seed, aiming to guide predictions away from the open-state configuration. The VSD and cytosolic domain were also included in this state to discourage pore closure during prediction. Using larger fragments, like the full membrane-spanning domains or additional cytosolic regions from the open-state structure might reduce AlphaFold2âs ability to deviate from the open-state conformation, undermining our goal of capturing more diverse, state-specific features.</p><p>It is worth noting that multiple strategies could potentially achieve the predicted models in our study, and here we only present examples of the paths we took and validated. It is likely that many of the steps may be unnecessary and could be skipped, and future work building on our approach can further explore and streamline this process. A consistent theme underlies our choices: for the closed state, we know the VSD should adopt a deactivated (âdownâ) conformation, so we provide AlphaFold2 with a specific fragment to guide this outcome; for the inactivated state, we recognize that the SF must change to a non-conductive conformation, so we grant AlphaFold2 flexibility to explore diverse conformations by minimizing initial constraints on the transmembrane region.</p><p>With greater sampling and computational resources, it is possible we could identify additional plausible, non-conductive conformations that might better represent an inactivated state, as hERG inactivation may encompass a spectrum of states. In this study, due to resource limitations, we focused on generating and validating a subset of conformations. Still, we acknowledge that broader exploration could further refine these models, which could be pursued in future studies. We updated the Methods and Discussion sections to reflect this perspective, and we are grateful for the reviewerâs input, which encourages us to clarify our rationale and highlight the adaptability of our approach.</p><p>To demonstrate the broader feasibility of this approach, we applied it to another ion channel system, voltage-gated sodium channel Na<sub>V</sub> 1.5, as illustrated in Figure S14. In this example, a deactivated VSD II from the cryo-EM structure of a homologous ion channel Na<sub>V</sub>1.7 (PDB 6N4R) (DOI: 10.1016/j.cell.2018.12.018), which was trapped in a deactivated state by a bound toxin, was used as a structural template. This guided AlphaFold to generate a Na<sub>V</sub>1.5 model in which all four voltage sensor domains (VSD IâIV) exhibit S4 helices in varying degrees of deactivation. Compared to the cryo-EM openstate Na<sub>V</sub>1.5 structure (PDB 6LQA) (DOI: 10.1002/anie.202102196), the predicted model displays a visibly narrower pore, representing a plausible closed state. This example underscores the versatility of our strategy in modeling alternative conformational states across diverse ion channels.</p><disp-quote content-type="editor-comment"><p>(2) While the authors rely on AF2 (ColabFold) for the closed and inactivated states, they use Rosetta to model loops of the open state. Why not just supply 5VA2 as a template to ColabFold and rebuild the loops that way? Without clear explanations, these sorts of choices give the impression that the authors were looking for specific answers that they knew from their extensive knowledge of the hERG system. While the modeling done in this paper is very nice, its generalizability is not obvious.</p></disp-quote><p>We appreciate the reviewerâs question about our use of Rosetta to model loops in the open-state hERG channel (PDB5VA2) rather than rebuilding it entirely with ColabFold. In the study, we conducted a control experiment supplying parts of PDB 5VA2 to ColabFold to rebuild the loops, generating 100 models (Figure 2a: predicted open state). The top-ranked model (by pLDDT) differed from our Rosetta-modelled structure by only 0.5 Ã RMSD, primarily due to the flexible extracellular loops as expected, with the pore and selectivity filter (our areas of focus) remaining nearly identical. We chose the Rosetta-refined cryo-EM structure as this structure and approach have been widely used as an open-state reference in our other hERG channel studies, such as by Miranda et al. (DOI: 10.1073/pnas.1909196117) and Yang et al. (DOI: 10.1161/CIRCRESAHA.119.316404), to ensure that our results are more directly comparable to prior work in the field. Nonetheless, as both models (with loops modeled by Rosetta or AlphaFold) were virtually identical, we would expect no significant differences if either were used to represent the open state in our study. We have incorporated this clarification into the main text.</p><disp-quote content-type="editor-comment"><p>(3) pLDDT scores were used as a measure of reliable and accurate predictions, but plDDT is not always reliable for selecting new/alternative conformations (see <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41467-024-515072">https://doi.org/10.1038/s41467-024-515072</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/s41467-024-51801-z">https://www.nature.com/articles/s41467-024-51801-z</ext-link>).</p></disp-quote><p>We acknowledge that while pLDDT is a valuable indicator of structural confidence in AlphaFold2 predictions, its limitations warrant consideration. In our revision, we mitigated this by not relying solely on pLDDT, but we also performed protein backbone dihedral angle analysis of the protein regions of focus in all predicted models to ensure comprehensive coverage of conformational variations. From our AlphaFold modeling results, we tested a model from cluster 3 of the inactivated-state sampling process, which exhibited lower pLDDT scores, and included these results in our revised analysis. We included a note in the revised manuscriptâs Discussion section: âAs noted in recent studies, pLDDT scores are not reliable indicators for selecting alternative conformations (DOI: 10.1038/s41467-024-51507-2 and DOI: 10.1038/s41467-024-51801-z). To address this, we performed a protein backbone dihedral angle analysis in the regions of interest to ensure that our evaluation captured a representative range of sampled conformations.â</p><disp-quote content-type="editor-comment"><p>(4) Extensive work has been done using AF2 to model alternative protein conformations (<ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2024.05.28.596195v1.abstract">https://www.biorxiv.org/content/10.1101/2024.05.28.596195v1.abstract</ext-link>, along with some references the authors cite, such as work by McHaourab); another group recently modeled the ion channel GLIC (<ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2024.09.05.611464v1.abstract">https://www.biorxiv.org/content/10.1101/2024.09.05.611464v1.abstract</ext-link>). Therefore, this work, though generally solid and thorough, seems more like a variation on a theme than a groundbreaking new methodology, especially because of the generalizability issues mentioned above.</p></disp-quote><p>We sincerely thank the reviewer for acknowledging the solidity of our study and for drawing our attention to the impressive recent efforts using AlphaFold2 to explore alternative protein conformations. These studies are valuable contributions that highlight the versatility of AlphaFold2, and we are grateful for their context in evaluating our work.</p><p>Building on these efforts, our approach not only enhances the prediction of conformational diversity but also introduces a twist by incorporating structural templates to guide AlphaFold2 toward specific functional protein states. More significantly, our study advances beyond mere structural modeling by integrating these conformations with their rigorous validation by incorporating multiple simulation results tested against experimental data to reveal that AlphaFold-predicted conformations can align with distinct physiological ion channel states. A key finding is that drug binding predictions using AlphaFold-derived hERG channel states substantially improve correlation with experimental data, which is a longstanding challenge in computational screening of multi-state proteins like the hERG channel, for which previous structural models have been mostly limited to the open state based on the cryo-EM structures. Our approach not only captures this critical state dependence but also reveals potential molecular determinants underlying enhanced drug binding during hERG channel inactivation, a phenomenon observed experimentally but poorly understood. These insights advance drug safety assessment by improving predictive screening for hERG-related cardiotoxicity, a major cause of drug attrition and withdrawal.</p><p>We view our methodology as a natural evolution of the advancements cited by the reviewer, offering an approach that predicts diverse hERG channel conformational states and links them to meaningful functional and pharmacological outcomes. To address the reviewerâs concern about generalizability, we have expanded the methodology section to make it easier to follow and include additional details. As an example, we show how our approach can be applied to model another ion channel system, Na<sub>V</sub>1.5, in Figure S14.</p><p>Furthermore, to enhance the applicability of our methodology, we have uploaded the scripts for analyzing AlphaFoldpredicted models to GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/k-ngo/AlphaFold_Analysis">https://github.com/k-ngo/AlphaFold_Analysis</ext-link>), ensuring they are adaptable for a wide range of scenarios with extensive documentation. This enables users, even those not focused on ion channels, to effectively apply our tools to analyze AlphaFold predictions for their own projects and produce publication-ready figures.</p><p>While it is likely that multiple modeling approaches could lead AlphaFold to model alternative protein conformations, the key challenge lies in validating the physiological relevance of those predicted states. This study is intended to support other researchers in applying our template-guided approach to different protein systems, and more importantly, in rigorously <italic>in silico</italic> testing and validation of the biological significance of the conformation-specific structural models they generate.</p><disp-quote content-type="editor-comment"><p>Minor concerns:</p><p>(1) The authors mention in the Introduction section that capturing conformational states, especially for membrane proteins that may be significant as drug targets, is crucial. It would be helpful to relate their work to the NMR studies domains of the hERG channel, particularly the N-terminal âeagâ domain, which is crucial for channel function and can provide insights into conformational changes associated with different channel states (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bbrc.2010.10.132">https://doi.org/10.1016/j.bbrc.2010.10.132</ext-link>).</p></disp-quote><p>We appreciate the reviewerâs insightful comment regarding the PAS domain and the potential influence of other regions, such as the N-linker and distal C-region, on drug binding and state transitions.</p><p>The PAS domain did appear in the starting templates used for initial structural modeling (as shown in Figure 1a, b, c), but it was not included in the final models used for subsequent analyses. The omission was primarily due to hardwareimposed constraints, as including these additional regions would exceed the memory capacity of our current graphics processing unit (GPU) card, leading to failures during the prediction step.</p><p>The PAS domain, even if not serving as a conventional direct drug-binding site, can influence the gating kinetics of hERG channels. By altering the probability and duration with which channels occupy specific states, it can indirectly affect how well drugs bind. For example, if the presence of the PAS domain shifts hERG channel gating so that more channels enter (and remain in) the inactivated state as was shown previously (e.g., DOI: 10.1085/jgp.201210870), drugs with a higher affinity for that state would appear to bind more potently, as observed in previous electrophysiological experiments (e.g., DOI: 10.1111/j.1476-5381.2011.01378.x). It is also plausible that the PAS domain could exert allosteric effects that alter the conformational landscape of the hERG channel during gating transitions, potentially impacting drug accessibility or binding stability. This is an intriguing hypothesis and an important avenue for future research.</p><p>With access to more powerful computational resources, it would be valuable to explore the full-length hERG channel, including the PAS domain and associated regions, to assess their potential contributions to drug binding and gating dynamics. We incorporated a discussion of these points into the main text, acknowledging the limitations of our current models and highlighting the need for future studies to explore these regions in greater detail. The addition reads: ââ¦Our models excluded the N-terminal PAS domain due to GPU memory limitations, despite its inclusion in initial templates. This omission may overlook its potential roles in gating kinetics and allosteric effects on drug binding (e.g., PMID: 21449979, PMID: 23319729, PMID: 29706893, PMID: 30826123, DOI:10.4103/jpp.JPP_158_17). Future research will explore the full-length hERG channel with enhanced computational resources to assess these regionsâ contributions to conformational state transitions and pharmacology.â</p><disp-quote content-type="editor-comment"><p>(2) In the second-to-last paragraph of the Introduction, the authors describe how AlphaFold2 works. They write, âAlphaFold2 primarily requires the amino acid sequence of a protein as its input, but the method utilizes other key elements: in addition to the amino acid sequence, AlphaFold2 can also utilize multiple sequence alignments (MSAs) of similar sequences from different species, templates of related protein structures when available, and/or homologous proteins (Jumper et al., 2021a). Evolutionarily conserved regions over multiple isoforms and species indicated that the sequence is crucial for structural integrityâ. The last sentence is confusing; if the authors mean that all information required to fold the protein into its 3D structure is present in its primary sequence, that has been the paradigm. It is unclear from this paragraph what the authors wanted to convey.</p></disp-quote><p>We apologize for any confusion caused by this phrasing. Our intent was not to restate the well-established paradigm that a proteinâs primary sequence contains the information needed for its 3D structure, but rather to emphasize how</p><p>AlphaFold2 leverages evolutionary conservation, via multiple sequence alignments (MSAs), to infer structural constraints beyond what a single sequence alone might reveal. Specifically, we aimed to highlight that conserved regions across species and isoforms provide additional context that AlphaFold2 uses to enhance the accuracy of its predictions, complementing the use of templates and homologous structures as described in Jumper et al. (2021). To clarify this, we revised the sentence in the manuscript to read: âAlphaFold2 primarily requires a protein's amino acid sequence as input, but it also leverages other critical data sources. In addition to the sequence, it incorporates multiple sequence alignments (MSAs) of related proteins from different species, available structural templates, and information on homologous proteins. While the primary sequence encodes the 3D structure, AlphaFold2 harnesses evolutionary conservation from MSAs to reveal structural insights that extend beyond what a single sequence can provide.â We thank the reviewer for pointing out this ambiguity.</p><disp-quote content-type="editor-comment"><p>(3) In the Results section, the authors state that the predictions generated by their method are evaluated by standard accuracy metrics, please elaborate - what standard metrics were used to judge the predictions and why (some references would be a nice addition). Further, on Page 6, the sentence âThere are fewer differences between the open- and closed-state models (Figure S2b, d)â is confusing, fewer differences than what? or there are a few differences between the two states/models? Please clarify.</p></disp-quote><p>The original sentence referring to âstandard accuracy metricsâ is somewhat misplaced, as our intent was not to apply any conventional âbenchmarkingâ to judge the predictions, but rather to evaluate functional and structural relevance in a physiologically meaningful context. Specifically, we assessed drug binding affinities from molecular docking simulations (in Rosetta Energy Units, R.E.U.) against experimental drug potency data (e.g., IC<sub>50</sub> values converted to free energies in kcal/mol, Figure 7), analyzed differences in interaction networks across states in relation to known mutations affecting hERG inactivation (Figure 4, Table 2), validated ion conduction properties through MD simulations with the applied voltage against expected state-dependent hERG channel behavior (Figure 5), and compared predicted structural models to available experimental cryo-EM structures (Figure 3). We clarified in the text that our assessment emphasized the physiological plausibility of the generated conformations, drawing on evidence from existing computational and experimental studies at each step of the analysis above.</p><p>As for the sentence on page 6, âThere are fewer differences between the open- and closed-state models,â we apologize for the ambiguity; we meant that the hydrogen bond networks in the selectivity filter region exhibit fewer differences between the open and closed states compared to the more pronounced variations seen between the open and inactivated states. We revised this sentence to read: âThe open- and closed-state models show fewer differences in their selectivity filter hydrogen bond networks compared to those between the open and inactivated states,â to enhance readability.</p><disp-quote content-type="editor-comment"><p>(4) In the Discussion, the authors reiterate that this methodology can be extended to sample multiple protein conformations, and their system of choice was hERG potassium channel. I think this methodology can be applied to a system when there is enough knowledge of static structures, and some information on dynamics (through simulations) and mutagenesis analysis available. A well-studied system can benefit from such a protocol to gauge other conformational states.</p></disp-quote><p>We agree that this approach is well-suited to systems with sufficient static structures, dynamic insights from simulations, and mutagenesis data, as seen with the hERG channel. We appreciate the reviewerâs implicit concern about generalizability to less-characterized systems and addressed this in the Discussion as a limitation, noting that the methodâs effectiveness may depend on prior knowledge. Future studies can explore whether the advent of AlphaFold3 and other deep learning approaches can enhance its applicability to systems with more limited data. We have added this comment to the Discussion: ââ¦A limitation of our methodology is its reliance on well-characterized systems with ample static structures, molecular dynamics simulation data, and mutagenesis insights, as demonstrated with the hERG channel, which may limit its applicability to less-studied proteins.â</p><disp-quote content-type="editor-comment"><p>(5) The Methods section must be broken down into steps to make it easier to follow for the reader (if they want to implement these steps for themselves on their system of choice).</p><p>a. Is possible to share example scripts and code used to piece templates together for AF2. Also, since the AF3 code is now available, the authors may comment on how their protocol can be applicable there or have plans to implement their protocol using AF3 (which is designed to work better for binding small molecules). Please see <ext-link ext-link-type="uri" xlink:href="https://github.com/google-deepmind/alphafold3">https://github.com/google-deepmind/alphafold3</ext-link> for the recently released code for AF3.</p></disp-quote><p>We appreciate the reviewerâs suggestion to improve the Methods section and their comments on scripts and AlphaFold3 (AF3). We revised the Methods to separate it into clear steps (e.g., template preparation, AF2 setup, clustering, and refinement) for better readability and reproducibility, and uploaded the sample scripts along with the instructions to GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/k-ngo/AlphaFold_Analysis">https://github.com/k-ngo/AlphaFold_Analysis</ext-link>).</p><p>Regarding AF3âs recent code release, we plan to explore the applicability of our methodology to AF3 in a follow-up study, leveraging its advanced features to refine conformational predictions and state-specific drug docking, and added a brief comment to the Discussion to reflect this future direction: ââ¦Following the recent release of AlphaFold3âs source code, we plan to explore the applicability of our template-guided methodology in a follow-up study, leveraging AF3âs advanced diffusion-based architecture to enhance protein conformational state predictions and state-specific drug docking, particularly given its improved capabilities for modeling small molecule â protein interactionsâ¦â</p><disp-quote content-type="editor-comment"><p>b. The authors modified the hERG protein by removing a segment, the N-terminal PAS domain (residues M1 - R397) because of graphics card memory limitation. Would the removal of the PAS domain affect the structure and function of the channel protein? HERG and other members of the âeag K<sup>+</sup> channelâ family contain a PAS domain on their cytoplasmic N terminus. Removal of this domain alters a physiologically important gating transition in HERG, and the addition of the isolated domain to the cytoplasm of cells expressing truncated HERG reconstitutes wild-type gating. (see <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0059265">https://doi.org/10.1371/journal.pone.0059265</ext-link>). Please elaborate on this.</p></disp-quote><p>We thank the reviewer for raising an important point about the removal of the N-terminal PAS domain and for highlighting its physiological role in hERG channel gating transitions. In our study, unlike experimental settings where PAS removal alters gating, we believe this omission has minimal impact on our key analyses.</p><p>The drug docking procedure focuses on optimizing drug binding poses with minor protein structural refinement around the putative drug binding site, which in our case is the hERG channel pore region, where hERG-blocking drugs predominantly bind. The cytoplasmic PAS domain, located distally from this site, remains outside the protein structure refinement zone during drug docking simulations. However, one aspect we have not yet considered is the potential effect of drug modulation of the hERG channel gating and vice versa particularly given the PAS domainâs role in gating. This interplay could be significant but requires investigation beyond our current drug docking framework. We plan to explore this in future studies using alternative simulation methodologies, such as extended MD simulations or enhanced sampling techniques, to comprehensively capture these dynamic protein - ligand interactions.</p><p>Similarly, in our 1 Î¼s long MD simulations assessing ion conductivity (Figure 4), the timescale is too short for PASmediated gating changes to propagate through the protein and meaningfully influence ion conduction and channel activation dynamics, which occurs on a millisecond time scale (see e.g., DOI: 10.3389/fphys.2018.00207). To fully address this limitation, we plan to explore the inclusion of the PAS domain in a follow-up study with enhanced computational resources, allowing us to investigate its structural and functional contributions more comprehensively.</p><disp-quote content-type="editor-comment"><p>(6) The first paragraph of the Methods reads as though AF2 has layers that recycle structures. We doubt that the authors meant it that way. Please update the language to clarify that recycling is an iterative process in which the pairwise representation, MSA, and predicted structures are passed (ârecycledâ) through the model multiple times to improve predictions.</p></disp-quote><p>We agree that the phrasing might suggest physical layers recycling structures, which was not our intent. Instead, we meant to describe AlphaFold2âs iterative refinement process, where intermediate outputs, such as the pairwise residue representations, multiple sequence alignments (MSAs), and predicted structures, are iteratively passed (or ârecycledâ) through the model to enhance prediction accuracy. To clarify this, we revised the relevant sentence to read: âA critical feature of AlphaFold2 is its iterative refinement, where pairwise residue representations, MSAs, and initial structural predictions are recycled through the model multiple times, improving accuracy with each iteration.â</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations for the authors):</bold></p><p>The authors should integrate the very recently published CryoEM experimental data of hERG inhibition by several drugs (Miyashita et al., Structure, 2024; DOI: 10.1016/j.str.2024.08.021).</p></disp-quote><p>We thank the reviewer for the suggestion. Here, we compare drug binding in our open-states (PDB 5VA2-derived and an additional AlphaFold-predicted model from Cluster 3 of inactivated-state-sampling attempt named âAF ic3â) and inactivated-state models, using the cationic forms of astemizole and E-4031, with the corresponding experimental structures (Figure S13). Drug binding in the closed state is excluded as the pore architecture deviates too much from those in the cryo-EM structures. Experimental data (DOI: 10.1124/mol.108.049056) indicate that both astemizole and E4031 bind more potently to the inactivated state of the hERG channel.</p><p>Astemizole (Figure S13a):</p><p>- In the PDB 5VA2-derived open-state model, astemizole binds centrally within the pore cavity, adopting a bent conformation that allows both aromatic ends of the molecule to engage in ÏâÏ stacking with the side chains of Y652 from two opposing subunits. Hydrophobic contacts are observed with S649 and F656 residues.</p><p>- In the AF ic3 open-state model, the ligand is stabilized through multiple ÏâÏ stacking interactions with Y652 residues from three subunits, forming a tight aromatic cage around its triazine and benzimidazole rings. Hydrophobic interactions are observed with hERG residues T623, S624, Y652, F656, and S660.</p><p>- In the inactivated-state model, astemizole adopts a compact, horizontally oriented pose deeper in the channel pore, forming the most extensive interaction network among all the states. The ligand is tightly stabilized by multiple ÏâÏ stacking interactions with Y652 residues across three subunits, and forms hydrogen bonds with residues S624 and Y652. Additional hydrophobic contacts are observed with residues F557, L622, S649, and Y652.</p><p>- Consistent with our findings, electrophysiology study by Saxena et al. identified hERG residues F557 and Y652 as crucial for astemizole binding, as determined through mutagenesis (DOI: 10.1038/srep24182).</p><p>- In the cryo-EM structure (PDB 8ZYO) (DOI: 10.1016/j.str.2024.08.021), astemizole is stabilized by ÏâÏ stacking with Y652 residues. However, no hydrogen bonds are detected which may reflect limitations in cryo-EM resolution rather than true absence of contacts. Additional hydrophobic interacts are observed with L622 and G648 residues.</p><p>E-4031 (Figure S13b):</p><p>- In the PDB 5VA2-derived open-state model, E-4031 binds within the central cavity primarily through polar interactions. It forms a ÏâÏ stacking interaction with residue Y652, anchoring one end of the molecule. Polar interactions are observed with residues A653 and S660. Additional hydrophobic contacts are observed with residues A652 and Y652.</p><p>- In the AF ic3 open-state model, E-4031 adopts a slightly deeper pose within the central cavity stabilized by dual ÏâÏ stacking interactions between its aromatic rings and hERG residue Y652. Additional hydrogen bonds are observed with residues S624 and Y652, and hydrophobic contacts are observed with residues T623 and S624.</p><p>- In the inactivated-state model, E-4031 adopts its deepest and most stabilized binding pose, consistent with its experimentally observed preference for this state. The ligand is stabilized by multiple ÏâÏ stacking interactions between its aromatic rings and hERG residues Y652 from opposing subunits. The sulfonamide nitrogen engages in hydrogen bonding with residue S649, while the piperidine nitrogen hydrogen bonds with residue Y652. Hydrophobic contacts with residues S624, Y652, and F656 further reinforce the binding, enclosing the ligand in a densely packed aromatic and polar environment.</p><p>- Previous mutagenesis study showed that mutations involving hERG residues F557, T623, S624, Y652, and F656 affect E-4031 binding (DOI: 10.3390/ph16091204).</p><p>- In the cryo-EM structure (PDB 8ZYP) (DOI: 10.1016/j.str.2024.08.021), E-4031 engages in a single ÏâÏ stacking interaction with hERG residue Y652, anchoring one end of the molecule. The remainder of the ligand is stabilized predominantly through hydrophobic contacts involving residues S621, L622, T623, S624, M645, G648, S649, and additional Y652 side chains, forming a largely nonpolar environment around the binding pocket.</p><p>In both cryo-EM structures, astemizole and E-4031 adopt binding poses that closely resembles the inactivated-state model in our docking study, consistent with experimental evidence that these drugs preferentially bind to the inactivated state (DOI: 10.1124/mol.108.049056). This raises the possibility that the cryo-EM structures may capture an inactivatedlike channel state. However, closer examination of the SF reveals that the cryo-EM conformations more closely resemble the open-state PDB 5VA2 structure (DOI: 10.1016/j.cell.2017.03.048), which has been shown to be conductive here and in previous studies (DOI: 10.1073/pnas.1909196117, 10.1161/CIRCRESAHA.119.316404).</p><p>The conformational differences between the cryo-EM and open-state docking results may reflect limitations of the docking protocol itself, as GALigandDock assumes a rigid protein backbone and cannot account for ligand-induced large conformational changes. In our open-state models, the hydrophobic pocket beneath the selectivity filter is too small to accommodate bulky ligands (Figure 3a, b), whereas the cryo-EM structures show a slight outward shift in the S6 helix that expands this space (Figure S13).These allosteric rearrangements, though small, falls outside the scope of the current docking protocol, which lacks flexibility to capture these local, ligand-induced adjustments (DOI: 10.3389/fphar.2024.1411428).</p><p>In contrast, docking to the AlphaFold-predicted inactivated-state model reveals a reorganization beneath the selectivity filter that creates a larger cavity, allowing deeper ligand insertion. Notably, neither our inactivated-state docking nor the available cryo-EM structures show strong interactions with F656 residues. However, in the AlphaFold-predicted inactivated model, the more extensive protrusion of F656 into the central cavity may further occlude the drugâs egress pathway, potentially trapping the ligand more effectively. This could explain why mutation of F656 significantly reduces the binding affinity of E-4031 (DOI: 10.3390/ph16091204). These findings suggest that inactivation may trigger a series of modular structural rearrangements that influence drug access and binding affinity, with different aspects potentially captured in various computational and experimental studies, rather than resulting from a single, uniform conformational change.</p><disp-quote content-type="editor-comment"><p>Discussion of the original Wang and Mackinnon finding, DOI: 10.1016/j.cell.2017.03.048 regarding C-inactivation, pore mutation S631A and F627 rearrangement is likely warranted. Since hERG inactivation is present at 0 mV in WT channels (the likely voltage for the CryoEM study) please discuss how this might affect interpretations of starting with this structure as a template for models presented here, perhaps as part of Figure S1.</p></disp-quote><p>We sincerely thank the reviewer for bringing up the insightful findings from Wang and MacKinnon regarding hERG C-type inactivation as well as the voltage context of their cryo-EM structure (PDB 5VA2). We recognize that WT hERG exhibits inactivation at 0 mV, likely the condition of the cryo-EM study, raising the possibility that PDB 5VA2, while classified as an open state, might subtly reflect features of inactivation. Notably, PDB 5VA2 has been widely adopted in numerous studies and consistently found to represent a conducting state, such as in Yang et al. (DOI: 10.1161/CIRCRESAHA.119.316404) and Miranda et al. (DOI: 10.1073/pnas.1909196117). Our MD simulations further support this, showing K<sup>+</sup> conduction in the 5VA2-based open-state model (Figure 4a, c), consistent with its selectivity filter conformation (Figure S1a). Although we used PDB 5VA2 as a starting template for predicting inactivated and closed states, our AlphaFold2 predictions did not rigidly adhere to this structure, as evidenced by distinct differences in hydrogen bond networks, drug binding affinities, pore radii, and ion conductivity between our state-specific hERG channel models (Figures S2, 5, 3b, 4). Nevertheless, this does not preclude the possibility that PDB 5VA2âs certain potential inactivated-like traits at 0 mV could subtly influence our predictions elsewhere in the model, which warrants further exploration in future studies. In our revised analysis, we also tested an alternative AlphaFold-predicted conformation, referred to as Open (AlphaFold cluster 3), which, while sharing some similarities with PDB 5VA2, exhibits subtle differences in the selectivity filter and pore conformations. This structure was also found to be conducting ions and showed a drug binding profile similar to that of the PDB 5VA2-based open-state model. We greatly appreciate this feedback which helped us refine and strengthen our analysis.</p><disp-quote content-type="editor-comment"><p>Page 8, the significance of 750 and 500 mV in terms of physiological role?</p></disp-quote><p>We appreciate this opportunity to clarify the methodological rationale. Although these voltages significantly exceed typical physiological membrane potentials, their use in MD simulations is a well-established practice to accelerate ion conduction events. This approach helps overcome the inherent timescale limitations of conventional MD simulations, as demonstrated in previous studies of hERG and other ion channels. For instance, Miranda et al. (DOI: 10.1073/pnas.1909196117), Lau et al. (DOI: 10.1038/s41467-024-51208-w), Yang et al. (DOI: 10.1161/CIRCRESAHA.119.316404) applied similarly high voltages (500~750 mV) to study hERG K<sup>+</sup> conduction, which is notably small under physiological conditions at ~2 pS (DOI: 10.1161/01.CIR.94.10.2572), necessitating amplification to observe meaningful permeation within nanosecond-to-microsecond timescales. Likewise, studies of other K<sup>+</sup> ion channels, such as Woltz et al. (DOI: 10.1073/pnas.2318900121) on small-conductance calcium-activated K<sup>+</sup> channel SK2 and Wood et al. (DOI: 10.1021/acs.jpcb.6b12639) on Shaker K<sup>+</sup> channel, have used elevated voltages (250~750 mV) to probe ion conduction mechanisms via MD simulations. In addition, the typical timescale of these simulations (1 Î¼s) is too short to capture major structural effects such as those leading to inactivation or deactivation which occur over milliseconds in physiological conditions.</p><disp-quote content-type="editor-comment"><p>The abstract could be edited a bit to more clearly state the novel findings in this study.</p></disp-quote><p>We thank the reviewer for their suggestion. We have revised the abstract to read: âTo design safe, selective, and effective new therapies, there must be a deep understanding of the structure and function of the drug target. One of the most difficult problems to solve has been resolution of discrete conformational states of transmembrane ion channel proteins. An example is K<sub>V</sub>11.1 (hERG), comprising the primary cardiac repolarizing current, <italic>Ikr</italic>. hERG is a notorious drug antitarget against which all promising drugs are screened to determine potential for arrhythmia. Drug interactions with the hERG inactivated state are linked to elevated arrhythmia risk, and drugs may become trapped during channel closure. While prior studies have applied AlphaFold to predict alternative protein conformations, we show that the inclusion of carefully chosen structural templates can guide these predictions toward distinct functional states. This targeted modeling approach is validated through comparisons with experimental data, including proposed state-dependent structural features, drug interactions from molecular docking, and ion conduction properties from molecular dynamics simulations. Remarkably, AlphaFold not only predicts inactivation mechanisms of the hERG channel that prevent ion conduction but also uncovers novel molecular features explaining enhanced drug binding observed during inactivation, offering a deeper understanding of hERG channel function and pharmacology. Furthermore, leveraging AlphaFold-derived states enhances computational screening by significantly improving agreement with experimental drug affinities, an important advance for hERG as a key drug safety target where traditional single-state models miss critical state-dependent effects. By mapping protein residue interaction networks across closed, open, and inactivated states, we identified critical residues driving state transitions validated by prior mutagenesis studies. This innovative methodology sets a new benchmark for integrating deep learning-based protein structure prediction with experimental validation. It also offers a broadly applicable approach using AlphaFold to predict discrete protein conformations, reconcile disparate data, and uncover novel structure-function relationships, ultimately advancing drug safety screening and enabling the design of safer therapeutics.â</p><disp-quote content-type="editor-comment"><p>Many of the Supplemental figures would fit in better in the main text, if possible, in my opinion. For instance, the network analysis (Fig. S2) appears to be novel and is mentioned in the abstract so may fit better in the main text. The discussion section could be focused a bit more, perhaps with headers to highlight the key points.</p></disp-quote><p>Yes, we agree with the reviewer and made the suggested changes. We moved Figure S2 as a new main-text figure.</p><p>Additionally, we revised the Discussion section to improve focus and clarity.</p></body></sub-article></article>